US20030144301A1 - Method of using 5-(arysulfonyl)-, 5-(arylsulfanyl)-and 5-(arylsulfanyl)thiazolidine-2,4-diones for inhibition of farnesyl-protein transferase - Google Patents
Method of using 5-(arysulfonyl)-, 5-(arylsulfanyl)-and 5-(arylsulfanyl)thiazolidine-2,4-diones for inhibition of farnesyl-protein transferase Download PDFInfo
- Publication number
- US20030144301A1 US20030144301A1 US10/226,815 US22681502A US2003144301A1 US 20030144301 A1 US20030144301 A1 US 20030144301A1 US 22681502 A US22681502 A US 22681502A US 2003144301 A1 US2003144301 A1 US 2003144301A1
- Authority
- US
- United States
- Prior art keywords
- ynyl
- thiazolidine
- dione
- pent
- sulfonyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 58
- 102000004357 Transferases Human genes 0.000 title claims description 10
- 108090000992 Transferases Proteins 0.000 title claims description 10
- 150000001473 2,4-thiazolidinediones Chemical class 0.000 title abstract description 8
- 230000005764 inhibitory process Effects 0.000 title description 10
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 34
- 210000001072 colon Anatomy 0.000 claims abstract description 8
- 210000001685 thyroid gland Anatomy 0.000 claims abstract description 8
- 210000000496 pancreas Anatomy 0.000 claims abstract description 7
- 210000003932 urinary bladder Anatomy 0.000 claims abstract description 7
- -1 8-quinolinyl Chemical group 0.000 claims description 126
- 150000001875 compounds Chemical class 0.000 claims description 121
- 125000004432 carbon atom Chemical group C* 0.000 claims description 47
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims description 46
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 37
- 125000000217 alkyl group Chemical group 0.000 claims description 36
- 239000001257 hydrogen Substances 0.000 claims description 33
- 229910052739 hydrogen Inorganic materials 0.000 claims description 33
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 28
- 150000003839 salts Chemical class 0.000 claims description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 201000010099 disease Diseases 0.000 claims description 19
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 18
- 125000003545 alkoxy group Chemical group 0.000 claims description 15
- 241000124008 Mammalia Species 0.000 claims description 14
- LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 claims description 14
- 125000001544 thienyl group Chemical group 0.000 claims description 12
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 11
- 230000002401 inhibitory effect Effects 0.000 claims description 11
- LYTKBYDLVDHHKO-UHFFFAOYSA-N 5-[5-(4-chlorophenyl)pent-4-ynyl]-5-(4-methoxyphenyl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CCCC#CC=2C=CC(Cl)=CC=2)C(=O)NC(=O)S1 LYTKBYDLVDHHKO-UHFFFAOYSA-N 0.000 claims description 10
- 230000002062 proliferating effect Effects 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 125000004076 pyridyl group Chemical group 0.000 claims description 9
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 9
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 8
- 125000001153 fluoro group Chemical group F* 0.000 claims description 8
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 claims description 6
- 230000004048 modification Effects 0.000 claims description 6
- 238000012986 modification Methods 0.000 claims description 6
- MYEBYOAXNWCTOZ-UHFFFAOYSA-N 5-[5-(4-chlorophenyl)pent-4-ynyl]-5-(4-methylphenyl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C1(CCCC#CC=2C=CC(Cl)=CC=2)C(=O)NC(=O)S1 MYEBYOAXNWCTOZ-UHFFFAOYSA-N 0.000 claims description 5
- 208000009905 Neurofibromatoses Diseases 0.000 claims description 5
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 5
- 125000000068 chlorophenyl group Chemical group 0.000 claims description 5
- 125000005059 halophenyl group Chemical group 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 201000004931 neurofibromatosis Diseases 0.000 claims description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 5
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 5
- JOYRKODLDBILNP-UHFFFAOYSA-N urethane group Chemical group NC(=O)OCC JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 claims description 5
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 4
- NTEBTYCWUJQGRT-UHFFFAOYSA-N 5-[11-(4-chlorophenyl)undec-10-ynyl]-5-(4-methoxyphenyl)sulfanyl-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1SC1(CCCCCCCCCC#CC=2C=CC(Cl)=CC=2)C(=O)NC(=O)S1 NTEBTYCWUJQGRT-UHFFFAOYSA-N 0.000 claims description 4
- DASAPVNSUJNRLM-UHFFFAOYSA-N 5-[3-(4-chlorophenyl)prop-2-ynyl]-5-(4-methoxyphenyl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CC#CC=2C=CC(Cl)=CC=2)C(=O)NC(=O)S1 DASAPVNSUJNRLM-UHFFFAOYSA-N 0.000 claims description 4
- YGZBGJDDWKXISM-UHFFFAOYSA-N 5-[5-(4-chlorophenyl)pent-4-ynyl]-5-(4-methoxyphenyl)sulfanyl-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1SC1(CCCC#CC=2C=CC(Cl)=CC=2)C(=O)NC(=O)S1 YGZBGJDDWKXISM-UHFFFAOYSA-N 0.000 claims description 4
- NYGWORNZHMGAOD-UHFFFAOYSA-N 5-[6-(4-chlorophenyl)hex-5-ynyl]-5-(4-methoxyphenyl)sulfanyl-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1SC1(CCCCC#CC=2C=CC(Cl)=CC=2)C(=O)NC(=O)S1 NYGWORNZHMGAOD-UHFFFAOYSA-N 0.000 claims description 4
- 201000009273 Endometriosis Diseases 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 206010027476 Metastases Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 230000033115 angiogenesis Effects 0.000 claims description 4
- 230000006907 apoptotic process Effects 0.000 claims description 4
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 4
- 235000010290 biphenyl Nutrition 0.000 claims description 4
- 239000004305 biphenyl Substances 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 230000009401 metastasis Effects 0.000 claims description 4
- ALCYUBGHVFSCJM-UHFFFAOYSA-N methyl 4-[5-[5-(4-methoxyphenyl)sulfonyl-2,4-dioxo-1,3-thiazolidin-5-yl]pent-1-ynyl]-3-methylbenzoate Chemical compound CC1=CC(C(=O)OC)=CC=C1C#CCCCC1(S(=O)(=O)C=2C=CC(OC)=CC=2)C(=O)NC(=O)S1 ALCYUBGHVFSCJM-UHFFFAOYSA-N 0.000 claims description 4
- 208000037803 restenosis Diseases 0.000 claims description 4
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims description 3
- QBEIZBFRMXQSFP-UHFFFAOYSA-N 2,2-dimethylpropyl 5-[5-[5-(2,2-dimethylpropoxycarbonylamino)-2-methylphenyl]pent-4-ynyl]-5-(4-methoxyphenyl)sulfonyl-2,4-dioxo-1,3-thiazolidine-3-carboxylate Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CCCC#CC=2C(=CC=C(NC(=O)OCC(C)(C)C)C=2)C)C(=O)N(C(=O)OCC(C)(C)C)C(=O)S1 QBEIZBFRMXQSFP-UHFFFAOYSA-N 0.000 claims description 3
- 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 claims description 3
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 3
- IWJYOPBHDQWIPH-UHFFFAOYSA-N 2-methylpropyl 5-(4-methoxyphenyl)sulfonyl-5-[5-[2-methyl-5-(2-methylpropoxycarbonylamino)phenyl]pent-4-ynyl]-2,4-dioxo-1,3-thiazolidine-3-carboxylate Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CCCC#CC=2C(=CC=C(NC(=O)OCC(C)C)C=2)C)C(=O)N(C(=O)OCC(C)C)C(=O)S1 IWJYOPBHDQWIPH-UHFFFAOYSA-N 0.000 claims description 3
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims description 3
- IEIPIBBICUJLMH-UHFFFAOYSA-N 4-[5-[5-(4-methoxyphenyl)sulfonyl-2,4-dioxo-1,3-thiazolidin-5-yl]pent-1-ynyl]-3-methylbenzoic acid Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CCCC#CC=2C(=CC(=CC=2)C(O)=O)C)C(=O)NC(=O)S1 IEIPIBBICUJLMH-UHFFFAOYSA-N 0.000 claims description 3
- BKBROVJYNCYJLA-UHFFFAOYSA-N 5-(4-bromophenyl)sulfonyl-5-(3-phenylprop-2-ynyl)-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(Br)=CC=C1S(=O)(=O)C1(CC#CC=2C=CC=CC=2)C(=O)NC(=O)S1 BKBROVJYNCYJLA-UHFFFAOYSA-N 0.000 claims description 3
- QXNSGTUZSGECLM-UHFFFAOYSA-N 5-(4-bromophenyl)sulfonyl-5-[3-(4-chlorophenyl)prop-2-ynyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(Cl)=CC=C1C#CCC1(S(=O)(=O)C=2C=CC(Br)=CC=2)C(=O)NC(=O)S1 QXNSGTUZSGECLM-UHFFFAOYSA-N 0.000 claims description 3
- OKESHHRFJMEUAB-UHFFFAOYSA-N 5-(4-chlorophenyl)sulfonyl-5-(3-phenylprop-2-ynyl)-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(Cl)=CC=C1S(=O)(=O)C1(CC#CC=2C=CC=CC=2)C(=O)NC(=O)S1 OKESHHRFJMEUAB-UHFFFAOYSA-N 0.000 claims description 3
- OMVWYXBUZMIAOR-UHFFFAOYSA-N 5-(4-chlorophenyl)sulfonyl-5-[3-(4-fluorophenyl)prop-2-ynyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(F)=CC=C1C#CCC1(S(=O)(=O)C=2C=CC(Cl)=CC=2)C(=O)NC(=O)S1 OMVWYXBUZMIAOR-UHFFFAOYSA-N 0.000 claims description 3
- LDHFHLNYYAZFLN-UHFFFAOYSA-N 5-(4-methoxyphenyl)sulfonyl-5-[5-(3-nitrophenyl)pent-4-ynyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CCCC#CC=2C=C(C=CC=2)[N+]([O-])=O)C(=O)NC(=O)S1 LDHFHLNYYAZFLN-UHFFFAOYSA-N 0.000 claims description 3
- MPFPNIKGPDPQDN-UHFFFAOYSA-N 5-(4-methylphenyl)sulfonyl-5-(5-pyridin-3-ylpent-4-ynyl)-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C1(CCCC#CC=2C=NC=CC=2)C(=O)NC(=O)S1 MPFPNIKGPDPQDN-UHFFFAOYSA-N 0.000 claims description 3
- BDROVFVHXMVUHU-UHFFFAOYSA-N 5-(4-methylphenyl)sulfonyl-5-[3-[4-(trifluoromethyl)phenyl]prop-2-ynyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C1(CC#CC=2C=CC(=CC=2)C(F)(F)F)C(=O)NC(=O)S1 BDROVFVHXMVUHU-UHFFFAOYSA-N 0.000 claims description 3
- ROOXCTKKAJUCCY-UHFFFAOYSA-N 5-(benzenesulfonyl)-5-(3-phenylprop-2-ynyl)-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1(S(=O)(=O)C=1C=CC=CC=1)CC#CC1=CC=CC=C1 ROOXCTKKAJUCCY-UHFFFAOYSA-N 0.000 claims description 3
- FMVUYDUOMACAFG-UHFFFAOYSA-N 5-(benzenesulfonyl)-5-[3-(2-chlorophenyl)prop-2-ynyl]-1,3-thiazolidine-2,4-dione Chemical compound ClC1=CC=CC=C1C#CCC1(S(=O)(=O)C=2C=CC=CC=2)C(=O)NC(=O)S1 FMVUYDUOMACAFG-UHFFFAOYSA-N 0.000 claims description 3
- IHEAFIUMBDQQTA-UHFFFAOYSA-N 5-(benzenesulfonyl)-5-[3-(3-chlorophenyl)prop-2-ynyl]-1,3-thiazolidine-2,4-dione Chemical compound ClC1=CC=CC(C#CCC2(C(NC(=O)S2)=O)S(=O)(=O)C=2C=CC=CC=2)=C1 IHEAFIUMBDQQTA-UHFFFAOYSA-N 0.000 claims description 3
- RVWMAMOSQJULBJ-UHFFFAOYSA-N 5-(benzenesulfonyl)-5-[3-(4-chlorophenyl)prop-2-ynyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(Cl)=CC=C1C#CCC1(S(=O)(=O)C=2C=CC=CC=2)C(=O)NC(=O)S1 RVWMAMOSQJULBJ-UHFFFAOYSA-N 0.000 claims description 3
- DVNGMIHOGAUFLG-UHFFFAOYSA-N 5-(benzenesulfonyl)-5-[3-[3,5-bis(trifluoromethyl)phenyl]prop-2-ynyl]-1,3-thiazolidine-2,4-dione Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C#CCC2(C(NC(=O)S2)=O)S(=O)(=O)C=2C=CC=CC=2)=C1 DVNGMIHOGAUFLG-UHFFFAOYSA-N 0.000 claims description 3
- KUSRENFTMMHVFQ-UHFFFAOYSA-N 5-(benzenesulfonyl)-5-[3-[4-(trifluoromethyl)phenyl]prop-2-ynyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(C(F)(F)F)=CC=C1C#CCC1(S(=O)(=O)C=2C=CC=CC=2)C(=O)NC(=O)S1 KUSRENFTMMHVFQ-UHFFFAOYSA-N 0.000 claims description 3
- SREMLRTUXDZPSO-HWKANZROSA-N 5-[(e)-5-(4-chlorophenyl)pent-4-enyl]-5-(4-methoxyphenyl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CCC\C=C\C=2C=CC(Cl)=CC=2)C(=O)NC(=O)S1 SREMLRTUXDZPSO-HWKANZROSA-N 0.000 claims description 3
- APVYCIPJDDAQCW-HYXAFXHYSA-N 5-[(z)-5-(4-chlorophenyl)pent-4-enyl]-5-(4-methylphenyl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C1(CCC\C=C/C=2C=CC(Cl)=CC=2)C(=O)NC(=O)S1 APVYCIPJDDAQCW-HYXAFXHYSA-N 0.000 claims description 3
- RKOPZYQJSWBFEL-UHFFFAOYSA-N 5-[3-(4-bromophenyl)prop-2-ynyl]-5-(4-chlorophenyl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(Cl)=CC=C1S(=O)(=O)C1(CC#CC=2C=CC(Br)=CC=2)C(=O)NC(=O)S1 RKOPZYQJSWBFEL-UHFFFAOYSA-N 0.000 claims description 3
- LXBRWNLPUFPAPP-UHFFFAOYSA-N 5-[3-(4-bromophenyl)prop-2-ynyl]-5-(4-methylphenyl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C1(CC#CC=2C=CC(Br)=CC=2)C(=O)NC(=O)S1 LXBRWNLPUFPAPP-UHFFFAOYSA-N 0.000 claims description 3
- XAFCGCVWZIDXCQ-UHFFFAOYSA-N 5-[3-(4-chlorophenyl)prop-2-ynyl]-5-(3-methylphenyl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound CC1=CC=CC(S(=O)(=O)C2(CC#CC=3C=CC(Cl)=CC=3)C(NC(=O)S2)=O)=C1 XAFCGCVWZIDXCQ-UHFFFAOYSA-N 0.000 claims description 3
- JFAFTOPGNJYGRP-UHFFFAOYSA-N 5-[3-(4-chlorophenyl)prop-2-ynyl]-5-(4-chlorophenyl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(Cl)=CC=C1C#CCC1(S(=O)(=O)C=2C=CC(Cl)=CC=2)C(=O)NC(=O)S1 JFAFTOPGNJYGRP-UHFFFAOYSA-N 0.000 claims description 3
- QOPWFNWEJMXARH-UHFFFAOYSA-N 5-[3-(4-chlorophenyl)prop-2-ynyl]-5-(4-fluorophenyl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(F)=CC=C1S(=O)(=O)C1(CC#CC=2C=CC(Cl)=CC=2)C(=O)NC(=O)S1 QOPWFNWEJMXARH-UHFFFAOYSA-N 0.000 claims description 3
- RNOFKNJMHCBTMY-UHFFFAOYSA-N 5-[3-(4-chlorophenyl)prop-2-ynyl]-5-(4-methylphenyl)sulfanyl-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(C)=CC=C1SC1(CC#CC=2C=CC(Cl)=CC=2)C(=O)NC(=O)S1 RNOFKNJMHCBTMY-UHFFFAOYSA-N 0.000 claims description 3
- TUFCYHGFXGQXSK-UHFFFAOYSA-N 5-[3-(4-chlorophenyl)prop-2-ynyl]-5-quinolin-2-ylsulfonyl-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(Cl)=CC=C1C#CCC1(S(=O)(=O)C=2N=C3C=CC=CC3=CC=2)C(=O)NC(=O)S1 TUFCYHGFXGQXSK-UHFFFAOYSA-N 0.000 claims description 3
- ZXDJTDZZPISHKM-UHFFFAOYSA-N 5-[3-(4-chlorophenyl)propyl]-5-(4-methoxyphenyl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CCCC=2C=CC(Cl)=CC=2)C(=O)NC(=O)S1 ZXDJTDZZPISHKM-UHFFFAOYSA-N 0.000 claims description 3
- QDEQVYZREAPDEL-UHFFFAOYSA-N 5-[3-(4-fluorophenyl)prop-2-ynyl]-5-(4-methylphenyl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C1(CC#CC=2C=CC(F)=CC=2)C(=O)NC(=O)S1 QDEQVYZREAPDEL-UHFFFAOYSA-N 0.000 claims description 3
- CWQSORDQXICIIT-UHFFFAOYSA-N 5-[3-(4-methoxyphenyl)prop-2-ynyl]-5-(4-methylphenyl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1C#CCC1(S(=O)(=O)C=2C=CC(C)=CC=2)C(=O)NC(=O)S1 CWQSORDQXICIIT-UHFFFAOYSA-N 0.000 claims description 3
- UXZJDVJEMOIBBO-UHFFFAOYSA-N 5-[3-(4-methylphenyl)prop-2-ynyl]-5-(4-methylphenyl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(C)=CC=C1C#CCC1(S(=O)(=O)C=2C=CC(C)=CC=2)C(=O)NC(=O)S1 UXZJDVJEMOIBBO-UHFFFAOYSA-N 0.000 claims description 3
- OUFSZBXOGHJJCV-UHFFFAOYSA-N 5-[3-[3,5-bis(trifluoromethyl)phenyl]prop-2-ynyl]-1,3-thiazolidine-2,4-dione Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C#CCC2C(NC(=O)S2)=O)=C1 OUFSZBXOGHJJCV-UHFFFAOYSA-N 0.000 claims description 3
- BOVXWKHZDQLIPM-UHFFFAOYSA-N 5-[3-[3,5-bis(trifluoromethyl)phenyl]prop-2-ynyl]-5-(4-methylphenyl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C1(CC#CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C(=O)NC(=O)S1 BOVXWKHZDQLIPM-UHFFFAOYSA-N 0.000 claims description 3
- WOQLRSOASWDNMU-UHFFFAOYSA-N 5-[5-(2,5-dichlorophenyl)pent-4-ynyl]-5-(4-methoxyphenyl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CCCC#CC=2C(=CC=C(Cl)C=2)Cl)C(=O)NC(=O)S1 WOQLRSOASWDNMU-UHFFFAOYSA-N 0.000 claims description 3
- OUPXDBJMWRSHSF-UHFFFAOYSA-N 5-[5-(2,5-dichlorophenyl)pent-4-ynyl]-5-(4-pyridin-4-yloxyphenyl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound ClC1=CC=C(Cl)C(C#CCCCC2(C(NC(=O)S2)=O)S(=O)(=O)C=2C=CC(OC=3C=CN=CC=3)=CC=2)=C1 OUPXDBJMWRSHSF-UHFFFAOYSA-N 0.000 claims description 3
- GJYITEKMHHVCLB-UHFFFAOYSA-N 5-[5-(3-aminophenyl)pent-4-ynyl]-5-(4-methoxyphenyl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CCCC#CC=2C=C(N)C=CC=2)C(=O)NC(=O)S1 GJYITEKMHHVCLB-UHFFFAOYSA-N 0.000 claims description 3
- VTGQOIWSUIUZFR-UHFFFAOYSA-N 5-[5-(4-chlorophenyl)pent-4-ynyl]-3-(3-imidazol-1-ylpropyl)-5-(4-methoxyphenyl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CCCC#CC=2C=CC(Cl)=CC=2)C(=O)N(CCCN2C=NC=C2)C(=O)S1 VTGQOIWSUIUZFR-UHFFFAOYSA-N 0.000 claims description 3
- VTZTVKFSUPIGIF-UHFFFAOYSA-N 5-[5-(4-chlorophenyl)pent-4-ynyl]-3-[(2,4-diethoxyphenyl)methyl]-5-(4-methylphenyl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound CCOC1=CC(OCC)=CC=C1CN1C(=O)C(CCCC#CC=2C=CC(Cl)=CC=2)(S(=O)(=O)C=2C=CC(C)=CC=2)SC1=O VTZTVKFSUPIGIF-UHFFFAOYSA-N 0.000 claims description 3
- LBBTUHJUBOHHGJ-UHFFFAOYSA-N 5-[5-(4-chlorophenyl)pent-4-ynyl]-5-(4-fluorophenyl)sulfanyl-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(F)=CC=C1SC1(CCCC#CC=2C=CC(Cl)=CC=2)C(=O)NC(=O)S1 LBBTUHJUBOHHGJ-UHFFFAOYSA-N 0.000 claims description 3
- AWODMFQAMUPOJM-UHFFFAOYSA-N 5-[5-(4-chlorophenyl)pent-4-ynyl]-5-(4-iodophenyl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(Cl)=CC=C1C#CCCCC1(S(=O)(=O)C=2C=CC(I)=CC=2)C(=O)NC(=O)S1 AWODMFQAMUPOJM-UHFFFAOYSA-N 0.000 claims description 3
- TZNXNVFJYOVVNX-UHFFFAOYSA-N 5-[5-(4-chlorophenyl)pent-4-ynyl]-5-(4-iodophenyl)sulfonyl-3-[(4-nitrophenyl)methyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC([N+](=O)[O-])=CC=C1CN1C(=O)C(CCCC#CC=2C=CC(Cl)=CC=2)(S(=O)(=O)C=2C=CC(I)=CC=2)SC1=O TZNXNVFJYOVVNX-UHFFFAOYSA-N 0.000 claims description 3
- XQNIMHLELLGYRA-UHFFFAOYSA-N 5-[5-(4-chlorophenyl)pent-4-ynyl]-5-(4-methoxyphenyl)sulfinyl-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1S(=O)C1(CCCC#CC=2C=CC(Cl)=CC=2)C(=O)NC(=O)S1 XQNIMHLELLGYRA-UHFFFAOYSA-N 0.000 claims description 3
- SIRAIDXUHARUGV-UHFFFAOYSA-N 5-[5-(4-chlorophenyl)pent-4-ynyl]-5-(4-methoxyphenyl)sulfonyl-3-methyl-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CCCC#CC=2C=CC(Cl)=CC=2)C(=O)N(C)C(=O)S1 SIRAIDXUHARUGV-UHFFFAOYSA-N 0.000 claims description 3
- NWSWUHSYHXREGW-UHFFFAOYSA-N 5-[5-(5-amino-2-methylphenyl)pent-4-ynyl]-5-(4-methoxyphenyl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CCCC#CC=2C(=CC=C(N)C=2)C)C(=O)NC(=O)S1 NWSWUHSYHXREGW-UHFFFAOYSA-N 0.000 claims description 3
- XKBWESBOQPOLFU-UHFFFAOYSA-N 5-[6-(4-chlorophenyl)hex-5-ynyl]-5-(4-methoxyphenyl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CCCCC#CC=2C=CC(Cl)=CC=2)C(=O)NC(=O)S1 XKBWESBOQPOLFU-UHFFFAOYSA-N 0.000 claims description 3
- NBFPPUUUEYUKJD-UHFFFAOYSA-N 5-naphthalen-2-ylsulfonyl-5-(3-phenylprop-2-ynyl)-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1(S(=O)(=O)C=1C=C2C=CC=CC2=CC=1)CC#CC1=CC=CC=C1 NBFPPUUUEYUKJD-UHFFFAOYSA-N 0.000 claims description 3
- KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 claims description 3
- IKOLJVSHRADQLN-UHFFFAOYSA-N benzyl 5-(4-methoxyphenyl)sulfonyl-5-[5-[2-methyl-5-(phenylmethoxycarbonylamino)phenyl]pent-4-ynyl]-2,4-dioxo-1,3-thiazolidine-3-carboxylate Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CCCC#CC=2C(=CC=C(NC(=O)OCC=3C=CC=CC=3)C=2)C)C(=O)N(C(=O)OCC=2C=CC=CC=2)C(=O)S1 IKOLJVSHRADQLN-UHFFFAOYSA-N 0.000 claims description 3
- NBWHLGLHUQNKPA-UHFFFAOYSA-N butyl 5-[5-[5-(butoxycarbonylamino)-2-methylphenyl]pent-4-ynyl]-5-(4-methoxyphenyl)sulfonyl-2,4-dioxo-1,3-thiazolidine-3-carboxylate Chemical compound CCCCOC(=O)NC1=CC=C(C)C(C#CCCCC2(C(N(C(=O)OCCCC)C(=O)S2)=O)S(=O)(=O)C=2C=CC(OC)=CC=2)=C1 NBWHLGLHUQNKPA-UHFFFAOYSA-N 0.000 claims description 3
- VTOJSGDPNQPUBM-UHFFFAOYSA-N methyl 5-[5-[5-(methoxycarbonylamino)-2-methylphenyl]pent-4-ynyl]-5-(4-methoxyphenyl)sulfonyl-2,4-dioxo-1,3-thiazolidine-3-carboxylate Chemical compound COC(=O)NC1=CC=C(C)C(C#CCCCC2(C(N(C(=O)OC)C(=O)S2)=O)S(=O)(=O)C=2C=CC(OC)=CC=2)=C1 VTOJSGDPNQPUBM-UHFFFAOYSA-N 0.000 claims description 3
- GLKQLFFDAYDJMH-UHFFFAOYSA-N n-[2-(4-chlorophenyl)ethyl]-3-[5-(4-methoxyphenyl)sulfonyl-2,4-dioxo-1,3-thiazolidin-5-yl]propanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CCC(=O)NCCC=2C=CC(Cl)=CC=2)C(=O)NC(=O)S1 GLKQLFFDAYDJMH-UHFFFAOYSA-N 0.000 claims description 3
- 125000006502 nitrobenzyl group Chemical group 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- JSDKFYOISFKYLU-UHFFFAOYSA-N propan-2-yl 5-(4-methoxyphenyl)sulfonyl-5-[5-[2-methyl-5-(propan-2-yloxycarbonylamino)phenyl]pent-4-ynyl]-2,4-dioxo-1,3-thiazolidine-3-carboxylate Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CCCC#CC=2C(=CC=C(NC(=O)OC(C)C)C=2)C)C(=O)N(C(=O)OC(C)C)C(=O)S1 JSDKFYOISFKYLU-UHFFFAOYSA-N 0.000 claims description 3
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims description 3
- 229940080818 propionamide Drugs 0.000 claims description 3
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims description 3
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- VLQRFROFWBBIJE-UHFFFAOYSA-N (4-chlorophenyl) n-[3-[5-[5-(4-methoxyphenyl)sulfonyl-2,4-dioxo-1,3-thiazolidin-5-yl]pent-1-ynyl]-4-methylphenyl]carbamate Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CCCC#CC=2C(=CC=C(NC(=O)OC=3C=CC(Cl)=CC=3)C=2)C)C(=O)NC(=O)S1 VLQRFROFWBBIJE-UHFFFAOYSA-N 0.000 claims description 2
- SDKVROCJCCVMTL-UHFFFAOYSA-N (4-nitrophenyl)methyl n-[3-[5-[5-(4-methoxyphenyl)sulfonyl-2,4-dioxo-1,3-thiazolidin-5-yl]pent-1-ynyl]-4-methylphenyl]carbamate Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CCCC#CC=2C(=CC=C(NC(=O)OCC=3C=CC(=CC=3)[N+]([O-])=O)C=2)C)C(=O)NC(=O)S1 SDKVROCJCCVMTL-UHFFFAOYSA-N 0.000 claims description 2
- QENRLLISEOKDBH-UHFFFAOYSA-N 1-(4-chlorophenyl)-3-[3-[5-[5-(4-methoxyphenyl)sulfonyl-2,4-dioxo-1,3-thiazolidin-5-yl]pent-1-ynyl]-4-methylphenyl]urea Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CCCC#CC=2C(=CC=C(NC(=O)NC=3C=CC(Cl)=CC=3)C=2)C)C(=O)NC(=O)S1 QENRLLISEOKDBH-UHFFFAOYSA-N 0.000 claims description 2
- BRUHKAAQTLBUDT-UHFFFAOYSA-N 1-(4-methoxyphenyl)-3-[3-[5-[5-(4-methoxyphenyl)sulfonyl-2,4-dioxo-1,3-thiazolidin-5-yl]pent-1-ynyl]-4-methylphenyl]urea Chemical compound C1=CC(OC)=CC=C1NC(=O)NC1=CC=C(C)C(C#CCCCC2(C(NC(=O)S2)=O)S(=O)(=O)C=2C=CC(OC)=CC=2)=C1 BRUHKAAQTLBUDT-UHFFFAOYSA-N 0.000 claims description 2
- VEKNBIVRYBEREI-UHFFFAOYSA-N 1-[3-[5-[5-(4-methoxyphenyl)sulfonyl-2,4-dioxo-1,3-thiazolidin-5-yl]pent-1-ynyl]-2-methylphenyl]-3-(4-methylphenyl)urea Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CCCC#CC=2C(=C(NC(=O)NC=3C=CC(C)=CC=3)C=CC=2)C)C(=O)NC(=O)S1 VEKNBIVRYBEREI-UHFFFAOYSA-N 0.000 claims description 2
- TVSMDSPETRFJOG-UHFFFAOYSA-N 1-benzyl-3-[3-[5-[5-(4-methoxyphenyl)sulfonyl-2,4-dioxo-1,3-thiazolidin-5-yl]pent-1-ynyl]-4-methylphenyl]urea Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CCCC#CC=2C(=CC=C(NC(=O)NCC=3C=CC=CC=3)C=2)C)C(=O)NC(=O)S1 TVSMDSPETRFJOG-UHFFFAOYSA-N 0.000 claims description 2
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- HEPAOTBRBCSXGD-UHFFFAOYSA-N 2,2-dimethylpropyl n-[3-[5-[5-(4-methoxyphenyl)sulfonyl-2,4-dioxo-1,3-thiazolidin-5-yl]pent-1-ynyl]-4-methylphenyl]carbamate Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CCCC#CC=2C(=CC=C(NC(=O)OCC(C)(C)C)C=2)C)C(=O)NC(=O)S1 HEPAOTBRBCSXGD-UHFFFAOYSA-N 0.000 claims description 2
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 2
- BSUMHLFAJKSNAC-UHFFFAOYSA-N 4-[5-[5-(4-methoxyphenyl)sulfonyl-2,4-dioxo-1,3-thiazolidin-5-yl]pent-1-ynyl]benzonitrile Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CCCC#CC=2C=CC(=CC=2)C#N)C(=O)NC(=O)S1 BSUMHLFAJKSNAC-UHFFFAOYSA-N 0.000 claims description 2
- FWCNUEVPZBMFFX-UHFFFAOYSA-N 4-chloro-n-[3-[5-[5-(4-methoxyphenyl)sulfonyl-2,4-dioxo-1,3-thiazolidin-5-yl]pent-1-ynyl]-4-methylphenyl]benzamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CCCC#CC=2C(=CC=C(NC(=O)C=3C=CC(Cl)=CC=3)C=2)C)C(=O)NC(=O)S1 FWCNUEVPZBMFFX-UHFFFAOYSA-N 0.000 claims description 2
- XCBLTJJVCDEZSH-UHFFFAOYSA-N 4-methoxy-n-[3-[5-[5-(4-methoxyphenyl)sulfonyl-2,4-dioxo-1,3-thiazolidin-5-yl]pent-1-ynyl]-4-methylphenyl]benzamide Chemical compound C1=CC(OC)=CC=C1C(=O)NC1=CC=C(C)C(C#CCCCC2(C(NC(=O)S2)=O)S(=O)(=O)C=2C=CC(OC)=CC=2)=C1 XCBLTJJVCDEZSH-UHFFFAOYSA-N 0.000 claims description 2
- MWCDDWYHTLLJMF-UHFFFAOYSA-N 4-tert-butyl-n-[3-[5-[5-(4-methoxyphenyl)sulfonyl-2,4-dioxo-1,3-thiazolidin-5-yl]pent-1-ynyl]-4-methylphenyl]benzamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CCCC#CC=2C(=CC=C(NC(=O)C=3C=CC(=CC=3)C(C)(C)C)C=2)C)C(=O)NC(=O)S1 MWCDDWYHTLLJMF-UHFFFAOYSA-N 0.000 claims description 2
- KAJMRTMAASEEIJ-UHFFFAOYSA-N 5-(3-methoxyphenyl)sulfonyl-5-(5-thiophen-2-ylpent-4-ynyl)-1,3-thiazolidine-2,4-dione Chemical compound COC1=CC=CC(S(=O)(=O)C2(CCCC#CC=3SC=CC=3)C(NC(=O)S2)=O)=C1 KAJMRTMAASEEIJ-UHFFFAOYSA-N 0.000 claims description 2
- UGQNVLJHUQIKRA-UHFFFAOYSA-N 5-(4-butoxyphenyl)sulfonyl-5-[5-(4-chlorophenyl)pent-4-ynyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(OCCCC)=CC=C1S(=O)(=O)C1(CCCC#CC=2C=CC(Cl)=CC=2)C(=O)NC(=O)S1 UGQNVLJHUQIKRA-UHFFFAOYSA-N 0.000 claims description 2
- AGPMHAMSTULYMP-UHFFFAOYSA-N 5-(4-fluorophenyl)sulfonyl-5-[3-[4-(trifluoromethyl)phenyl]prop-2-ynyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(F)=CC=C1S(=O)(=O)C1(CC#CC=2C=CC(=CC=2)C(F)(F)F)C(=O)NC(=O)S1 AGPMHAMSTULYMP-UHFFFAOYSA-N 0.000 claims description 2
- OZCSLPMVKJVZFJ-UHFFFAOYSA-N 5-(4-methoxyphenyl)sulfanyl-5-(5-thiophen-2-ylpent-4-ynyl)-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1SC1(CCCC#CC=2SC=CC=2)C(=O)NC(=O)S1 OZCSLPMVKJVZFJ-UHFFFAOYSA-N 0.000 claims description 2
- KFXQZSVPWWIJAN-UHFFFAOYSA-N 5-(4-methoxyphenyl)sulfonyl-5-(3-pyridin-3-ylprop-2-ynyl)-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CC#CC=2C=NC=CC=2)C(=O)NC(=O)S1 KFXQZSVPWWIJAN-UHFFFAOYSA-N 0.000 claims description 2
- ANZGAXPCBNFYNS-UHFFFAOYSA-N 5-(4-methoxyphenyl)sulfonyl-5-(5-thiophen-2-ylpent-4-ynyl)-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CCCC#CC=2SC=CC=2)C(=O)NC(=O)S1 ANZGAXPCBNFYNS-UHFFFAOYSA-N 0.000 claims description 2
- QTVGOAFLOHFYNF-UHFFFAOYSA-N 5-(4-methoxyphenyl)sulfonyl-5-[3-(4-phenylphenyl)prop-2-ynyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CC#CC=2C=CC(=CC=2)C=2C=CC=CC=2)C(=O)NC(=O)S1 QTVGOAFLOHFYNF-UHFFFAOYSA-N 0.000 claims description 2
- HRILNVCUCQKRJO-UHFFFAOYSA-N 5-(4-methoxyphenyl)sulfonyl-5-[5-(2-methyl-4-nitrophenyl)pent-4-ynyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CCCC#CC=2C(=CC(=CC=2)[N+]([O-])=O)C)C(=O)NC(=O)S1 HRILNVCUCQKRJO-UHFFFAOYSA-N 0.000 claims description 2
- HTEJJLOXCZWPCA-UHFFFAOYSA-N 5-(4-methoxyphenyl)sulfonyl-5-[5-(2-methyl-5-nitrophenyl)pent-4-ynyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CCCC#CC=2C(=CC=C(C=2)[N+]([O-])=O)C)C(=O)NC(=O)S1 HTEJJLOXCZWPCA-UHFFFAOYSA-N 0.000 claims description 2
- VDFPFTUCHRBMQM-UHFFFAOYSA-N 5-(4-methoxyphenyl)sulfonyl-5-[5-(4-nitrophenyl)pent-4-ynyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CCCC#CC=2C=CC(=CC=2)[N+]([O-])=O)C(=O)NC(=O)S1 VDFPFTUCHRBMQM-UHFFFAOYSA-N 0.000 claims description 2
- GFIKRMKRQYLQBL-UHFFFAOYSA-N 5-(4-methoxyphenyl)sulfonyl-5-[5-(4-pyrrol-1-ylphenyl)pent-4-ynyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CCCC#CC=2C=CC(=CC=2)N2C=CC=C2)C(=O)NC(=O)S1 GFIKRMKRQYLQBL-UHFFFAOYSA-N 0.000 claims description 2
- DWMRPVBMXWXXHC-UHFFFAOYSA-N 5-(4-methoxyphenyl)sulfonyl-5-[5-[4-(trifluoromethoxy)phenyl]pent-4-ynyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CCCC#CC=2C=CC(OC(F)(F)F)=CC=2)C(=O)NC(=O)S1 DWMRPVBMXWXXHC-UHFFFAOYSA-N 0.000 claims description 2
- DEWVDBQUMCKUAP-UHFFFAOYSA-N 5-(4-methoxyphenyl)sulfonyl-5-[5-[4-(trifluoromethyl)phenyl]pent-4-ynyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CCCC#CC=2C=CC(=CC=2)C(F)(F)F)C(=O)NC(=O)S1 DEWVDBQUMCKUAP-UHFFFAOYSA-N 0.000 claims description 2
- VNLHDLZMZDKCAJ-UHFFFAOYSA-N 5-(4-methylphenyl)sulfonyl-5-(3-thiophen-2-ylprop-2-ynyl)-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C1(CC#CC=2SC=CC=2)C(=O)NC(=O)S1 VNLHDLZMZDKCAJ-UHFFFAOYSA-N 0.000 claims description 2
- JUZFVSCHOFVQKO-UHFFFAOYSA-N 5-(4-methylphenyl)sulfonyl-5-(5-thiophen-2-ylpent-4-ynyl)-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C1(CCCC#CC=2SC=CC=2)C(=O)NC(=O)S1 JUZFVSCHOFVQKO-UHFFFAOYSA-N 0.000 claims description 2
- REPXKBXNHNZCDM-UHFFFAOYSA-N 5-(4-methylphenyl)sulfonyl-5-[3-(4-phenoxyphenyl)prop-2-ynyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C1(CC#CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C(=O)NC(=O)S1 REPXKBXNHNZCDM-UHFFFAOYSA-N 0.000 claims description 2
- NVMQXXOAVBIUSO-UHFFFAOYSA-N 5-(4-methylphenyl)sulfonyl-5-[3-(4-phenylphenyl)prop-2-ynyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C1(CC#CC=2C=CC(=CC=2)C=2C=CC=CC=2)C(=O)NC(=O)S1 NVMQXXOAVBIUSO-UHFFFAOYSA-N 0.000 claims description 2
- BPTQILBVBDNOJE-UHFFFAOYSA-N 5-(4-methylphenyl)sulfonyl-5-[5-(4-methylsulfonylphenyl)pent-4-ynyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C1(CCCC#CC=2C=CC(=CC=2)S(C)(=O)=O)C(=O)NC(=O)S1 BPTQILBVBDNOJE-UHFFFAOYSA-N 0.000 claims description 2
- HBAWOVUMHCDOOK-UHFFFAOYSA-N 5-(5-chlorothiophen-2-yl)sulfonyl-5-[5-(2,5-dichlorophenyl)pent-4-ynyl]-1,3-thiazolidine-2,4-dione Chemical compound S1C(Cl)=CC=C1S(=O)(=O)C1(CCCC#CC=2C(=CC=C(Cl)C=2)Cl)C(=O)NC(=O)S1 HBAWOVUMHCDOOK-UHFFFAOYSA-N 0.000 claims description 2
- PQYNGDIWIJHGBW-UHFFFAOYSA-N 5-[11-(4-chlorophenyl)undec-10-ynyl]-5-(4-methoxyphenyl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CCCCCCCCCC#CC=2C=CC(Cl)=CC=2)C(=O)NC(=O)S1 PQYNGDIWIJHGBW-UHFFFAOYSA-N 0.000 claims description 2
- QMKHRCILSDRQCT-UHFFFAOYSA-N 5-[3-(3-chlorophenyl)prop-2-ynyl]-5-(4-methylphenyl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C1(CC#CC=2C=C(Cl)C=CC=2)C(=O)NC(=O)S1 QMKHRCILSDRQCT-UHFFFAOYSA-N 0.000 claims description 2
- TXOGIXYYOJWPFV-UHFFFAOYSA-N 5-[5-(2,4-dichlorophenyl)pent-4-ynyl]-5-(4-methoxyphenyl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CCCC#CC=2C(=CC(Cl)=CC=2)Cl)C(=O)NC(=O)S1 TXOGIXYYOJWPFV-UHFFFAOYSA-N 0.000 claims description 2
- QDODWLFRDRRSBH-UHFFFAOYSA-N 5-[5-(2,4-dimethylphenyl)pent-4-ynyl]-5-(4-iodophenyl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound CC1=CC(C)=CC=C1C#CCCCC1(S(=O)(=O)C=2C=CC(I)=CC=2)C(=O)NC(=O)S1 QDODWLFRDRRSBH-UHFFFAOYSA-N 0.000 claims description 2
- DBLOMUSTVPHFPD-UHFFFAOYSA-N 5-[5-(2,4-dimethylphenyl)pent-4-ynyl]-5-(4-methoxyphenyl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CCCC#CC=2C(=CC(C)=CC=2)C)C(=O)NC(=O)S1 DBLOMUSTVPHFPD-UHFFFAOYSA-N 0.000 claims description 2
- XVWYYMZCRKZKPT-UHFFFAOYSA-N 5-[5-(2,5-dichlorophenyl)pent-4-ynyl]-5-(3,4-dimethoxyphenyl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound C1=C(OC)C(OC)=CC=C1S(=O)(=O)C1(CCCC#CC=2C(=CC=C(Cl)C=2)Cl)C(=O)NC(=O)S1 XVWYYMZCRKZKPT-UHFFFAOYSA-N 0.000 claims description 2
- KHGRFXLEXKTADY-UHFFFAOYSA-N 5-[5-(2,5-dichlorophenyl)pent-4-ynyl]-5-(4-iodophenyl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound ClC1=CC=C(Cl)C(C#CCCCC2(C(NC(=O)S2)=O)S(=O)(=O)C=2C=CC(I)=CC=2)=C1 KHGRFXLEXKTADY-UHFFFAOYSA-N 0.000 claims description 2
- COTJXUIMHXMWID-UHFFFAOYSA-N 5-[5-(2,5-dichlorophenyl)pent-4-ynyl]-5-thiophen-2-ylsulfonyl-1,3-thiazolidine-2,4-dione Chemical compound ClC1=CC=C(Cl)C(C#CCCCC2(C(NC(=O)S2)=O)S(=O)(=O)C=2SC=CC=2)=C1 COTJXUIMHXMWID-UHFFFAOYSA-N 0.000 claims description 2
- QNUWDQMIOJNBAT-UHFFFAOYSA-N 5-[5-(2,5-dimethylphenyl)pent-4-ynyl]-5-(4-iodophenyl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound CC1=CC=C(C)C(C#CCCCC2(C(NC(=O)S2)=O)S(=O)(=O)C=2C=CC(I)=CC=2)=C1 QNUWDQMIOJNBAT-UHFFFAOYSA-N 0.000 claims description 2
- ZZQGDNAHCACPRN-UHFFFAOYSA-N 5-[5-(2,5-dimethylphenyl)pent-4-ynyl]-5-(4-methoxyphenyl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CCCC#CC=2C(=CC=C(C)C=2)C)C(=O)NC(=O)S1 ZZQGDNAHCACPRN-UHFFFAOYSA-N 0.000 claims description 2
- YFADQIBDADUQSO-UHFFFAOYSA-N 5-[5-(2-chlorophenyl)pent-4-ynyl]-5-(4-methoxyphenyl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CCCC#CC=2C(=CC=CC=2)Cl)C(=O)NC(=O)S1 YFADQIBDADUQSO-UHFFFAOYSA-N 0.000 claims description 2
- RGCBDMKGGNGDSK-UHFFFAOYSA-N 5-[5-(2-methoxy-4-nitrophenyl)pent-4-ynyl]-5-(4-methoxyphenyl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CCCC#CC=2C(=CC(=CC=2)[N+]([O-])=O)OC)C(=O)NC(=O)S1 RGCBDMKGGNGDSK-UHFFFAOYSA-N 0.000 claims description 2
- QMZPBBNBDLMTRG-UHFFFAOYSA-N 5-[5-(2-methoxy-5-nitrophenyl)pent-4-ynyl]-5-(4-methoxyphenyl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CCCC#CC=2C(=CC=C(C=2)[N+]([O-])=O)OC)C(=O)NC(=O)S1 QMZPBBNBDLMTRG-UHFFFAOYSA-N 0.000 claims description 2
- LIXJNLREGRQUPR-UHFFFAOYSA-N 5-[5-(2-methyl-4-nitrophenyl)pent-4-ynyl]-5-(4-phenoxyphenyl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound CC1=CC([N+]([O-])=O)=CC=C1C#CCCCC1(S(=O)(=O)C=2C=CC(OC=3C=CC=CC=3)=CC=2)C(=O)NC(=O)S1 LIXJNLREGRQUPR-UHFFFAOYSA-N 0.000 claims description 2
- QEGQAOWLWINNME-UHFFFAOYSA-N 5-[5-(2-methyl-4-nitrophenyl)pent-4-ynyl]-5-(4-pyridin-4-yloxyphenyl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound CC1=CC([N+]([O-])=O)=CC=C1C#CCCCC1(S(=O)(=O)C=2C=CC(OC=3C=CN=CC=3)=CC=2)C(=O)NC(=O)S1 QEGQAOWLWINNME-UHFFFAOYSA-N 0.000 claims description 2
- DACPEWQSMYCDQI-UHFFFAOYSA-N 5-[5-(2-methyl-5-nitrophenyl)pent-4-ynyl]-5-(4-phenoxyphenyl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound CC1=CC=C([N+]([O-])=O)C=C1C#CCCCC1(S(=O)(=O)C=2C=CC(OC=3C=CC=CC=3)=CC=2)C(=O)NC(=O)S1 DACPEWQSMYCDQI-UHFFFAOYSA-N 0.000 claims description 2
- FMTSEJXASOAPKG-UHFFFAOYSA-N 5-[5-(2-methyl-5-nitrophenyl)pent-4-ynyl]-5-naphthalen-1-ylsulfonyl-1,3-thiazolidine-2,4-dione Chemical compound CC1=CC=C([N+]([O-])=O)C=C1C#CCCCC1(S(=O)(=O)C=2C3=CC=CC=C3C=CC=2)C(=O)NC(=O)S1 FMTSEJXASOAPKG-UHFFFAOYSA-N 0.000 claims description 2
- YYNFORHRYGXQTQ-UHFFFAOYSA-N 5-[5-(2-methyl-5-nitrophenyl)pent-4-ynyl]-5-naphthalen-2-ylsulfonyl-1,3-thiazolidine-2,4-dione Chemical compound CC1=CC=C([N+]([O-])=O)C=C1C#CCCCC1(S(=O)(=O)C=2C=C3C=CC=CC3=CC=2)C(=O)NC(=O)S1 YYNFORHRYGXQTQ-UHFFFAOYSA-N 0.000 claims description 2
- OYCXAHHKFJNBDZ-UHFFFAOYSA-N 5-[5-(3-chlorophenyl)pent-4-ynyl]-5-(4-methoxyphenyl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CCCC#CC=2C=C(Cl)C=CC=2)C(=O)NC(=O)S1 OYCXAHHKFJNBDZ-UHFFFAOYSA-N 0.000 claims description 2
- RKUWMBJNEYFNIR-UHFFFAOYSA-N 5-[5-(3-fluoro-5-nitrophenyl)pent-4-ynyl]-5-(4-methoxyphenyl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CCCC#CC=2C=C(C=C(F)C=2)[N+]([O-])=O)C(=O)NC(=O)S1 RKUWMBJNEYFNIR-UHFFFAOYSA-N 0.000 claims description 2
- SQFGBWALCNONTK-UHFFFAOYSA-N 5-[5-(3-nitrophenyl)pent-4-ynyl]-5-(4-phenoxyphenyl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound [O-][N+](=O)C1=CC=CC(C#CCCCC2(C(NC(=O)S2)=O)S(=O)(=O)C=2C=CC(OC=3C=CC=CC=3)=CC=2)=C1 SQFGBWALCNONTK-UHFFFAOYSA-N 0.000 claims description 2
- FTZBQCLAXRBCHK-UHFFFAOYSA-N 5-[5-(4-bromo-2-methylphenyl)pent-4-ynyl]-5-(4-iodophenyl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound CC1=CC(Br)=CC=C1C#CCCCC1(S(=O)(=O)C=2C=CC(I)=CC=2)C(=O)NC(=O)S1 FTZBQCLAXRBCHK-UHFFFAOYSA-N 0.000 claims description 2
- HENDWKXTANTHCN-UHFFFAOYSA-N 5-[5-(4-chloro-2-methylphenyl)pent-4-ynyl]-5-(4-iodophenyl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound CC1=CC(Cl)=CC=C1C#CCCCC1(S(=O)(=O)C=2C=CC(I)=CC=2)C(=O)NC(=O)S1 HENDWKXTANTHCN-UHFFFAOYSA-N 0.000 claims description 2
- KDPUBZAHMNDXIQ-UHFFFAOYSA-N 5-[5-(4-chloro-2-methylphenyl)pent-4-ynyl]-5-(4-methoxyphenyl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CCCC#CC=2C(=CC(Cl)=CC=2)C)C(=O)NC(=O)S1 KDPUBZAHMNDXIQ-UHFFFAOYSA-N 0.000 claims description 2
- DBBIZEBWHXQAPO-UHFFFAOYSA-N 5-[5-(4-chloro-2-methylphenyl)pent-4-ynyl]-5-[4-(trifluoromethoxy)phenyl]sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound CC1=CC(Cl)=CC=C1C#CCCCC1(S(=O)(=O)C=2C=CC(OC(F)(F)F)=CC=2)C(=O)NC(=O)S1 DBBIZEBWHXQAPO-UHFFFAOYSA-N 0.000 claims description 2
- ZAZFNLGFDARPOP-UHFFFAOYSA-N 5-[5-(4-chlorophenyl)pent-4-ynyl]-5-(3,4-dimethoxyphenyl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound C1=C(OC)C(OC)=CC=C1S(=O)(=O)C1(CCCC#CC=2C=CC(Cl)=CC=2)C(=O)NC(=O)S1 ZAZFNLGFDARPOP-UHFFFAOYSA-N 0.000 claims description 2
- CKWSUJFPOMCPCN-UHFFFAOYSA-N 5-[5-(4-chlorophenyl)pent-4-ynyl]-5-(4-fluorophenyl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(F)=CC=C1S(=O)(=O)C1(CCCC#CC=2C=CC(Cl)=CC=2)C(=O)NC(=O)S1 CKWSUJFPOMCPCN-UHFFFAOYSA-N 0.000 claims description 2
- DHLPWBNKGWZHGH-UHFFFAOYSA-N 5-[5-(4-chlorophenyl)pent-4-ynyl]-5-(4-nitrophenyl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)C1(CCCC#CC=2C=CC(Cl)=CC=2)C(=O)NC(=O)S1 DHLPWBNKGWZHGH-UHFFFAOYSA-N 0.000 claims description 2
- KTHRFGDHJRBXAQ-UHFFFAOYSA-N 5-[5-(4-chlorophenyl)pent-4-ynyl]-5-(4-phenoxyphenyl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(Cl)=CC=C1C#CCCCC1(S(=O)(=O)C=2C=CC(OC=3C=CC=CC=3)=CC=2)C(=O)NC(=O)S1 KTHRFGDHJRBXAQ-UHFFFAOYSA-N 0.000 claims description 2
- UNLLDTUXUKXYSX-UHFFFAOYSA-N 5-[5-(4-chlorophenyl)pent-4-ynyl]-5-(4-phenylmethoxyphenyl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(Cl)=CC=C1C#CCCCC1(S(=O)(=O)C=2C=CC(OCC=3C=CC=CC=3)=CC=2)C(=O)NC(=O)S1 UNLLDTUXUKXYSX-UHFFFAOYSA-N 0.000 claims description 2
- YKMJQYRYAWMCSA-UHFFFAOYSA-N 5-[5-(4-chlorophenyl)pent-4-ynyl]-5-(4-pyridin-4-yloxyphenyl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(Cl)=CC=C1C#CCCCC1(S(=O)(=O)C=2C=CC(OC=3C=CN=CC=3)=CC=2)C(=O)NC(=O)S1 YKMJQYRYAWMCSA-UHFFFAOYSA-N 0.000 claims description 2
- JTTGEHUEYHPLBS-UHFFFAOYSA-N 5-[5-(4-chlorophenyl)pent-4-ynyl]-5-(5-chlorothiophen-2-yl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound S1C(Cl)=CC=C1S(=O)(=O)C1(CCCC#CC=2C=CC(Cl)=CC=2)C(=O)NC(=O)S1 JTTGEHUEYHPLBS-UHFFFAOYSA-N 0.000 claims description 2
- ARTRQUPRVCTVRH-UHFFFAOYSA-N 5-[5-(4-chlorophenyl)pent-4-ynyl]-5-(5-pyridin-2-ylthiophen-2-yl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(Cl)=CC=C1C#CCCCC1(S(=O)(=O)C=2SC(=CC=2)C=2N=CC=CC=2)C(=O)NC(=O)S1 ARTRQUPRVCTVRH-UHFFFAOYSA-N 0.000 claims description 2
- YQYAEAJYALGHHF-UHFFFAOYSA-N 5-[5-(4-chlorophenyl)pent-4-ynyl]-5-naphthalen-1-ylsulfonyl-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(Cl)=CC=C1C#CCCCC1(S(=O)(=O)C=2C3=CC=CC=C3C=CC=2)C(=O)NC(=O)S1 YQYAEAJYALGHHF-UHFFFAOYSA-N 0.000 claims description 2
- BHOXDWCYLGKLNX-UHFFFAOYSA-N 5-[5-(4-chlorophenyl)pent-4-ynyl]-5-naphthalen-2-ylsulfonyl-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(Cl)=CC=C1C#CCCCC1(S(=O)(=O)C=2C=C3C=CC=CC3=CC=2)C(=O)NC(=O)S1 BHOXDWCYLGKLNX-UHFFFAOYSA-N 0.000 claims description 2
- DUPPDGWWSIOBDR-UHFFFAOYSA-N 5-[5-(4-chlorophenyl)pent-4-ynyl]-5-quinolin-8-ylsulfonyl-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(Cl)=CC=C1C#CCCCC1(S(=O)(=O)C=2C3=NC=CC=C3C=CC=2)C(=O)NC(=O)S1 DUPPDGWWSIOBDR-UHFFFAOYSA-N 0.000 claims description 2
- VPAYUNHGVSAIKT-UHFFFAOYSA-N 5-[5-(4-chlorophenyl)pent-4-ynyl]-5-thiophen-2-ylsulfonyl-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(Cl)=CC=C1C#CCCCC1(S(=O)(=O)C=2SC=CC=2)C(=O)NC(=O)S1 VPAYUNHGVSAIKT-UHFFFAOYSA-N 0.000 claims description 2
- XUYFWZZLUSUDDP-UHFFFAOYSA-N 5-[5-(4-pyrrol-1-ylphenyl)pent-4-ynyl]-5-[4-(trifluoromethoxy)phenyl]sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(OC(F)(F)F)=CC=C1S(=O)(=O)C1(CCCC#CC=2C=CC(=CC=2)N2C=CC=C2)C(=O)NC(=O)S1 XUYFWZZLUSUDDP-UHFFFAOYSA-N 0.000 claims description 2
- KRWOSHUGCSLCKO-UHFFFAOYSA-N 5-[5-(4-tert-butylphenyl)pent-4-ynyl]-5-(4-methoxyphenyl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CCCC#CC=2C=CC(=CC=2)C(C)(C)C)C(=O)NC(=O)S1 KRWOSHUGCSLCKO-UHFFFAOYSA-N 0.000 claims description 2
- IJWQASFSRTVHLN-UHFFFAOYSA-N 5-[5-(4-tert-butylphenyl)pent-4-ynyl]-5-(4-methylphenyl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C1(CCCC#CC=2C=CC(=CC=2)C(C)(C)C)C(=O)NC(=O)S1 IJWQASFSRTVHLN-UHFFFAOYSA-N 0.000 claims description 2
- SMVKVVDMJKOSLB-UHFFFAOYSA-N 5-[5-(5-chloro-2-methylphenyl)pent-4-ynyl]-5-(4-methoxyphenyl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CCCC#CC=2C(=CC=C(Cl)C=2)C)C(=O)NC(=O)S1 SMVKVVDMJKOSLB-UHFFFAOYSA-N 0.000 claims description 2
- BYLUFHPGNVBSAE-UHFFFAOYSA-N 5-[5-(5-chloro-2-methylphenyl)pent-4-ynyl]-5-[4-(trifluoromethoxy)phenyl]sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound CC1=CC=C(Cl)C=C1C#CCCCC1(S(=O)(=O)C=2C=CC(OC(F)(F)F)=CC=2)C(=O)NC(=O)S1 BYLUFHPGNVBSAE-UHFFFAOYSA-N 0.000 claims description 2
- AZHYYXZWHSRJPD-UHFFFAOYSA-N butyl n-[3-[5-[5-(4-methoxyphenyl)sulfonyl-2,4-dioxo-1,3-thiazolidin-5-yl]pent-1-ynyl]-4-methylphenyl]carbamate Chemical compound CCCCOC(=O)NC1=CC=C(C)C(C#CCCCC2(C(NC(=O)S2)=O)S(=O)(=O)C=2C=CC(OC)=CC=2)=C1 AZHYYXZWHSRJPD-UHFFFAOYSA-N 0.000 claims description 2
- 125000005392 carboxamide group Chemical group NC(=O)* 0.000 claims description 2
- LPHAWMRZQHQCGV-UHFFFAOYSA-N methyl 3-[5-[5-(4-methoxyphenyl)sulfonyl-2,4-dioxo-1,3-thiazolidin-5-yl]pent-1-ynyl]-4-methylbenzoate Chemical compound COC(=O)C1=CC=C(C)C(C#CCCCC2(C(NC(=O)S2)=O)S(=O)(=O)C=2C=CC(OC)=CC=2)=C1 LPHAWMRZQHQCGV-UHFFFAOYSA-N 0.000 claims description 2
- VTPOTHFMQIZLKZ-UHFFFAOYSA-N methyl n-[3-[5-[5-(4-methoxyphenyl)sulfonyl-2,4-dioxo-1,3-thiazolidin-5-yl]pent-1-ynyl]-4-methylphenyl]carbamate Chemical compound COC(=O)NC1=CC=C(C)C(C#CCCCC2(C(NC(=O)S2)=O)S(=O)(=O)C=2C=CC(OC)=CC=2)=C1 VTPOTHFMQIZLKZ-UHFFFAOYSA-N 0.000 claims description 2
- 208000025113 myeloid leukemia Diseases 0.000 claims description 2
- WNOQLHSRWSSAQB-UHFFFAOYSA-N n-[3-[5-[5-(4-methoxyphenyl)sulfonyl-2,4-dioxo-1,3-thiazolidin-5-yl]pent-1-ynyl]-4-methylphenyl]-2,2-dimethylpropanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CCCC#CC=2C(=CC=C(NC(=O)C(C)(C)C)C=2)C)C(=O)NC(=O)S1 WNOQLHSRWSSAQB-UHFFFAOYSA-N 0.000 claims description 2
- JHLHVKMNGDZAIU-UHFFFAOYSA-N n-[3-[5-[5-(4-methoxyphenyl)sulfonyl-2,4-dioxo-1,3-thiazolidin-5-yl]pent-1-ynyl]-4-methylphenyl]-2-methylpropanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CCCC#CC=2C(=CC=C(NC(=O)C(C)C)C=2)C)C(=O)NC(=O)S1 JHLHVKMNGDZAIU-UHFFFAOYSA-N 0.000 claims description 2
- WFKNSRGELOUWRP-UHFFFAOYSA-N n-[3-[5-[5-(4-methoxyphenyl)sulfonyl-2,4-dioxo-1,3-thiazolidin-5-yl]pent-1-ynyl]-4-methylphenyl]-2-phenylacetamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CCCC#CC=2C(=CC=C(NC(=O)CC=3C=CC=CC=3)C=2)C)C(=O)NC(=O)S1 WFKNSRGELOUWRP-UHFFFAOYSA-N 0.000 claims description 2
- BYNZWLNTLBKGGJ-UHFFFAOYSA-N n-[3-[5-[5-(4-methoxyphenyl)sulfonyl-2,4-dioxo-1,3-thiazolidin-5-yl]pent-1-ynyl]-4-methylphenyl]-3,3-dimethylbutanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CCCC#CC=2C(=CC=C(NC(=O)CC(C)(C)C)C=2)C)C(=O)NC(=O)S1 BYNZWLNTLBKGGJ-UHFFFAOYSA-N 0.000 claims description 2
- PCECRBQVZFEPGM-UHFFFAOYSA-N n-[3-[5-[5-(4-methoxyphenyl)sulfonyl-2,4-dioxo-1,3-thiazolidin-5-yl]pent-1-ynyl]-4-methylphenyl]-4-phenylbenzamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CCCC#CC=2C(=CC=C(NC(=O)C=3C=CC(=CC=3)C=3C=CC=CC=3)C=2)C)C(=O)NC(=O)S1 PCECRBQVZFEPGM-UHFFFAOYSA-N 0.000 claims description 2
- JHDGAOUASBOJDW-UHFFFAOYSA-N n-[4-[[5-[5-(4-chlorophenyl)pent-4-ynyl]-2,4-dioxo-1,3-thiazolidin-5-yl]sulfonyl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1S(=O)(=O)C1(CCCC#CC=2C=CC(Cl)=CC=2)C(=O)NC(=O)S1 JHDGAOUASBOJDW-UHFFFAOYSA-N 0.000 claims description 2
- WQULJSNGHUDPCM-UHFFFAOYSA-N n-tert-butyl-3-[5-(2,4-dioxo-5-thiophen-2-ylsulfonyl-1,3-thiazolidin-5-yl)pent-1-ynyl]-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC(C)(C)C)C=C1C#CCCCC1(S(=O)(=O)C=2SC=CC=2)C(=O)NC(=O)S1 WQULJSNGHUDPCM-UHFFFAOYSA-N 0.000 claims description 2
- ZDNSBAHELURNQX-UHFFFAOYSA-N n-tert-butyl-3-[5-[2,4-dioxo-5-(5-pyridin-2-ylthiophen-2-yl)sulfonyl-1,3-thiazolidin-5-yl]pent-1-ynyl]-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC(C)(C)C)C=C1C#CCCCC1(S(=O)(=O)C=2SC(=CC=2)C=2N=CC=CC=2)C(=O)NC(=O)S1 ZDNSBAHELURNQX-UHFFFAOYSA-N 0.000 claims description 2
- LKPHEYOKDVFGQA-UHFFFAOYSA-N n-tert-butyl-3-[5-[5-(3,4-dimethoxyphenyl)sulfonyl-2,4-dioxo-1,3-thiazolidin-5-yl]pent-1-ynyl]-4-methylbenzamide Chemical compound C1=C(OC)C(OC)=CC=C1S(=O)(=O)C1(CCCC#CC=2C(=CC=C(C=2)C(=O)NC(C)(C)C)C)C(=O)NC(=O)S1 LKPHEYOKDVFGQA-UHFFFAOYSA-N 0.000 claims description 2
- KNPLQHRZCSQBHA-UHFFFAOYSA-N n-tert-butyl-3-[5-[5-(4-iodophenyl)sulfonyl-2,4-dioxo-1,3-thiazolidin-5-yl]pent-1-ynyl]-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC(C)(C)C)C=C1C#CCCCC1(S(=O)(=O)C=2C=CC(I)=CC=2)C(=O)NC(=O)S1 KNPLQHRZCSQBHA-UHFFFAOYSA-N 0.000 claims description 2
- SLAVSEFBGYEOLZ-UHFFFAOYSA-N n-tert-butyl-3-[5-[5-(5-chlorothiophen-2-yl)sulfonyl-2,4-dioxo-1,3-thiazolidin-5-yl]pent-1-ynyl]-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC(C)(C)C)C=C1C#CCCCC1(S(=O)(=O)C=2SC(Cl)=CC=2)C(=O)NC(=O)S1 SLAVSEFBGYEOLZ-UHFFFAOYSA-N 0.000 claims description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 2
- HHCCNPIFAMHGFL-UHFFFAOYSA-N propan-2-yl n-[3-[5-[5-(4-methoxyphenyl)sulfonyl-2,4-dioxo-1,3-thiazolidin-5-yl]pent-1-ynyl]-4-methylphenyl]carbamate Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CCCC#CC=2C(=CC=C(NC(=O)OC(C)C)C=2)C)C(=O)NC(=O)S1 HHCCNPIFAMHGFL-UHFFFAOYSA-N 0.000 claims description 2
- KLTZCMORAALMPG-UHFFFAOYSA-N tert-butyl n-[3-[5-(2,4-dioxo-5-thiophen-2-ylsulfonyl-1,3-thiazolidin-5-yl)pent-1-ynyl]-4-methylphenyl]carbamate Chemical compound CC1=CC=C(NC(=O)OC(C)(C)C)C=C1C#CCCCC1(S(=O)(=O)C=2SC=CC=2)C(=O)NC(=O)S1 KLTZCMORAALMPG-UHFFFAOYSA-N 0.000 claims description 2
- QUQABFMQFNGOML-UHFFFAOYSA-N tert-butyl n-[3-[5-[2,4-dioxo-5-(4-pyridin-4-yloxyphenyl)sulfonyl-1,3-thiazolidin-5-yl]pent-1-ynyl]-4-methylphenyl]carbamate Chemical compound CC1=CC=C(NC(=O)OC(C)(C)C)C=C1C#CCCCC1(S(=O)(=O)C=2C=CC(OC=3C=CN=CC=3)=CC=2)C(=O)NC(=O)S1 QUQABFMQFNGOML-UHFFFAOYSA-N 0.000 claims description 2
- OFJMYKXJCFXWHC-UHFFFAOYSA-N tert-butyl n-[3-[5-[5-(3,4-dimethoxyphenyl)sulfonyl-2,4-dioxo-1,3-thiazolidin-5-yl]pent-1-ynyl]-4-methylphenyl]carbamate Chemical compound C1=C(OC)C(OC)=CC=C1S(=O)(=O)C1(CCCC#CC=2C(=CC=C(NC(=O)OC(C)(C)C)C=2)C)C(=O)NC(=O)S1 OFJMYKXJCFXWHC-UHFFFAOYSA-N 0.000 claims description 2
- ZOWJACKLOSWLPK-UHFFFAOYSA-N tert-butyl n-[3-[5-[5-(4-methoxyphenyl)sulfonyl-2,4-dioxo-1,3-thiazolidin-5-yl]pent-1-ynyl]-4-methylphenyl]carbamate Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CCCC#CC=2C(=CC=C(NC(=O)OC(C)(C)C)C=2)C)C(=O)NC(=O)S1 ZOWJACKLOSWLPK-UHFFFAOYSA-N 0.000 claims description 2
- RPNJUTOJPJFIEP-UHFFFAOYSA-N tert-butyl n-[3-[5-[5-(5-chlorothiophen-2-yl)sulfonyl-2,4-dioxo-1,3-thiazolidin-5-yl]pent-1-ynyl]-4-methylphenyl]carbamate Chemical compound CC1=CC=C(NC(=O)OC(C)(C)C)C=C1C#CCCCC1(S(=O)(=O)C=2SC(Cl)=CC=2)C(=O)NC(=O)S1 RPNJUTOJPJFIEP-UHFFFAOYSA-N 0.000 claims description 2
- VNXQKINJXFIDHY-UHFFFAOYSA-N tert-butyl n-[3-chloro-4-[5-[5-(4-methoxyphenyl)sulfonyl-2,4-dioxo-1,3-thiazolidin-5-yl]pent-1-ynyl]phenyl]carbamate Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CCCC#CC=2C(=CC(NC(=O)OC(C)(C)C)=CC=2)Cl)C(=O)NC(=O)S1 VNXQKINJXFIDHY-UHFFFAOYSA-N 0.000 claims description 2
- BZPJMBJMIULLAA-UHFFFAOYSA-N tert-butyl n-[4-[5-[5-(4-methoxyphenyl)sulfonyl-2,4-dioxo-1,3-thiazolidin-5-yl]pent-1-ynyl]-3-(trifluoromethyl)phenyl]carbamate Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CCCC#CC=2C(=CC(NC(=O)OC(C)(C)C)=CC=2)C(F)(F)F)C(=O)NC(=O)S1 BZPJMBJMIULLAA-UHFFFAOYSA-N 0.000 claims description 2
- OOOUVCFQXCQSNT-UHFFFAOYSA-N tert-butyl n-[4-[5-[5-(4-methoxyphenyl)sulfonyl-2,4-dioxo-1,3-thiazolidin-5-yl]pent-1-ynyl]-3-methylphenyl]carbamate Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CCCC#CC=2C(=CC(NC(=O)OC(C)(C)C)=CC=2)C)C(=O)NC(=O)S1 OOOUVCFQXCQSNT-UHFFFAOYSA-N 0.000 claims description 2
- GJGKKHISENJBCQ-UHFFFAOYSA-N tert-butyl n-[4-[5-[5-(4-methoxyphenyl)sulfonyl-2,4-dioxo-1,3-thiazolidin-5-yl]pent-1-ynyl]phenyl]carbamate Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CCCC#CC=2C=CC(NC(=O)OC(C)(C)C)=CC=2)C(=O)NC(=O)S1 GJGKKHISENJBCQ-UHFFFAOYSA-N 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 16
- CDKLKEPURKVTMB-UHFFFAOYSA-N benzyl n-[3-[5-[5-(4-methoxyphenyl)sulfonyl-2,4-dioxo-1,3-thiazolidin-5-yl]pent-1-ynyl]-4-methylphenyl]carbamate Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CCCC#CC=2C(=CC=C(NC(=O)OCC=3C=CC=CC=3)C=2)C)C(=O)NC(=O)S1 CDKLKEPURKVTMB-UHFFFAOYSA-N 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 210000002615 epidermis Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 108700042226 ras Genes Proteins 0.000 abstract description 14
- 230000001419 dependent effect Effects 0.000 abstract description 9
- 239000003112 inhibitor Substances 0.000 abstract description 7
- 238000011275 oncology therapy Methods 0.000 abstract description 2
- 0 [6*]N1C(=O)SC(C[Ar])(C[W]C)C1=O Chemical compound [6*]N1C(=O)SC(C[Ar])(C[W]C)C1=O 0.000 description 40
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 39
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 35
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 34
- 239000000243 solution Substances 0.000 description 32
- OVJGYUVBHOVELE-UHFFFAOYSA-N CC(C)C#CC(C)C Chemical compound CC(C)C#CC(C)C OVJGYUVBHOVELE-UHFFFAOYSA-N 0.000 description 31
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 29
- 108010014186 ras Proteins Proteins 0.000 description 27
- 102000016914 ras Proteins Human genes 0.000 description 27
- 239000007787 solid Substances 0.000 description 27
- 238000006243 chemical reaction Methods 0.000 description 24
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 23
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 229910001868 water Inorganic materials 0.000 description 20
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- 239000000047 product Substances 0.000 description 18
- 239000002585 base Substances 0.000 description 17
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 16
- 150000002431 hydrogen Chemical group 0.000 description 16
- 239000002904 solvent Substances 0.000 description 16
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 15
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
- 235000019441 ethanol Nutrition 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- CRWVOXFUXPYTRK-UHFFFAOYSA-N pent-4-yn-1-ol Chemical compound OCCCC#C CRWVOXFUXPYTRK-UHFFFAOYSA-N 0.000 description 14
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 13
- 239000003921 oil Substances 0.000 description 13
- 235000019198 oils Nutrition 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 229910052708 sodium Inorganic materials 0.000 description 12
- 239000011734 sodium Substances 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 12
- 239000000741 silica gel Substances 0.000 description 11
- 229910002027 silica gel Inorganic materials 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 10
- 229960000583 acetic acid Drugs 0.000 description 10
- 229910052783 alkali metal Inorganic materials 0.000 description 10
- 150000001345 alkine derivatives Chemical class 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 8
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 235000019439 ethyl acetate Nutrition 0.000 description 8
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
- 150000001412 amines Chemical class 0.000 description 7
- 230000001276 controlling effect Effects 0.000 description 7
- 239000013078 crystal Substances 0.000 description 7
- DOUHZFSGSXMPIE-UHFFFAOYSA-N hydroxidooxidosulfur(.) Chemical class [O]SO DOUHZFSGSXMPIE-UHFFFAOYSA-N 0.000 description 7
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 230000029936 alkylation Effects 0.000 description 6
- 238000005804 alkylation reaction Methods 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- 125000002346 iodo group Chemical group I* 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- KRBBGMOONSUDGO-UHFFFAOYSA-N 5-bromo-1,3-thiazolidine-2,4-dione Chemical compound BrC1SC(=O)NC1=O KRBBGMOONSUDGO-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 150000001336 alkenes Chemical class 0.000 description 5
- 125000001246 bromo group Chemical group Br* 0.000 description 5
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Substances [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 231100000590 oncogenic Toxicity 0.000 description 5
- 230000002246 oncogenic effect Effects 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 229910000104 sodium hydride Inorganic materials 0.000 description 5
- 235000009518 sodium iodide Nutrition 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 238000010998 test method Methods 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- GDDKNALPTLBPFL-UHFFFAOYSA-N 1-chloro-4-(5-iodopent-1-ynyl)benzene Chemical compound ClC1=CC=C(C#CCCCI)C=C1 GDDKNALPTLBPFL-UHFFFAOYSA-N 0.000 description 4
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 4
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 4
- 101710113436 GTPase KRas Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- AMIMRNSIRUDHCM-UHFFFAOYSA-N Isopropylaldehyde Chemical compound CC(C)C=O AMIMRNSIRUDHCM-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 150000001340 alkali metals Chemical class 0.000 description 4
- 239000002168 alkylating agent Substances 0.000 description 4
- 229940100198 alkylating agent Drugs 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 4
- 230000005595 deprotonation Effects 0.000 description 4
- 238000010537 deprotonation reaction Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000012312 sodium hydride Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- GWQSENYKCGJTRI-UHFFFAOYSA-N 1-chloro-4-iodobenzene Chemical compound ClC1=CC=C(I)C=C1 GWQSENYKCGJTRI-UHFFFAOYSA-N 0.000 description 3
- NBZRYYMVXOISGF-UHFFFAOYSA-N 3-(4-phenoxyphenyl)prop-2-yn-1-ol Chemical compound C1=CC(C#CCO)=CC=C1OC1=CC=CC=C1 NBZRYYMVXOISGF-UHFFFAOYSA-N 0.000 description 3
- XXKAOSQHKZFJNA-UHFFFAOYSA-N 5-(2,5-dichlorophenyl)pent-4-yn-1-ol Chemical compound OCCCC#CC1=CC(Cl)=CC=C1Cl XXKAOSQHKZFJNA-UHFFFAOYSA-N 0.000 description 3
- RUJWWUMNBVHHKF-UHFFFAOYSA-N 5-(4-methylphenyl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C1C(=O)NC(=O)S1 RUJWWUMNBVHHKF-UHFFFAOYSA-N 0.000 description 3
- GIDRTJSLUOIWKG-UHFFFAOYSA-N 5-(4-methylsulfonylphenyl)pent-4-yn-1-ol Chemical compound CS(=O)(=O)C1=CC=C(C#CCCCO)C=C1 GIDRTJSLUOIWKG-UHFFFAOYSA-N 0.000 description 3
- 102000030782 GTP binding Human genes 0.000 description 3
- 108091000058 GTP-Binding Proteins 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 102100026379 Neurofibromin Human genes 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 101150040459 RAS gene Proteins 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 3
- 150000008046 alkali metal hydrides Chemical class 0.000 description 3
- 150000001503 aryl iodides Chemical class 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 3
- 125000005805 dimethoxy phenyl group Chemical group 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 3
- 125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 125000006501 nitrophenyl group Chemical group 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000013823 prenylation Effects 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- ZKSJISOFWIPFIJ-UHFFFAOYSA-N (4-nitrophenyl)methyl 5-(4-methoxyphenyl)sulfonyl-5-[5-[2-methyl-5-[(4-nitrophenyl)methoxycarbonylamino]phenyl]pent-4-ynyl]-2,4-dioxo-1,3-thiazolidine-3-carboxylate Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CCCC#CC=2C(=CC=C(NC(=O)OCC=3C=CC(=CC=3)[N+]([O-])=O)C=2)C)C(=O)N(C(=O)OCC=2C=CC(=CC=2)[N+]([O-])=O)C(=O)S1 ZKSJISOFWIPFIJ-UHFFFAOYSA-N 0.000 description 2
- GETTZEONDQJALK-UHFFFAOYSA-N (trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC=C1 GETTZEONDQJALK-UHFFFAOYSA-N 0.000 description 2
- WOCIJDOYSFIRGC-UHFFFAOYSA-N 3-(4-methylphenyl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C(=O)SCC1=O WOCIJDOYSFIRGC-UHFFFAOYSA-N 0.000 description 2
- GUAIUFBDFGVULL-UHFFFAOYSA-N 3-(4-phenoxyphenyl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1S(=O)(=O)C(C=C1)=CC=C1OC1=CC=CC=C1 GUAIUFBDFGVULL-UHFFFAOYSA-N 0.000 description 2
- AWPOGWOBQAXYFP-UHFFFAOYSA-N 3-naphthalen-2-ylsulfonyl-1,3-thiazolidine-2,4-dione Chemical compound C1=C(C=CC2=CC=CC=C12)S(=O)(=O)N1C(SCC1=O)=O AWPOGWOBQAXYFP-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- VJPPLCNBDLZIFG-ZDUSSCGKSA-N 4-[(3S)-3-(but-2-ynoylamino)piperidin-1-yl]-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide Chemical class C(C#CC)(=O)N[C@@H]1CN(CCC1)C1=C2C(=C(NC2=C(C=C1F)C(=O)N)C)C VJPPLCNBDLZIFG-ZDUSSCGKSA-N 0.000 description 2
- LUOTVZDPBXZBIM-UHFFFAOYSA-N 5-(4-chlorophenyl)pent-4-yn-1-ol Chemical compound OCCCC#CC1=CC=C(Cl)C=C1 LUOTVZDPBXZBIM-UHFFFAOYSA-N 0.000 description 2
- RTAKEQJENIMEIM-UHFFFAOYSA-N 5-(4-methoxyphenyl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1C(=O)NC(=O)S1 RTAKEQJENIMEIM-UHFFFAOYSA-N 0.000 description 2
- ATMJQKWDKRZZPU-UHFFFAOYSA-N 5-(4-methylphenyl)sulfonyl-5-pent-4-ynyl-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C1(CCCC#C)C(=O)NC(=O)S1 ATMJQKWDKRZZPU-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 241000167854 Bourreria succulenta Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 108091006027 G proteins Proteins 0.000 description 2
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 2
- 102100039788 GTPase NRas Human genes 0.000 description 2
- 108091006109 GTPases Proteins 0.000 description 2
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 2
- YBIMKXARZPMCJM-UHFFFAOYSA-N Ic1ccc(cc1)[S](=O)=O Chemical group Ic1ccc(cc1)[S](=O)=O YBIMKXARZPMCJM-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920003091 Methocel™ Polymers 0.000 description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 2
- BNUHAJGCKIQFGE-UHFFFAOYSA-N Nitroanisol Chemical compound COC1=CC=C([N+]([O-])=O)C=C1 BNUHAJGCKIQFGE-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 102000043276 Oncogene Human genes 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 229940123464 Thiazolidinedione Drugs 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- JBVNMOALBOAVRM-UHFFFAOYSA-N [N].O=C1CSC(=O)N1 Chemical group [N].O=C1CSC(=O)N1 JBVNMOALBOAVRM-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 150000001499 aryl bromides Chemical class 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 150000001540 azides Chemical class 0.000 description 2
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzenecarbonitrile Natural products N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 2
- PUJDIJCNWFYVJX-UHFFFAOYSA-N benzyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1 PUJDIJCNWFYVJX-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 2
- QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000000423 cell based assay Methods 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000019693 cherries Nutrition 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 2
- 230000006126 farnesylation Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- GOQJMMHTSOQIEI-UHFFFAOYSA-N hex-5-yn-1-ol Chemical compound OCCCCC#C GOQJMMHTSOQIEI-UHFFFAOYSA-N 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- GTCAXTIRRLKXRU-UHFFFAOYSA-N methyl carbamate Chemical compound COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000017095 negative regulation of cell growth Effects 0.000 description 2
- PPSSQRUPSRPZON-UHFFFAOYSA-N nitrobenzene;sodium Chemical compound [Na].[O-][N+](=O)C1=CC=CC=C1 PPSSQRUPSRPZON-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 2
- 230000020477 pH reduction Effects 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- TVDSBUOJIPERQY-UHFFFAOYSA-N prop-2-yn-1-ol Chemical compound OCC#C TVDSBUOJIPERQY-UHFFFAOYSA-N 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000003457 sulfones Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- FQFILJKFZCVHNH-UHFFFAOYSA-N tert-butyl n-[3-[(5-bromo-2-chloropyrimidin-4-yl)amino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNC1=NC(Cl)=NC=C1Br FQFILJKFZCVHNH-UHFFFAOYSA-N 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- 125000003944 tolyl group Chemical group 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- GVURYEOXXOUZQP-UHFFFAOYSA-N (2,4-diethoxyphenyl)methanol Chemical compound CCOC1=CC=C(CO)C(OCC)=C1 GVURYEOXXOUZQP-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- DOMQFIFVDIAOOT-ROUUACIJSA-N (2S,3R)-N-[4-(2,6-dimethoxyphenyl)-5-(5-methylpyridin-3-yl)-1,2,4-triazol-3-yl]-3-(5-methylpyrimidin-2-yl)butane-2-sulfonamide Chemical compound COC1=C(C(=CC=C1)OC)N1C(=NN=C1C=1C=NC=C(C=1)C)NS(=O)(=O)[C@@H](C)[C@H](C)C1=NC=C(C=N1)C DOMQFIFVDIAOOT-ROUUACIJSA-N 0.000 description 1
- CCENBZDJMALWCH-UHFFFAOYSA-N (4-chlorophenyl) carbamate Chemical compound NC(=O)OC1=CC=C(Cl)C=C1 CCENBZDJMALWCH-UHFFFAOYSA-N 0.000 description 1
- YMVFJGSXZNNUDW-UHFFFAOYSA-N (4-chlorophenyl)methanamine Chemical compound NCC1=CC=C(Cl)C=C1 YMVFJGSXZNNUDW-UHFFFAOYSA-N 0.000 description 1
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
- ZXTJDYFCIHHIHN-UHFFFAOYSA-N *.CC#CC.CC#CC.CI.CI.[H]C#CC Chemical compound *.CC#CC.CC#CC.CI.CI.[H]C#CC ZXTJDYFCIHHIHN-UHFFFAOYSA-N 0.000 description 1
- VEFLKXRACNJHOV-UHFFFAOYSA-N 1,3-dibromopropane Chemical compound BrCCCBr VEFLKXRACNJHOV-UHFFFAOYSA-N 0.000 description 1
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 1
- BNPHXZAEXOFELH-UHFFFAOYSA-N 1,4-dichloro-2-(5-iodopent-1-ynyl)benzene Chemical compound ClC1=CC=C(Cl)C(C#CCCCI)=C1 BNPHXZAEXOFELH-UHFFFAOYSA-N 0.000 description 1
- SBHVNORGKIPGCL-UHFFFAOYSA-N 1,4-dichloro-2-iodobenzene Chemical compound ClC1=CC=C(Cl)C(I)=C1 SBHVNORGKIPGCL-UHFFFAOYSA-N 0.000 description 1
- HHKBAIVAQIIXGU-UHFFFAOYSA-N 1-(3-bromoprop-1-ynyl)-4-phenoxybenzene Chemical compound C1=CC(C#CCBr)=CC=C1OC1=CC=CC=C1 HHKBAIVAQIIXGU-UHFFFAOYSA-N 0.000 description 1
- FJLFSYRGFJDJMQ-UHFFFAOYSA-N 1-bromo-4-methylsulfonylbenzene Chemical compound CS(=O)(=O)C1=CC=C(Br)C=C1 FJLFSYRGFJDJMQ-UHFFFAOYSA-N 0.000 description 1
- PKJBWOWQJHHAHG-UHFFFAOYSA-N 1-bromo-4-phenylbenzene Chemical group C1=CC(Br)=CC=C1C1=CC=CC=C1 PKJBWOWQJHHAHG-UHFFFAOYSA-N 0.000 description 1
- CGHIBGNXEGJPQZ-UHFFFAOYSA-N 1-hexyne Chemical compound CCCCC#C CGHIBGNXEGJPQZ-UHFFFAOYSA-N 0.000 description 1
- SDCNPJGBYJVXAS-UHFFFAOYSA-N 11-(4-chlorophenyl)undec-10-yn-1-ol Chemical compound OCCCCCCCCCC#CC1=CC=C(Cl)C=C1 SDCNPJGBYJVXAS-UHFFFAOYSA-N 0.000 description 1
- SRXFXCKTIGELTI-UHFFFAOYSA-N 2-(4-chlorophenyl)ethanamine Chemical compound NCCC1=CC=C(Cl)C=C1 SRXFXCKTIGELTI-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- TUCRZHGAIRVWTI-UHFFFAOYSA-N 2-bromothiophene Chemical compound BrC1=CC=CS1 TUCRZHGAIRVWTI-UHFFFAOYSA-N 0.000 description 1
- CFBYEGUGFPZCNF-UHFFFAOYSA-N 2-nitroanisole Chemical compound COC1=CC=CC=C1[N+]([O-])=O CFBYEGUGFPZCNF-UHFFFAOYSA-N 0.000 description 1
- VWFJDQUYCIWHTN-YFVJMOTDSA-N 2-trans,6-trans-farnesyl diphosphate Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CO[P@](O)(=O)OP(O)(O)=O VWFJDQUYCIWHTN-YFVJMOTDSA-N 0.000 description 1
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
- SODXALJKSMLDEQ-UHFFFAOYSA-N 3-(3-bromopropyl)-5-[5-(4-chlorophenyl)pent-4-ynyl]-5-(4-methoxyphenyl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CCCC#CC=2C=CC(Cl)=CC=2)C(=O)N(CCCBr)C(=O)S1 SODXALJKSMLDEQ-UHFFFAOYSA-N 0.000 description 1
- MMSVPQJJHFFDTB-UHFFFAOYSA-N 3-(4-phenylphenyl)prop-2-yn-1-ol Chemical compound C1=CC(C#CCO)=CC=C1C1=CC=CC=C1 MMSVPQJJHFFDTB-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- KKGSVSCZDIMBQC-UHFFFAOYSA-N 3-[(2,4-diethoxyphenyl)methyl]-5-(4-methylphenyl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound CCOC1=CC(OCC)=CC=C1CN1C(=O)C(S(=O)(=O)C=2C=CC(C)=CC=2)SC1=O KKGSVSCZDIMBQC-UHFFFAOYSA-N 0.000 description 1
- YGYGASJNJTYNOL-CQSZACIVSA-N 3-[(4r)-2,2-dimethyl-1,1-dioxothian-4-yl]-5-(4-fluorophenyl)-1h-indole-7-carboxamide Chemical compound C1CS(=O)(=O)C(C)(C)C[C@@H]1C1=CNC2=C(C(N)=O)C=C(C=3C=CC(F)=CC=3)C=C12 YGYGASJNJTYNOL-CQSZACIVSA-N 0.000 description 1
- ZNXNYVRBRIMYEU-UHFFFAOYSA-N 3-bromo-1,3-thiazolidine-2,4-dione Chemical compound BrN1C(=O)CSC1=O ZNXNYVRBRIMYEU-UHFFFAOYSA-N 0.000 description 1
- RUROFEVDCUGKHD-UHFFFAOYSA-N 3-bromoprop-1-enylbenzene Chemical compound BrCC=CC1=CC=CC=C1 RUROFEVDCUGKHD-UHFFFAOYSA-N 0.000 description 1
- KBRSJPHSCOAFDR-UHFFFAOYSA-N 3-chloro-6-methyl-5,5-dioxo-11h-benzo[c][2,1]benzothiazepin-11-ol Chemical compound O=S1(=O)N(C)C2=CC=CC=C2C(O)C2=CC=C(Cl)C=C21 KBRSJPHSCOAFDR-UHFFFAOYSA-N 0.000 description 1
- QMVAZEHZOPDGHA-UHFFFAOYSA-N 3-methoxybenzenethiol Chemical compound COC1=CC=CC(S)=C1 QMVAZEHZOPDGHA-UHFFFAOYSA-N 0.000 description 1
- CXKUWYCLLJMOQJ-UHFFFAOYSA-N 3-naphthalen-1-ylsulfonyl-1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1S(=O)(=O)C1=CC=CC2=CC=CC=C12 CXKUWYCLLJMOQJ-UHFFFAOYSA-N 0.000 description 1
- SVYGRAAJWLKOCZ-UHFFFAOYSA-N 3-thiophen-2-ylprop-2-yn-1-ol Chemical compound OCC#CC1=CC=CS1 SVYGRAAJWLKOCZ-UHFFFAOYSA-N 0.000 description 1
- OKIHXNKYYGUVTE-UHFFFAOYSA-N 4-Fluorothiophenol Chemical compound FC1=CC=C(S)C=C1 OKIHXNKYYGUVTE-UHFFFAOYSA-N 0.000 description 1
- XYWIPYBIIRTJMM-IBGZPJMESA-N 4-[[(2S)-2-[4-[5-chloro-2-[4-(trifluoromethyl)triazol-1-yl]phenyl]-5-methoxy-2-oxopyridin-1-yl]butanoyl]amino]-2-fluorobenzamide Chemical compound CC[C@H](N1C=C(OC)C(=CC1=O)C1=C(C=CC(Cl)=C1)N1C=C(N=N1)C(F)(F)F)C(=O)NC1=CC(F)=C(C=C1)C(N)=O XYWIPYBIIRTJMM-IBGZPJMESA-N 0.000 description 1
- JDUYPUMQALQRCN-UHFFFAOYSA-N 4-bromophenyl phenyl ether Chemical compound C1=CC(Br)=CC=C1OC1=CC=CC=C1 JDUYPUMQALQRCN-UHFFFAOYSA-N 0.000 description 1
- VOLRSQPSJGXRNJ-UHFFFAOYSA-N 4-nitrobenzyl bromide Chemical compound [O-][N+](=O)C1=CC=C(CBr)C=C1 VOLRSQPSJGXRNJ-UHFFFAOYSA-N 0.000 description 1
- ZPTVNYMJQHSSEA-UHFFFAOYSA-N 4-nitrotoluene Chemical compound CC1=CC=C([N+]([O-])=O)C=C1 ZPTVNYMJQHSSEA-UHFFFAOYSA-N 0.000 description 1
- LUQVCHRDAGWYMG-UHFFFAOYSA-N 4-phenylbenzamide Chemical compound C1=CC(C(=O)N)=CC=C1C1=CC=CC=C1 LUQVCHRDAGWYMG-UHFFFAOYSA-N 0.000 description 1
- AVTGAYBULGDEJU-UHFFFAOYSA-N 5-(2,4-dichlorophenyl)pent-4-yn-1-ol Chemical compound OCCCC#CC1=CC=C(Cl)C=C1Cl AVTGAYBULGDEJU-UHFFFAOYSA-N 0.000 description 1
- DZQUQJCQYUZOGB-UHFFFAOYSA-N 5-(2,4-dimethylphenyl)pent-4-yn-1-ol Chemical compound CC1=CC=C(C#CCCCO)C(C)=C1 DZQUQJCQYUZOGB-UHFFFAOYSA-N 0.000 description 1
- VCJGMIXNCNEBOV-UHFFFAOYSA-N 5-(2,5-dimethylphenyl)pent-4-yn-1-ol Chemical compound CC1=CC=C(C)C(C#CCCCO)=C1 VCJGMIXNCNEBOV-UHFFFAOYSA-N 0.000 description 1
- HFPNVXOMGUVSLF-UHFFFAOYSA-N 5-(2-chlorophenyl)pent-4-yn-1-ol Chemical compound OCCCC#CC1=CC=CC=C1Cl HFPNVXOMGUVSLF-UHFFFAOYSA-N 0.000 description 1
- WEJNKXSMFOOXGD-UHFFFAOYSA-N 5-(2-methoxy-4-nitrophenyl)pent-4-yn-1-ol Chemical compound COC1=CC([N+]([O-])=O)=CC=C1C#CCCCO WEJNKXSMFOOXGD-UHFFFAOYSA-N 0.000 description 1
- GSUOHAITNYVAGO-UHFFFAOYSA-N 5-(2-methoxy-5-nitrophenyl)pent-4-yn-1-ol Chemical compound COC1=CC=C([N+]([O-])=O)C=C1C#CCCCO GSUOHAITNYVAGO-UHFFFAOYSA-N 0.000 description 1
- DAGWWAJMMUAGFJ-UHFFFAOYSA-N 5-(2-methyl-4-nitrophenyl)pent-4-yn-1-ol Chemical compound CC1=CC([N+]([O-])=O)=CC=C1C#CCCCO DAGWWAJMMUAGFJ-UHFFFAOYSA-N 0.000 description 1
- PDSNTDRXBZZKLA-UHFFFAOYSA-N 5-(2-methyl-5-nitrophenyl)pent-4-yn-1-ol Chemical compound CC1=CC=C([N+]([O-])=O)C=C1C#CCCCO PDSNTDRXBZZKLA-UHFFFAOYSA-N 0.000 description 1
- UTLDUSSDYJEMQU-UHFFFAOYSA-N 5-(3-chlorophenyl)pent-4-yn-1-ol Chemical compound OCCCC#CC1=CC=CC(Cl)=C1 UTLDUSSDYJEMQU-UHFFFAOYSA-N 0.000 description 1
- WTWCLIXHOVDOGM-UHFFFAOYSA-N 5-(3-fluoro-4-methoxy-5-nitrophenyl)pent-4-yn-1-ol Chemical compound COC1=C(F)C=C(C#CCCCO)C=C1[N+]([O-])=O WTWCLIXHOVDOGM-UHFFFAOYSA-N 0.000 description 1
- CDWHWOLAPKYBRQ-UHFFFAOYSA-N 5-(3-fluoro-5-nitrophenyl)pent-4-yn-1-ol Chemical compound OCCCC#CC1=CC(F)=CC([N+]([O-])=O)=C1 CDWHWOLAPKYBRQ-UHFFFAOYSA-N 0.000 description 1
- PJDIKWDELOXEGJ-UHFFFAOYSA-N 5-(4-bromo-2-methylphenyl)pent-4-yn-1-ol Chemical compound CC1=CC(Br)=CC=C1C#CCCCO PJDIKWDELOXEGJ-UHFFFAOYSA-N 0.000 description 1
- OXULIAHJWPCBLY-UHFFFAOYSA-N 5-(4-chloro-2-methylphenyl)pent-4-yn-1-ol Chemical compound CC1=CC(Cl)=CC=C1C#CCCCO OXULIAHJWPCBLY-UHFFFAOYSA-N 0.000 description 1
- HVMUGVFULHLERR-UHFFFAOYSA-N 5-(4-chlorophenyl)pent-4-ynyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCCCC#CC1=CC=C(Cl)C=C1 HVMUGVFULHLERR-UHFFFAOYSA-N 0.000 description 1
- RYTRBUNYHLTXHQ-UHFFFAOYSA-N 5-(4-methoxy-2-nitrophenyl)pent-4-yn-1-ol Chemical compound COC1=CC=C(C#CCCCO)C([N+]([O-])=O)=C1 RYTRBUNYHLTXHQ-UHFFFAOYSA-N 0.000 description 1
- PDCWNHCDHRJJRT-UHFFFAOYSA-N 5-(4-pyrrol-1-ylphenyl)pent-4-yn-1-ol Chemical compound C1=CC(C#CCCCO)=CC=C1N1C=CC=C1 PDCWNHCDHRJJRT-UHFFFAOYSA-N 0.000 description 1
- MEZODOGJGJCHQB-UHFFFAOYSA-N 5-(4-tert-butylphenyl)pent-4-yn-1-ol Chemical compound CC(C)(C)C1=CC=C(C#CCCCO)C=C1 MEZODOGJGJCHQB-UHFFFAOYSA-N 0.000 description 1
- DKZJMCBARFURPZ-UHFFFAOYSA-N 5-(5-chloro-2-methylphenyl)pent-4-yn-1-ol Chemical compound CC1=CC=C(Cl)C=C1C#CCCCO DKZJMCBARFURPZ-UHFFFAOYSA-N 0.000 description 1
- NKXNQTWHGHJVNQ-UHFFFAOYSA-N 5-[1-(4-chlorophenyl)undec-10-ynyl]-5-(4-methoxyphenyl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(C(CCCCCCCCC#C)C=2C=CC(Cl)=CC=2)C(=O)NC(=O)S1 NKXNQTWHGHJVNQ-UHFFFAOYSA-N 0.000 description 1
- APPCQNCDQULMKN-UHFFFAOYSA-N 5-[4-(trifluoromethoxy)phenyl]pent-4-yn-1-ol Chemical compound OCCCC#CC1=CC=C(OC(F)(F)F)C=C1 APPCQNCDQULMKN-UHFFFAOYSA-N 0.000 description 1
- CYEOBVJMECXTLN-UHFFFAOYSA-N 5-[4-(trifluoromethyl)phenyl]pent-4-yn-1-ol Chemical compound OCCCC#CC1=CC=C(C(F)(F)F)C=C1 CYEOBVJMECXTLN-UHFFFAOYSA-N 0.000 description 1
- QVMSOYFSRGOVNY-UHFFFAOYSA-N 5-[4-nitro-2-(trifluoromethyl)phenyl]pent-4-yn-1-ol Chemical compound OCCCC#CC1=CC=C([N+]([O-])=O)C=C1C(F)(F)F QVMSOYFSRGOVNY-UHFFFAOYSA-N 0.000 description 1
- RKZMQOKIWHZNEZ-UHFFFAOYSA-N 5-[5-(2,5-dichlorophenyl)pent-4-ynyl]-5-(5-pyridin-2-ylthiophen-2-yl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound ClC1=CC=C(Cl)C(C#CCCCC2(C(NC(=O)S2)=O)S(=O)(=O)C=2SC(=CC=2)C=2N=CC=CC=2)=C1 RKZMQOKIWHZNEZ-UHFFFAOYSA-N 0.000 description 1
- JSBCBHRTXCTMLL-UHFFFAOYSA-N 5-[5-(4-bromo-2-methylphenyl)pent-4-ynyl]-5-(4-ethoxyphenyl)sulfonyl-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(OCC)=CC=C1S(=O)(=O)C1(CCCC#CC=2C(=CC(Br)=CC=2)C)C(=O)NC(=O)S1 JSBCBHRTXCTMLL-UHFFFAOYSA-N 0.000 description 1
- SEHFYZRHGUPLSY-UHFFFAOYSA-N 5-iodopent-1-yne Chemical compound ICCCC#C SEHFYZRHGUPLSY-UHFFFAOYSA-N 0.000 description 1
- XUFCYFURAWHVSF-UHFFFAOYSA-N 5-naphthalen-1-ylsulfonyl-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1S(=O)(=O)C1=CC=CC2=CC=CC=C12 XUFCYFURAWHVSF-UHFFFAOYSA-N 0.000 description 1
- YICDSXMBUCNLOG-UHFFFAOYSA-N 6-(4-chlorophenyl)hex-5-yn-1-ol Chemical compound OCCCCC#CC1=CC=C(Cl)C=C1 YICDSXMBUCNLOG-UHFFFAOYSA-N 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- FPKKVWZCZGTMRL-UHFFFAOYSA-N C(CCC)OC1=CC=CC=C1.[Na] Chemical compound C(CCC)OC1=CC=CC=C1.[Na] FPKKVWZCZGTMRL-UHFFFAOYSA-N 0.000 description 1
- LMBOKDOJMYWTMA-UHFFFAOYSA-O C=[Al]S(C(C(N1)=O)SC1=O)=O Chemical compound C=[Al]S(C(C(N1)=O)SC1=O)=O LMBOKDOJMYWTMA-UHFFFAOYSA-O 0.000 description 1
- KKCAZDLWJZMPKI-GDNGEXCGSA-N CC.CC#CC[SH]1C(=O)NC(=O)C1S(=O)(=O)[Ar].CCI.[H]/C(C)=C(\[H])C[SH]1C(=O)NC(=O)C1S(=O)(=O)[Ar] Chemical compound CC.CC#CC[SH]1C(=O)NC(=O)C1S(=O)(=O)[Ar].CCI.[H]/C(C)=C(\[H])C[SH]1C(=O)NC(=O)C1S(=O)(=O)[Ar] KKCAZDLWJZMPKI-GDNGEXCGSA-N 0.000 description 1
- FIUFOLDEIAUXTG-UHFFFAOYSA-L CCC.CCC1(S(=O)(=O)[Ar])SC(=O)NC1=O.CCC1(S[Ar])SC(=O)NC1=O.CI.I.I.I[V]I.O=C1NC(=O)C(S[Ar])S1 Chemical compound CCC.CCC1(S(=O)(=O)[Ar])SC(=O)NC1=O.CCC1(S[Ar])SC(=O)NC1=O.CI.I.I.I[V]I.O=C1NC(=O)C(S[Ar])S1 FIUFOLDEIAUXTG-UHFFFAOYSA-L 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010048832 Colon adenoma Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 241000501308 Conus spectrum Species 0.000 description 1
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- VWFJDQUYCIWHTN-UHFFFAOYSA-N Farnesyl pyrophosphate Natural products CC(C)=CCCC(C)=CCCC(C)=CCOP(O)(=O)OP(O)(O)=O VWFJDQUYCIWHTN-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- NEVLIZHAKSODDC-UHFFFAOYSA-H I[V](I)I.O=C1NC(=O)C(Br)S1.O=C1NC(=O)C(S(=O)(=O)[Ar])S1.O=C1NC(=O)C(S(=O)[Ar])S1.O=C1NC(=O)C(S)S1.S.[Ar].[Ar].[V]I.[V]I.[V]I Chemical compound I[V](I)I.O=C1NC(=O)C(Br)S1.O=C1NC(=O)C(S(=O)(=O)[Ar])S1.O=C1NC(=O)C(S(=O)[Ar])S1.O=C1NC(=O)C(S)S1.S.[Ar].[Ar].[V]I.[V]I.[V]I NEVLIZHAKSODDC-UHFFFAOYSA-H 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 241000238367 Mya arenaria Species 0.000 description 1
- FEYNFHSRETUBEM-UHFFFAOYSA-N N-[3-(1,1-difluoroethyl)phenyl]-1-(4-methoxyphenyl)-3-methyl-5-oxo-4H-pyrazole-4-carboxamide Chemical compound COc1ccc(cc1)N1N=C(C)C(C(=O)Nc2cccc(c2)C(C)(F)F)C1=O FEYNFHSRETUBEM-UHFFFAOYSA-N 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- DRBWRJPFNOBNIO-KOLCDFICSA-N [(2r)-1-[(2r)-2-(pyridine-4-carbonylamino)propanoyl]pyrrolidin-2-yl]boronic acid Chemical compound N([C@H](C)C(=O)N1[C@@H](CCC1)B(O)O)C(=O)C1=CC=NC=C1 DRBWRJPFNOBNIO-KOLCDFICSA-N 0.000 description 1
- VZBJSPLZJUFRQU-UHFFFAOYSA-N [3-[5-[5-(4-methoxyphenyl)sulfonyl-2,4-dioxo-1,3-thiazolidin-5-yl]pent-1-ynyl]-4-methylphenyl]carbamic acid Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CCCC#CC=2C(=CC=C(NC(O)=O)C=2)C)C(=O)NC(=O)S1 VZBJSPLZJUFRQU-UHFFFAOYSA-N 0.000 description 1
- KYIKRXIYLAGAKQ-UHFFFAOYSA-N abcn Chemical compound C1CCCCC1(C#N)N=NC1(C#N)CCCCC1 KYIKRXIYLAGAKQ-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000003855 acyl compounds Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002058 anti-hyperglycaemic effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000001504 aryl thiols Chemical class 0.000 description 1
- YCOXTKKNXUZSKD-UHFFFAOYSA-N as-o-xylenol Natural products CC1=CC=C(O)C=C1C YCOXTKKNXUZSKD-UHFFFAOYSA-N 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- NBLAIKHFQBOVPV-UHFFFAOYSA-N bis(ethoxycarbonyl)azaniumylideneazanide Chemical compound CCOC(=O)[N+](=[N-])C(=O)OCC NBLAIKHFQBOVPV-UHFFFAOYSA-N 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- SKKTUOZKZKCGTB-UHFFFAOYSA-N butyl carbamate Chemical compound CCCCOC(N)=O SKKTUOZKZKCGTB-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- DGLFSNZWRYADFC-UHFFFAOYSA-N chembl2334586 Chemical compound C1CCC2=CN=C(N)N=C2C2=C1NC1=CC=C(C#CC(C)(O)C)C=C12 DGLFSNZWRYADFC-UHFFFAOYSA-N 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000007958 cherry flavor Substances 0.000 description 1
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 230000030944 contact inhibition Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- SQKZZFWTOOPCDQ-UHFFFAOYSA-N dichloromethane;ethyl acetate;hexane Chemical compound ClCCl.CCCCCC.CCOC(C)=O SQKZZFWTOOPCDQ-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- SGDINNZGYDHHKM-UHFFFAOYSA-N dilithium;trimethylsilylazanide Chemical compound [Li+].[Li+].C[Si](C)(C)[NH-].C[Si](C)(C)[NH-] SGDINNZGYDHHKM-UHFFFAOYSA-N 0.000 description 1
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Natural products C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- GCFHZZWXZLABBL-UHFFFAOYSA-N ethanol;hexane Chemical compound CCO.CCCCCC GCFHZZWXZLABBL-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- TUHMQDODLHWPCC-UHFFFAOYSA-N formyl cyanide Chemical compound O=CC#N TUHMQDODLHWPCC-UHFFFAOYSA-N 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- GEOVEUCEIQCBKH-UHFFFAOYSA-N hypoiodous acid Chemical compound IO GEOVEUCEIQCBKH-UHFFFAOYSA-N 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000004694 iodide salts Chemical class 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- SNHMUERNLJLMHN-UHFFFAOYSA-N iodobenzene Chemical compound IC1=CC=CC=C1 SNHMUERNLJLMHN-UHFFFAOYSA-N 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000006122 isoprenylation Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- GUWHRJQTTVADPB-UHFFFAOYSA-N lithium azide Chemical compound [Li+].[N-]=[N+]=[N-] GUWHRJQTTVADPB-UHFFFAOYSA-N 0.000 description 1
- DHMTURDWPRKSOA-RUZDIDTESA-N lonafarnib Chemical compound C1CN(C(=O)N)CCC1CC(=O)N1CCC([C@@H]2C3=C(Br)C=C(Cl)C=C3CCC3=CC(Br)=CN=C32)CC1 DHMTURDWPRKSOA-RUZDIDTESA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- OHMTXXGIIHKIKY-UHFFFAOYSA-N methyl 3-(5-hydroxypent-1-ynyl)-4-methylbenzoate Chemical compound COC(=O)C1=CC=C(C)C(C#CCCCO)=C1 OHMTXXGIIHKIKY-UHFFFAOYSA-N 0.000 description 1
- YIYZNTTWHIYCOO-UHFFFAOYSA-N methyl 3-iodopropanoate Chemical compound COC(=O)CCI YIYZNTTWHIYCOO-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- FMASTMURQSHELY-UHFFFAOYSA-N n-(4-fluoro-2-methylphenyl)-3-methyl-n-[(2-methyl-1h-indol-4-yl)methyl]pyridine-4-carboxamide Chemical compound C1=CC=C2NC(C)=CC2=C1CN(C=1C(=CC(F)=CC=1)C)C(=O)C1=CC=NC=C1C FMASTMURQSHELY-UHFFFAOYSA-N 0.000 description 1
- NNKPHNTWNILINE-UHFFFAOYSA-N n-cyclopropyl-3-fluoro-4-methyl-5-[3-[[1-[2-[2-(methylamino)ethoxy]phenyl]cyclopropyl]amino]-2-oxopyrazin-1-yl]benzamide Chemical compound CNCCOC1=CC=CC=C1C1(NC=2C(N(C=3C(=C(F)C=C(C=3)C(=O)NC3CC3)C)C=CN=2)=O)CC1 NNKPHNTWNILINE-UHFFFAOYSA-N 0.000 description 1
- GNGKNPMEWGQQSY-UHFFFAOYSA-N n-tert-butyl-3-(5-hydroxypent-1-ynyl)-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC(C)(C)C)C=C1C#CCCCO GNGKNPMEWGQQSY-UHFFFAOYSA-N 0.000 description 1
- CREQAXITHOFILW-UHFFFAOYSA-N n-tert-butyl-3-[5-[5-(4-methoxyphenyl)sulfonyl-2,4-dioxo-1,3-thiazolidin-5-yl]pent-1-ynyl]-4-methylbenzamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1(CCCC#CC=2C(=CC=C(C=2)C(=O)NC(C)(C)C)C)C(=O)NC(=O)S1 CREQAXITHOFILW-UHFFFAOYSA-N 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 239000003880 polar aprotic solvent Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- IILVFSMKWWTVRT-UHFFFAOYSA-M sodium;4-iodobenzenesulfinate Chemical compound [Na+].[O-]S(=O)C1=CC=C(I)C=C1 IILVFSMKWWTVRT-UHFFFAOYSA-M 0.000 description 1
- ITAWMPSVROAMOE-UHFFFAOYSA-N sodium;imidazol-3-ide Chemical compound [Na+].C1=C[N-]C=N1 ITAWMPSVROAMOE-UHFFFAOYSA-N 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 229910000080 stannane Inorganic materials 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- LILJBAZBRIDZCL-UHFFFAOYSA-N tert-butyl N-[3-(5-hydroxypent-1-ynyl)-4-methylphenyl]carbamate Chemical compound Cc1ccc(NC(=O)OC(C)(C)C)cc1C#CCCCO LILJBAZBRIDZCL-UHFFFAOYSA-N 0.000 description 1
- KKGWUARQJOMISN-UHFFFAOYSA-N tert-butyl N-[3-chloro-4-(5-hydroxypent-1-ynyl)phenyl]carbamate Chemical compound CC(C)(C)OC(=O)Nc1ccc(C#CCCCO)c(Cl)c1 KKGWUARQJOMISN-UHFFFAOYSA-N 0.000 description 1
- WFMOBUKWPXJCJL-UHFFFAOYSA-N tert-butyl N-[4-(5-hydroxypent-1-ynyl)-3-methylphenyl]carbamate Chemical compound Cc1cc(NC(=O)OC(C)(C)C)ccc1C#CCCCO WFMOBUKWPXJCJL-UHFFFAOYSA-N 0.000 description 1
- FXMSMQBTFARSLC-UHFFFAOYSA-N tert-butyl n-[3-[5-[2,4-dioxo-5-(5-pyridin-2-ylthiophen-2-yl)sulfonyl-1,3-thiazolidin-5-yl]pent-1-ynyl]-4-methylphenyl]carbamate Chemical compound CC1=CC=C(NC(=O)OC(C)(C)C)C=C1C#CCCCC1(S(=O)(=O)C=2SC(=CC=2)C=2N=CC=CC=2)C(=O)NC(=O)S1 FXMSMQBTFARSLC-UHFFFAOYSA-N 0.000 description 1
- VLOLMZZAGCXJKN-UHFFFAOYSA-N tert-butyl n-[4-(5-hydroxypent-1-ynyl)phenyl]carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=C(C#CCCCO)C=C1 VLOLMZZAGCXJKN-UHFFFAOYSA-N 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- 208000013076 thyroid tumor Diseases 0.000 description 1
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- DBGVGMSCBYYSLD-UHFFFAOYSA-N tributylstannane Chemical compound CCCC[SnH](CCCC)CCCC DBGVGMSCBYYSLD-UHFFFAOYSA-N 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- YUQZOUNRPZBQJK-UHFFFAOYSA-N undec-10-yn-1-ol Chemical compound OCCCCCCCCCC#C YUQZOUNRPZBQJK-UHFFFAOYSA-N 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
Definitions
- This invention relates to a method of using novel 5-(arylsulfonyl)-, 5-(arylsulfinyl)- and 5-(arylsulfanyl)thiazolidine-2,4-diones of formula (I) as inhibitors of Ras FPTase, and may be used as an alternative to, or in conjunction with, traditional cancer therapy for treating ras- oncogene-dependent tumors, such as cancers of the pancreas, colon, bladder, and thyroid.
- Compounds in the invention may also be useful for controlling metastasis, suppressing angiogenesis, inducing apoptosis, and in treating Ras-associated proliferative diseases other than cancer, such as restenosis, neuro-fibromatosis, endometriosis, and psoriasis. These compounds may also inhibit prenylation of proteins other than Ras, and thus be effective in the treatment of diseases associated with other prenyl modifications of proteins.
- Mammalian H-, K-, and N-Ras proteins encoded by H-, K-, and N-ras proto-oncogenes, respectively, are 21 kD GTP-binding proteins which possess intrinsic GTPase activity and play a fundamental role in cell proliferation and differentiation (G. L. Bolton, J. S. Sebolt-Leopold, and J. C. Hodges, Annu. Rep. Med. Chem., 1994, 29, 165; R. J. A. Grand in “New Molecular Targets in Cancer Chemotherapy” J. D. Kerr, and P. Workman, Eds., CRC Press, Boca Raton, Fla., 1994, p. 97).
- ras oncogenes are found in approximately 25% of all human cancers, including 90% of pancreatic, 50% of colon, and 50% of thyroid tumors (J. L. Bos, Cancer Res., 1989, 49, 4682). It has been shown that normal cells transfected with mutant ras gene become cancerous and that unfarnesylated, cytosolic mutant Ras protein does not anchor in cell membranes and cannot induce this transformation (J. F. Hancock, H. Paterson, and C. J. Marshall, Cell, 1990, 63, 133).
- FPTase farnesyl-protein transferase
- This invention is concerned with a method of treating, inhibiting or controlling a ras-associated disease by inhibiting farnesyl-protein transferase(FPTase) enzyme in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of Formula (I):
- Ar is 1 -naphthyl, 2-naphthyl, 8-quinolinyl, 2-thienyl, 5-chloro-2-thienyl, 5-(2-pyridyl)-2-thienyl, 2-pyridinyl, substituted 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 2-quinolinyl, 2-pyrimidinyl, 2-benzoxazolyl, 2-benzthiazolyl, 2-benzimidazolyl, 2-furanyl, 2-benzo-[b]-furanyl, 2-benzo-[b]-thienyl or a moiety of the formula:
- R 1 is hydrogen, fluoro, bromo, chloro, iodo, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms,4-pyridyloxy, azido, nitro, acetamido, trifluoromethoxy, phenoxy, or benzyloxy;
- R 2 is hydrogen, fluoro, bromo, chloro, iodo, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, trifluoromethoxy, phenoxy, or benzyloxy;
- m is 0, 1 or 2;
- R 6 is hydrogen, alkyl of 1 to 6 carbon atoms, benzyl, substituted benzyl, imidazolylpropyl, or —CO 2 Y;
- Y is 2-methoxyethyl, alkyl is 1 to 6 carbon atoms, benzyl, or substituted benzyl; W is
- n is an integer of 1 to 9;
- Ar′ is thienyl, pyridinyl or a moiety of the formula
- R 3 , R 4 , R 5 are independently selected from hydrogen, alkoxy of 1 to 6 carbon atoms, alkyl of 1 to 6 carbon atoms, fluoro, bromo, chloro, iodo, nitro, amino, hydroxy, azido, cyano, phenyl, phenoxy, trifluoromethyl, trifluoromethoxy, methanesulphonyl, 1-pyrrolyl, —CO 2 R 7 , —CONHR 8 , —CH 2 CONHR 9 , —NHCO 2 R 10 , —NHCOR 11 , and —NHCONHR 12 ;
- R 7 is selected from H, and alkyl of 1 to 6 carbon atoms
- R 8 is selected from H, and alkyl of 1 to 6 carbon atoms
- R 9 is selected from H, and alkyl of 1 to 6 carbon atoms
- R 10 is selected from alkyl of 1 to 6 carbon atoms, benzyl, nitrobenzyl, and chlorophenyl;
- R 11 is selected from alkyl of 1 to 6 carbon atoms, benzyl, phenyl, halophenyl, alkyl(1 to 6 carbon atoms)phenyl, alkoxy(1 to 6 carbon atoms)phenyl, and biphenyl;
- R 12 is benzyl, alkyl of 1 to 6 carbon atoms, alkoxy(1 to 6 carbon atoms)phenyl, halophenyl, and alkyl(1 to 6 carbon atoms)phenyl;
- n is other than 2 or pharmaceutically acceptable salts thereof.
- R 6 is hydrogen, n is 1, m is 2, W is
- R 6 is hydrogen, n is 3, m is 2, W is
- R 6 is hydrogen, n is 3-6, m is 2, W is
- R 6 is hydrogen, n is 1, m is 2, W is
- Ar is a moiety of the formula
- R 6 is hydrogen, n is 3, m is 2, W is
- Ar is a moiety of the formula
- R 6 is hydrogen, n is 3-6, m is 2, W is
- Ar is a moiety of the formula
- R 6 is hydrogen, n is 1, m is 2, W is
- Ar is a moiety of the formula
- Ar′ is a moiety of the formula
- R6 is hydrogen, n is 3, m is 2, W is
- Ar is a moiety of the formula
- Ar′ is a moiety of the formula
- R 6 is hydrogen, n is 3-6, m is 2, W is
- Ar is a moiety of the formula
- Ar′ is a moiety of the formula
- R 6 is hydrogen, n is 1, m is 2, W is
- Ar is a moiety of the formula
- Ar′ is thienyl or pyridinyl
- R 6 is hydrogen, n is 3, m is 2, W is
- Ar is a moiety of the formula
- Ar′ is thienyl or pyridinyl
- R 6 is hydrogen, n is 3-6, m is 2, W is
- Ar is a moiety of the formula
- Ar′ is thienyl or pyridinyl
- compounds of this invention include compounds of Formula (I) in which m is 2, Ar is phenyl substituted in the 4-position by iodo, methoxy, trifluoromethoxy, 4-pyridyloxy; Ar′ is phenyl substituted in the 2-position by chloro or methyl, and in the 5-position by amino, chloro, a carbamic acid ester, a substituted carboxamide group, or in the 4-position by nitro or a carbamic acid ester; W is an acetylenic group, and n is the integer 3.
- Specifically preferred compounds of this invention according to Formula (I) for treating or controlling ras oncogene-dependent tumors and associated proliferative diseases in warm-blooded animals preferably mammals, most preferably humans in need thereof are the following compounds or a pharmaceutically acceptable salt thereof:
- the pharmaceutically acceptable salts of the basic compounds of this invention are those derived from such organic and inorganic acids as: lactic, citric, acetic, tartaric, fumaric, succinic, maleic, malonic, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, methanesulfonic, and similarly known acceptable acids.
- R 1 to R 12 , or Y contains a carboxyl group
- salts of the compounds in this invention may be formed with bases such as alkali metals (Na, K, Li) or alkaline earth metals (Ca or Mg).
- Halogen as used herein means chloro, fluoro, bromo and iodo.
- Alkyl as used herein means a branched or straight chain having from 1 to 6 carbon atoms.
- exemplary alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl and hexyl.
- Aryl as used herein means an aromatic radical wherein Ar is 1 -naphthyl, 2-naphthyl, 8-quinolinyl, 2-thienyl, 5-chloro-2-thienyl, 5-(2-pyridyl)-2-thienyl, 2-pyridinyl, substituted 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 2-quinolinyl, 2-pyrimidinyl, 2-benzoxazolyl, 2-benzthiazolyl, 2-benzimidazolyl, 2-furanyl, 2-benzo-[b]-furanyl, 2-benzo-[b]-furanyl, 2-benzo-[b]-thienyl or a moiety of the formula:
- an aromatic radical Ar′ is thienyl, pyridinyl or a moiety of the formula
- Alkoxy as used herein means an —O-alkyl group in which the alkyl group is as previously described.
- exemplary alkoxy groups include methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, and t-butoxy.
- Alkyne as used herein means an alkynyl group
- Phenyl as used herein refers to a 6-membered aromatic ring.
- Carbamic acid ester is —NHCO 2 R 10 where preferred R 10 is alkyl of 1 to 6 carbon atoms.
- Substituted carboxamide is —CONHR 8 wherein R 8 is alkyl of 1 to 6 carbon atoms.
- Substituted 2-pyridinyl and substituted benzyl unless otherwise provided for herein, preferably has from 1 to 3 substituents independently selected from fluoro, chloro, bromo, iodo, nitro, cyano, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, trifluoromethyl and trifluoromethoxy.
- This invention provides a method of treatment, by administration of an effective amount of compounds of Formula (I), of ras oncogene-dependent tumors, which include cancers of the pancreas, colon, bladder, and thyroid; a method of controlling metastasis, suppressing angiogenesis, and inducing apoptosis; a method of treating Ras-associated proliferative diseases other than cancer, which include restenosis, neuro-fibromatosis, endometriosis, and psoriasis
- the compounds of Formula (I) may also inhibit prenylation of proteins other than Ras, and thus provide a method of treatment of diseases associated with other prenyl modifications of proteins.
- the compounds of Formula (I) inhibit farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.
- this invention further provides a method of inhibiting farnesyl protein transferase, (e.g., Ras farnesyl protein transferase) in mammals, especially humans, by the administration of an effective amount of the compounds of Formula (I).
- farnesyl protein transferase e.g., Ras farnesyl protein transferase
- the administration of the compounds of this invention to patients, to inhibit farnesyl protein transferase is useful in the treatment of the cancers and other diseases described below.
- This invention provides a method for inhibiting or treating the abnormal growth of cells, including transformed cells by administering an effective amount of a compound of Formula (I).
- Abnormal growth of cells refers to cell growth independent of normal regulatory mechanisms (e.g., loss of contact inhibition). This includes abnormal growth of tumor cells (tumors) expressing an activated Ras oncogene; tumor cells in which the Ras protein is activated as a result of oncogenic mutation in another gene; and benign and malignant cells of other proliferative diseases in which aberrant Ras activation occurs.
- This invention also provides a method for inhibiting or treating tumor growth by administering an effective amount of a compound of Formula (I), described herein, to a mammal (e.g., a human) in need of such treatment.
- a mammal e.g., a human
- this invention provides a method for inhibiting or treating the growth of tumors expressing an activated Ras oncogene by administration of an effective amount of a compound of Formula (I).
- tumors which may be inhibited or treated include, but are not limited to, lung cancer (e.g., lung adenocarcinoma), pancreatic cancers (e.g., pancreatic carcinoma such as, for example, exocrine pancreatic carcinoma), colon cancers (e.g., colorectal carcinomas, such as, for example, colon adenocarcinoma and colon adenoma), myeloid leukemias (for example, acute myelogenous leukemia (AML)), thyroid follicular cancer, myelodysplastic syndrome (MDS), bladder carcinoma, epidermal carcinoma, breast cancer and prostate cancer.
- lung cancer e.g., lung adenocarcinoma
- pancreatic cancers e.g., pancreatic carcinoma such as, for example, exocrine pancreatic carcinoma
- colon cancers e.g., colorectal carcinomas, such as, for example, colon adenocarcinoma and colon adenoma
- This invention also provides a method for inhibiting or treating proliferative diseases, both benign and malignant, wherein Ras proteins are aberrantly activated as a result of oncogenic mutation in other genes-i.e., the Ras gene itself is not activated by mutation to an oncogenic form-with said inhibition or treatment being accomplished by the administration of an effective amount of a compound of Formula (I), to a mammal (e.g., a human) in need of such treatment.
- a mammal e.g., a human
- the benign proliferative disorder neurofibromatosis, or tumors in which Ras is activated due to mutation or overexpression of tyrosine kinase oncogenes may be inhibited or treated by the compounds of Formula (I).
- this invention provides a method of inhibition or treating the abnormal growth of cells, by administration of an effective amount of compounds of Formula (I), of ras-oncogene-dependent tumors, which tumors include cancers of the pancreas, colon, bladder, and thyroid.
- these compounds may function through the inhibition of G-protein function, such as ras p21, by blocking G-protein isoprenylation, thus making them useful in the treatment of proliferative diseases such as tumor growth and cancer.
- the compounds of Formula (I) inhibit Ras farnesyl-protein transferase, and thus antiproliferative activity of ras-transformed cells and other prenyl modifications of proteins.
- arylthiol VI where Ar is hereinbefore defined is reacted with 2 or more equivalents of a strong base such as lithium diisopropylamide, lithium bis(trimethylsilylamide), and the like followed by reaction with one or more equivalents of 5-bromothiazolidine-2,4-dione IV(Zask et al, J. Med. Chem. 1990, 33, 1418-1423) to produce a 5-arylsulfanylthiazolidine-2,4-dione VII in an aprotic solvent such as tetrahydrofuran (THF) or hexane at temperatures (e.g. 0° to ⁇ 78° C.) followed by warming to about ambient temperature for 1 to 10 h.
- aprotic solvent such as tetrahydrofuran (THF) or hexane
- the 5-arylsulfanylthiazolidine-2,4-dione VII may then be oxidized to afford 5-arylsulfonylthiazolidine-2,4-dione V.
- the oxidation is conveniently performed using excess (2 to 20 equivalents) aqueous hydrogen peroxide in acetic acid at ambient or higher (30° to 80° C.) reaction temperatures for 1 to 10 h.
- the 5-arylsulfanylthiazolidine-2,4dione VII may also be oxidized to afford 5-arylsulfinylthiazolidine-2,4-dione Va by bubbling oxygen in the presence of isobutyraldehyde in a solvent which includes acetonitrile for 18 hours.
- the 5-arylsulfonylthiazolidine-2,4-dione V may also be prepared by reacting one or more equivalents of an alkali metal arylsulfinate VIII, where M is an alkali metal with 5-bromothiazolidine-2,4-dione IV in suitable solvents which include polar aprotic solvents such as N,N-dimethylformamide (DMF), tetrahydrofuran (THF) or protic solvents such as low molecular weight alcohols (methyl alcohol, ethyl alcohol and isopropanol and the like), or water.
- suitable solvents which include polar aprotic solvents such as N,N-dimethylformamide (DMF), tetrahydrofuran (THF) or protic solvents such as low molecular weight alcohols (methyl alcohol, ethyl alcohol and isopropanol and the like), or water.
- the alkali metal arylsulfinate VIII can also be prepared by reduction of an arylsulfonyl chloride with sodium iodide in acetone (Harwood, Julia, and Thuillier, Tetrahedron, 1980, 36, 2483-2487).
- arylalkynes XI wherein Ar′ is as previously defined, and LG is a suitable leaving group which include iodo, bromo and p-toluenesulfonyloxy, can be prepared via a two step process from commercially available aryl iodides or aryl bromides where Ar′ is hereinbefoe defined or those aryl iodides or aryl bromides described in the the art.
- alcohol X is prepared by the reaction of the appropriate aryl iodide or bromide with one or more equivalents of a terminal alkyne-ol IX, in the presence of a catalytic amount of a palladium(II) reagent such as dichlorobis(triphenylphosphine)palladium(II) and a catalytic amount of a copper(I) reagent such as copper(I) iodide.
- a palladium(II) reagent such as dichlorobis(triphenylphosphine)palladium(II)
- a copper(I) reagent such as copper(I) iodide.
- This reaction is also performed in the presence of one or more equivalents of a secondary or tertiary amine such as diethylamine or triethylamine.
- the secondary or tertiary amine may be used as solvent, or alternatively a halocarbon solvent such as chloroform may be s employed. Temperatures up to 80° C. are commonly used, with reaction times varying from 1 h to 2 days.
- Alkyne XI wherein Ar′ is hereinbefore defined and LG is p-toluenesulfonyloxy is most conveniently prepared from alcohol X by reaction with p-toluenesulfonyl chloride in a solvent such as dichloromethane and in the presence of N,N-dimethylaminopyridine and triethylamine at 0° C.
- alkyne XI wherein LG is p-toluenesulfonyloxy is reacted with sodium iodide in acetone at room temperature from 8 hours to 36 hours to give alkyne XI wherein LG is iodo; or when LG is bromo, X is reacted with carbon tetrabromide in the presence of triphenylphosphine in a solvent such as THF at 0° C. to 35° C. for 8 hours to 72 hours to give alkyne XI wherein LG is bromo.
- a solvent such as THF
- 5-substituted-5-(arylsulfanyl)thiazolidine-2,4-diones of Formula (I) may be prepared by reaction of the appropriate 5-(arylsulfanyl)thiazolidine-2,4-dione VII with 2 or more equivalents of a base. Two equivalents of base effect deprotonation of both the thiazolidinedione nitrogen atom and at the C-5 position to form a dianion.
- alkali metal hydrides such as sodium hydride
- alkali metal alkyls such as butyl lithium
- alkali metal amide bases such as lithium diisopropylamide or lithium bis(trimethylsilyl)amide.
- Convenient solvents include THF and DMF. Reaction temperatures may be varied from ⁇ 78° C. to room temperature. Two minutes to 1 h after the base is introduced, one or more equivalents of the appropriate alkylating agent, alkyne XI is added to the reaction mixture and this is allowed to stir at 0° C. or room temperature for a period of from 1 h to 3 days.
- 5-substituted-5-(arylsulfinyl)thiazolidine-2,4-diones of Formula (I) may be prepared by reaction of the appropriate 5-(arylsulfinyl)thiazolidine-2,4-dione Va in the presence of a base.
- bases include alkali metal hydrides such as sodium hydride, alkali metal alkyls such as butyl lithium or alkali metal amide bases such as lithium diisopropylamide or lithium bis(trimethylsilyl)amide.
- Convenient solvents include THF and DMF. Reaction temperatures may be varied from ⁇ 78° C. to room temperature.
- alkyne XI is added to the reaction mixture and this is allowed to stir at 0° C. or room temperature for a period of from 1 h to 3 days.
- 5-substituted-5-(arylsulfonyl)thiazolidine-2,4-diones of Formula (I) may be prepared by reaction of the appropriate 5-(arylsulfonyl)thiazolidine-2,4-dione V with 2 or more equivalents of a base. Two equivalents of base effect deprotonation of both the thiazolidinedione nitrogen atom and at the C-5 position to form a dianion.
- alkali metal hydrides such as sodium hydride
- alkali metal alkyls such as butyl lithium or alkali metal amide bases such as lithium diisopropylamide or lithium bis(trimethylsilyl)amide.
- Convenient solvents include THF and DMF.
- Reaction temperatures vary from ⁇ 78° C. to room temperature. Two minutes to 1 h after the base is introduced, one or more equivalents of the appropriate alkylating agent, alkyne XI is added to the reaction mixture and the reaction is allowed to stir at 0° C. or room temperature for a period of from 1 h to 3 days. Alkylation occurs exclusively on the thiazolidindione C-5 carbon atom to afford the 5-substituted-5-(arylsulfonyl)thiazolidine-2,4-dione of formula (I).
- [0259] is a nitro group, and as shown in formula I′ where R 3 is a nitro group, is reacted with a reducing agent, such as iron in acetic acid or tin in hydrochloric acid, or other agents known to effect this reduction to give an amine XIII.
- a reducing agent such as iron in acetic acid or tin in hydrochloric acid, or other agents known to effect this reduction to give an amine XIII.
- compounds of Formula (I), wherein at least one of R 3 , R 4 , or R 5 is amino, as shown in amine XIII can be prepared by hydrolysis of carbamate XII, wherein at least one of R 3 , R 4 , or R 5 of Formula (I) is a t-butoxycarbonylamino group, by the use of an acid, such as trifluoroacetic acid, or aqueous hydrochloric acid at 0° C. to 60° C., from 0.5 h to 4 h.
- an acid such as trifluoroacetic acid, or aqueous hydrochloric acid at 0° C. to 60° C., from 0.5 h to 4 h.
- Substituted amine XIV wherein at least one of R 3 , R 4 , or R 5 is —NHCO 2 R 10 wherein R 10 is selected from alkyl of 1 to 6 carbon atoms, benzyl, nitrobenzyl, chlorophenyl; substituted amine XV, wherein at least one of R 3 , R 4 , or R 5 is —NHCOR 11 , wherein R 11 is selected from alkyl of 1 to 6 carbon atoms, benzyl, phenyl, alkyl(1 to 6 carbon atoms)phenyl, alkoxy(1 to 6 carbon atoms)phenyl, biphenyl; substituted amine XVI wherein at least one of R 3 , R 4 , or R 5 is —NHCONHR 12 wherein R 12 is benzyl, alkoxy(1 to 6 carbon atoms)phenyl, halophenyl, alkyl(1 to 6 carbon atoms)phenyl
- compounds of formula (I), wherein at least one of R 3 , R 4 , or R 5 is the azido group, as in azide XVII may be prepared from amine XIII, by reaction with sodium nitrite in acetic acid at 0° C. to 20° C., for 10 min to 30 min, followed by a metal azide, such as lithium azide for 1 h to 3 h at 10° C. to 25° C.
- compounds of formula (I), wherein at least one of R 3 , R 4 , or R 5 is a carboxyl group as in carboxylic acid XIX can be prepared from the corresponding ester, such as the methyl ester as in ester XVIII by hydrolysis with a base such as potassium carbonate in a solvent such as methanol, or water, followed by acidification with an acid, such as hydrochloric acid.
- alkyne XX by reduction with hydrogen and a catalyst, such as platinum or palladium in a solvent such as an alcohol, or THF at 0° to 30° C. for 1 ⁇ 2 h to 8 h;
- a catalyst such as platinum or palladium in a solvent such as an alcohol, or THF at 0° to 30° C. for 1 ⁇ 2 h to 8 h;
- Alkenes XXIV wherein W is E- —CH ⁇ CH— can be prepared by coupling an iodophenyl compound where Ar′ is hereinbefore defined with an E-stannane XXII in the presence of tetrakistriphenyl-phosphine palladium(0) and copper(I) iodide in a solvent such as DMF at room temperature for 1 h to 3 days and subsequent conversion to alcohol XXIII to alkene XXIV, wherein LG is iodo, may be accomplished in a manner analogous to that shown in Scheme II.
- a compound such as XXV, above, wherein LG is a leaving group, such as, bromo or iodo is used to alkylate 5-arylsulfonylthiazolidine-2,4-dione V as described herein before in Scheme III.
- Enzyme test procedure FPTase inhibition in vitro assay was performed according to James, G. L., Brown, M. S., and Goldstein, J. L., Methods in Enzymology, 1995, 255, 38-46; and Garcia, M. A., et al., J. Biol. Chem., 1993, 268, 18415-18420.
- Cell Lines Human tumor cell lines LS174T, HTB39, LoVo and CaCo2.
- Cell Media RPMI 1640 (or DMEM medium and McCoy's medium) with 10% Fetal Bovine Serum supplemented with L-glutamine and Pennicilin/Streptomycin.
- Compounds Supplied usually as a 10 mM stock in 100% DMSO.
- Normal Saline 150 mM NaCl Trichloroacetic Acid (TCA): 50% (w/v) in water.
- Tris Base 10 mM in water.
- Cells are plated at 2000 cells per well, per 200 ⁇ l media, and allowed to adhere overnight at 37° C. At 24 h post plating, compounds are added directly at a volume of 0.5 ⁇ l. Compound is first diluted in DMSO to generate concentrations of compound or reference standard of: 1, 5, 10 and 25 ⁇ M. Dilutions can be made in an identical 96 well plate so that compounds can be added using a multichannel micropipettor set at 0.5 ⁇ l.
- the cells are then incubated for four days after which the media is removed using a 12 well manifold by first tipping the plate forward at a 45 degree angle and then inserting the manifold in an upright orientation to prevent the tips of the manifold from disturbing cells at the bottom of the plate.
- 200 ⁇ l of normal saline is then added to each well using an 8 well multichannel pipettor, followed by the careful addition of 50 ⁇ l of 50% TCA.
- the plates are then incubated for 2 h at 4° C, after which the supernatant is removed using the same technique as above and the plates washed twice with 200 ⁇ l water.
- the plates are then air dried and 50 ⁇ l of SRB stock solution is carefully added so that the entire bottom of each well is covered.
- the SRB is incubated with fixed cells for 15 min at room temperature, after which the SRB is removed with the manifold as described above and the plates washed twice with 350 ⁇ l of 1% acetic acid per well each time. The plates are then air dried after which the bound SRB is released from protein by the addition of 200 ⁇ l of Tris base. Resolubilizing the SRB is aided by placing the plates on a rotator for 15-30 min. The absorbance of each well is determined at 550 or 562 nm using a microtiter plate reader.
- Cell Lines Human tumor cell lines DLD-1 and LoVo; ras-transformed rat fibroblast cell lines, RAT-H-ras and RAT-K-ras (growth inhibited by standard FPTase inhibitors), and the parent cell line RAT-2 (resistant to standard FPTase inhibitors).
- Cell Media RPMI 1640 (or DMEM medium and McCoy's medium) with 10% Fetal Bovine Serum supplemented with L-glutamine and Pennicilin/Streptomycin.
- Compounds Supplied usually as a 10 mM stock in 100% DMSO.
- Examples 239-267of this invention were tested in cell-based assays against human tumor cell lines DLD-1 and LoVo and ras-transformed rat fibroblast cell lines, RAT-H-ras and RAT-K-ras, and the parent cell line RAT-2, as described under Assays.
- the compounds of this invention are useful as agents for treating, inhibiting or controlling ras-associated diseases by inhibiting farnesyl-protein transferase enzyme, when administered in amounts ranging from about 10 to about 200 mg/kg of body weight per day.
- a preferred regimen for optimum results would be from about 10 mg to about 100 mg/kg of body weight per day and such dosage units are employed that a total of from about 100 mg to about 1000 mg of the active compound for a subject of about 70 kg of body weight are administered in a 24 hour period.
- the dosage regimen for treating mammals may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation.
- a decidedly practical advantage is that these active compounds may be administered in any convenient manner such as by the oral, intravenous, intramuscular or subcutaneous routes.
- the active compounds may be orally administered, for example, with an inert diluent or with an assimilable edible carrier, or they may be enclosed in hard or soft shell gelatin capsules, or they may be compressed into tablets or they may be incorporated directly with the food of the diet.
- these active compounds may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers and the like.
- Such compositions and preparations should contain at least 0.1% of active compound.
- the percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 2% to about 60% of the weight of the unit.
- compositions or preparations according to the present invention are prepared so that an oral dosage unit form contains between 10 and 1000 mg of active compound.
- the tablets, troches, pills, capsules and the like may also contain the following: a binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose, or saccharin may be added or a flavoring agnet such as peppermint, oil of wintergreen or cherry flavoring.
- a binder such as gum tragacanth, acacia, corn starch or gelatin
- excipients such as dicalcium phosphate
- a disintegrating agent such as corn starch, potato starch, alginic acid and the like
- a lubricant such as magnesium stearate
- the dosage unit form When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills or capsules may be coated with shellac, sugar or both.
- a syrup or elixir may contain the active compound, sucrose, as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavoring such as cherry or orange flavor.
- any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts used.
- these active compounds may be incorporated into sustained-release preparations and formulations.
- active compounds may also be administered parenterally or intraperitoneally.
- Solutions or suspensions of these active compounds as a free base or pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant such as hydroxypropylcellulose.
- Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures therof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth or microorganisms.
- the pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
- the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and starage and must be prepared against the contaminating action of microorganisms such as bacteria and fungi.
- the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid poly-ethylene glycol), suitable mixtures thereof, and vegetable oils.
- the present invention accordingly provides a pharmaceutical composition which comprises a compound of Formula (I) of this invention in combination or association with a pharmaceutically acceptable carrier.
- the present invention provides a pharmaceutical composition which comprises an effective amount of a compound of this invention and a pharmaceutically acceptable carrier.
- the term providing an effective amount of a compound means either directly administering such compound, or administering a prodrug, derivative, or analog which will form an effective amount of the compound within the body.
- the present invention provides a method of treatment of ras oncogene-dependent tumors, such as cancers of the pancreas, colon, bladder, and thyroid; a method of controlling metastasis, suppressing angiogenesis, and inducing apoptosis; a method of treating Ras-associated proliferative diseases other than cancer, such as restenosis, neuro-fibromatosis, endometriosis, and psoriasis.
- the compounds of the present invention may also inhibit prenylation of proteins other than Ras, and thus provide a method of treatment of diseases associated with other prenyl modifications of proteins.
- Example 100 In a manner essentially that of Example 100, the following products of Examples 101-171 were obtained by alkylation of an arylthiazolidine-2,4-dione with the appropriate iodo or bromo compound. All structures were verified by NMR and gave spectra consistent with that shown in Example 100: Ex. melting mass No. Product point ° C.
- benzenesulfonyl]thiazolidine- 2,4-dione 129 5-[5-(2-Methyl-4-nitrophenyl)pent-4-ynyl]-5- 210-212 549.6 (4-phenoxybenzenesulfonyl)-thiazolidine- 2,4-dione 130 5-(4-Methoxybenzenesulfonyl)-5-[5-(2- yellow 487.5 methyl-4-nitrophenyl)-pent-4-ynyl]- glass thiazolidine-2,4-dione 131 5-(4-Iodobenzenesulfonyl)-5-[5-(2-methyl-4- 150-152 657.5 nitrophenyl)pent-4-ynyl]-thiazolidine-2,4- dione 132 5-(4-Methoxybenzenesulfonyl)-5-[5-(2- yellow 503.5 methoxy-4-nitrophenyl)pent-4- gum y
- thiazolidine-2,4-dione 140 5-[5-(4-Chloro-2-methylphenyl)pent-4- 197 559.9 ynyl]-5-(4-trifluoromethoxy- decomp. benzenesulfonyl)-thiazolidine-2,4-dione 141 5-[5-(4-Chloro-2-methylphenyl)-pent-4- 93-99 591.4 ynyl]-5-(4-iodobenzene-sulfonyl)- thiazolidine-2,4-dione 142 5-[5-(4-Chloro-2-methylphenyl)pent-4- yellow 477.0 ynyl]-5-(4-methoxybenzene-sulfonyl)- foam thiazolidine-2,4-dione 143 5-[5-(4-Bromo-2-methy-phenyl)pent-4- white 540.0 ynyl]
- Tri-n-butyl(4-pentenol)-5-ylstannane(1.0 equiv.) was added, followed by tetrakis-triphenylphosphinePd(0)(0.1 equiv.) and Cul (0.75 equiv.).
- the reaction was stirred at room temperature overnight.
- the reaction was diluted with ether, filtered through a small pad of celite and an excess of saturated aqueous NH 4 Cl was added, and this was stirred for 1 h.
- Combined organics were washed with brine, and dried over MgSO 4 to afford a tan semi-solid. This was purified using silica and 4:1 Hex: MeOtBu to 1:1. Obtained three cuts: 20% pure ‘Z’ isomer, 26% mix, 19.6% ‘E’ isomer (desired trans isomer) which was a light tan low melting solid.
- Example 150 The compound of Example 150 was chromatographed on a chiral column with hexane-ethanol 4:1 to give a less polar enantiomer, retention time 14.5-16 min.
- Example 92 By the method of Example 92, the compound of Example 224, above, is converted to the title compound.
- Example 97 The compound of Example 97 is reacted with 1,3-dibromopropane and potassium carbonate in DMF to give 5-[5-(4-chlorophenyl)pent-4-ynyl]-3-(3-bromopropyl)-5-(4-methoxybenzenesulfonyl)-thiazolidine-2,4-dione, and this is reacted with imidazole, sodium salt in DMF, and in the presence of a catalytic amount of potassium iodide to give the title compound as a light tan solid, mp 111-113° C.
- Example 237 The product of Example 237 is reacted with sodium hexamethyldisilazide in DMF, followed by the addition of 1-chloro-4-(5-iodopent-1-ynyl)-benzene to give the title compound as colorless crystals, mp 151-153° C.
- Examples 239-267 were synthesized using the methods described in U.S. Pat. Nos. 5,605918 and 5,574051 and in Wrobel, J., et al., J. Med. Chem. 1998, 41 (7), 1084-91.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
- “This application claims priority from copending provisional application Serial No. 60/314,621 filed Aug. 24, 2001 the entire disclosures of which is hereby incorporated by reference.”
- This invention relates to a method of using novel 5-(arylsulfonyl)-, 5-(arylsulfinyl)- and 5-(arylsulfanyl)thiazolidine-2,4-diones of formula (I) as inhibitors of Ras FPTase, and may be used as an alternative to, or in conjunction with, traditional cancer therapy for treating ras- oncogene-dependent tumors, such as cancers of the pancreas, colon, bladder, and thyroid. Compounds in the invention may also be useful for controlling metastasis, suppressing angiogenesis, inducing apoptosis, and in treating Ras-associated proliferative diseases other than cancer, such as restenosis, neuro-fibromatosis, endometriosis, and psoriasis. These compounds may also inhibit prenylation of proteins other than Ras, and thus be effective in the treatment of diseases associated with other prenyl modifications of proteins.
- Mammalian H-, K-, and N-Ras proteins, encoded by H-, K-, and N-ras proto-oncogenes, respectively, are 21 kD GTP-binding proteins which possess intrinsic GTPase activity and play a fundamental role in cell proliferation and differentiation (G. L. Bolton, J. S. Sebolt-Leopold, and J. C. Hodges,Annu. Rep. Med. Chem., 1994, 29, 165; R. J. A. Grand in “New Molecular Targets in Cancer Chemotherapy” J. D. Kerr, and P. Workman, Eds., CRC Press, Boca Raton, Fla., 1994, p. 97). Specific mutations in the ras gene impair GTPase activity of Ras, leading to uninterrupted growth signals and to the transformation of normal cells into malignant phenotypes. Mutant ras oncogenes are found in approximately 25% of all human cancers, including 90% of pancreatic, 50% of colon, and 50% of thyroid tumors (J. L. Bos, Cancer Res., 1989, 49, 4682). It has been shown that normal cells transfected with mutant ras gene become cancerous and that unfarnesylated, cytosolic mutant Ras protein does not anchor in cell membranes and cannot induce this transformation (J. F. Hancock, H. Paterson, and C. J. Marshall, Cell, 1990, 63, 133). Posttranslational modification and plasma membrane association of mutant Ras is essential for this transforming activity. The first and required step in the processing of Ras is farnesylation at the cysteine residue of its carboxyl terminal motif, CAAX (C=Cys-186, A=aliphatic amino acid, X=usually methionine, serine or glutamine). Since its identification, the enzyme farnesyl-protein transferase (FPTase) that catalyzes this first processing step has emerged as a promising target for therapeutic intervention (H. -W. Park, S. R. Boduluri, J. F. Moomaw, P. J. Casey, and L. S. Beese, Science, 1997, 275,1800; P. J. Casey, P. A. Solski, C. J. Der, and J. E. Buss, Proc. Natl. Acad. Sci. U.S.A., 1989, 86, 8323; S. Ayral-Kaloustian and J. S. Skotnicki, Annu. Rep. Med. Chem., 1996, 31, 165, and references therein). Major milestones have been achieved with small molecules, such as mimics of the tetrapeptide CAAX and analogs of farnesyl pyrophosphate, that show efficacy without toxicity in vitro as well as in mouse models bearing ras-dependent tumors or human xenografts with H-, N-, or K-ras mutations (S. Ayral-Kaloustian and J. S. Skotnicki, Annu. Rep. Med. Chem., 1996, 31, 165, and references therein; T. M. Williams, Exp. Opin. Ther. Patents, 1998, 8, 553, and references therein). Several low-molecular weight compounds that inhibit FPTase have entered Phase I trials in humans (SCH-66336, Pharmaprojects, 1998, No. 5128; R-115777, Pharmaprojects, 1998, No. 5532).
- 5-[3-aryl-prop-2-ynyl]-5-(arylsulfonyl)thiazolidine-2,4-diones and 5-[3-aryl-prop-2-ynyl]-5-(arylsulfanyl)thiazolidine-2,4-diones which possess antihyperglycemic activity, are reported in U.S. Pat. Nos. 5,574,051 and 5,605,918.
- Accordingly, there is still a need for drugs for treating and preventing cancer. In particular, there is a need for drugs which inhibit or treat the growth of tumors expressing an activated Ras oncogene and which include cancers of the pancreas, colon, bladder and thyroid.
-
- wherein:
- Ar is 1 -naphthyl, 2-naphthyl, 8-quinolinyl, 2-thienyl, 5-chloro-2-thienyl, 5-(2-pyridyl)-2-thienyl, 2-pyridinyl, substituted 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 2-quinolinyl, 2-pyrimidinyl, 2-benzoxazolyl, 2-benzthiazolyl, 2-benzimidazolyl, 2-furanyl, 2-benzo-[b]-furanyl, 2-benzo-[b]-thienyl or a moiety of the formula:
- R1 is hydrogen, fluoro, bromo, chloro, iodo, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms,4-pyridyloxy, azido, nitro, acetamido, trifluoromethoxy, phenoxy, or benzyloxy;
- R2 is hydrogen, fluoro, bromo, chloro, iodo, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, trifluoromethoxy, phenoxy, or benzyloxy;
- m is 0, 1 or 2;
- R6 is hydrogen, alkyl of 1 to 6 carbon atoms, benzyl, substituted benzyl, imidazolylpropyl, or —CO2Y;
-
- E- and Z- —CH═CH—, —CONH—, —CONHCH2—, —CONHCH2CH2— or —CH2—CH2—;
- n is an integer of 1 to 9;
-
- R3, R4, R5, are independently selected from hydrogen, alkoxy of 1 to 6 carbon atoms, alkyl of 1 to 6 carbon atoms, fluoro, bromo, chloro, iodo, nitro, amino, hydroxy, azido, cyano, phenyl, phenoxy, trifluoromethyl, trifluoromethoxy, methanesulphonyl, 1-pyrrolyl, —CO2R7, —CONHR8, —CH2CONHR9, —NHCO2R10, —NHCOR11, and —NHCONHR12;
- R7 is selected from H, and alkyl of 1 to 6 carbon atoms,
- R8 is selected from H, and alkyl of 1 to 6 carbon atoms;
- R9 is selected from H, and alkyl of 1 to 6 carbon atoms;
- R10 is selected from alkyl of 1 to 6 carbon atoms, benzyl, nitrobenzyl, and chlorophenyl;
- R11 is selected from alkyl of 1 to 6 carbon atoms, benzyl, phenyl, halophenyl, alkyl(1 to 6 carbon atoms)phenyl, alkoxy(1 to 6 carbon atoms)phenyl, and biphenyl;
- R12 is benzyl, alkyl of 1 to 6 carbon atoms, alkoxy(1 to 6 carbon atoms)phenyl, halophenyl, and alkyl(1 to 6 carbon atoms)phenyl;
-
- n is other than 2 or pharmaceutically acceptable salts thereof.
- Among the preferred groups of compounds of Formula (I) of this invention including pharmaceutically acceptable salts thereof are those in the subgroups below, wherein the other variables of Formula (I) in the subgroups are as defined above wherein:
-
-
-
-
-
-
-
-
-
-
-
- Ar′ is a moiety of the formula
-
-
-
-
-
- Ar′ is a moiety of the formula
-
-
- Ar′ is thienyl or pyridinyl;
-
-
- Ar′ is thienyl or pyridinyl;
-
-
- Ar′ is thienyl or pyridinyl;
- Additionally preferred compounds of this invention include compounds of Formula (I) in which m is 2, Ar is phenyl substituted in the 4-position by iodo, methoxy, trifluoromethoxy, 4-pyridyloxy; Ar′ is phenyl substituted in the 2-position by chloro or methyl, and in the 5-position by amino, chloro, a carbamic acid ester, a substituted carboxamide group, or in the 4-position by nitro or a carbamic acid ester; W is an acetylenic group, and n is the integer 3.
- Specifically preferred compounds of this invention according to Formula (I) for treating or controlling ras oncogene-dependent tumors and associated proliferative diseases in warm-blooded animals preferably mammals, most preferably humans in need thereof are the following compounds or a pharmaceutically acceptable salt thereof:
- 5-[5-(4-Chlorophenyl)pent-4-ynyl]-5-(4-methoxyphenylsulfanyl)thiazolidine-2,4-dione,
- 5-[6-(4-Chlorophenyl)hex-5-ynyl]-5-(4-methoxyphenylsulfanyl)thiazolidine-2,4-dione,
- 5-[11-(4-Chlorophenyl)undec-10-ynyl]-5-(4-methoxy-phenylsulfanyl)thiazolidine-2,4-dione,
- 5-(4-Methoxyphenylsulfanyl)-5-(5-thiophen-2-yl-pent-4-ynyl)thiazolidine-2,4-dione,
- 5-[5-(4-Chlorophenyl)pent-4-ynyl]-5-(4-fluorophenylsulfanyl)thiazolidine-2,4-dione,
- 5-[5-(4-Chlorophenyl)pent-4-ynyl]-5-(4-methoxyphenylsulfonyl)thiazolidine-2,4-dione,
- 5-[6-(4-Chlorophenyl)hex-5-ynyl]-5-(4-methoxyphenylsulfonyl)thiazolidine-2,4-dione,
- 5-[11 -(4-Chlorophenyl)undec-10-ynyl]-5-(4-methoxyphenyl-sulfonyl)thiazolidine-2,4-dione,
- 5-[5-(4-Chlorophenyl)pent-4-ynyl]-5-(4-methoxyphenylsulfonyl)thiazolidine-2,4-dione,
- 5-[5-(2-Chlorophenyl)pent-4-ynyl]-5-(4-methoxybenzenesulfonyl)thiazolidine-2,4-dione,
- 5-[5-(3-Chlorophenyl)pent-4-ynyl]-5-(4-methoxybenzenesulfonyl)thiazolidine-2,4-dione,
- 5-[5-(4-Chlorophenyl)pent-4-ynyl]-5-(p-tolylsulfonyl)thiazolidine-2,4-dione,
- 5-[5-(4-Chlorophenyl)pent-4-ynyl]-5-(4-iodobenzenesulfonyl)thiazolidine-2,4-dione,
- 5-[5-(4-Chlorophenyl)pent-4-ynyl]-5-(4-fluorobenzenesulfonyl)thiazolidine-2,4-dione,
- 5-[5-(4-Chlorophenyl)pent-4-ynyl]-5-(4-phenoxybenzenesulfonyl)thiazolidine-2,4-dione,
- 5-[5-(4-Chlorophenyl)pent-4-ynyl]-5-(naphthalene-2-sulfonyl)thiazolidine-2,4-dione,
- N-(4-{5-[5-(4-Chlorophenyl)pent-4-ynyl]-2,4-dioxothiazolidine-5-sulfonyl}phenyl)acetamide,
- 5-[5-(4-Chlorophenyl)pent-4-ynyl]-5-(quinoline-8-sulfonyl)thiazolidine-2,4-dione,
- 5-[5-(4-Chlorophenyl)pent-4-ynyl]-5-(4-nitrobenzenesulfonyl)thiazolidine-2,4-dione,
- 5-(4-Benzyloxybenzenesulfonyl)-5-[5-(4-chlorophenyl)pent-4-ynyl]thiazolidine-2,4-dione,
- 5-(4-Butoxybenzenesulfonyl)-5-[5-(4-chlorophenyl)-pent-4-ynyl]thiazolidine-2,4-dione,
- 5-[5-(4-Chlorophenyl)pent-4-ynyl]-5-(naphthalene-1 -sulfonyl)thiazolidine-2,4-dione,
- 5-[5-(2,5-Dichloro-phenyl)pent-4-ynyl]-5-(4-methoxy-benzenesulfonyl)thiazolidine-2,4-dione,
- 5-[5-(2,5-Dichloro-phenyl)pent-4-ynyl]-5-(4-iodobenzenesulfonyl)thiazolidine-2,4-dione,
- 5-[5-(2,5-Dichlorophenyl)pent-4-ynyl]-5-[4-(pyridin-4-yloxy)benzenesulfonyl]thiazolidine-2,4-dione,
- 5-[5-(2,4-Dichlorophenyl)pent-4-ynyl]-5-(4-methoxybenzenesulfonyl)thiazolidine-2,4-dione,
- 5-(4-Methoxybenzenesulfonyl)-5-[5-(3-nitrophenyl)pent-4-ynyl]thiazolidine-2,4-dione,
- 5-[5-(3-Nitrophenyl)pent-4-ynyl]-5-(4-phenoxybenzenesulfonyl)thiazolidine-2,4-dione,
- 5-(4-lodobenzenesulfonyl)-5-[5-(4-nitrophenyl)pent-4-ynyl]thiazolidine-2,4-dione,
- 5-(4-Methoxybenzene sulfonyl)-5-[5-(4-nitrophenyl)pent-4-ynyl]thiazolidine-2,4-dione,
- 5-(4-Methoxybenzene sulfonyl)-5-[5-(2-methyl-5-nitrophenyl)pent-4-ynyl]thiazolidine-2,4-dione,
- 5-(4-Methoxybenzenesulfonyl)-5-[5-(2-methoxy-5-nitrophenyl)pent-4-ynyl]thiazolidine-2,4-dione,
- 5-[5-(2-Methyl-5-nitrophenyl)pent-4-ynyl] -5-(4-phenoxybenzenesulfonyl)thiazolidine-2,4-dione,
- 5-(4-lodobenzenesulfonyl)-5-[5-(2-methyl-5-nitrophenyl)pent-4-ynyl]thiazolidine-2,4-dione,
- 5-[5-(2-Methyl-5-nitrophenyl)pent-4-ynyl]-5-(naphthalene-1-sulfonyl)thiazolidine-2,4-dione
- 5-[5-(2-Methyl-5-nitrophenyl)pent-4-ynyl]-5-(naphthalene-2-sulfonyl)thiazolidine-2,4-dione,
- 5-[5-(2-Methyl-4-nitrophenyl)pent-4-ynyl]-5-[4-(pyridin-4-yloxy)-benzenesulfonyl]-thiazolidine-2,4-dione,
- 5-[5-(2-Methyl-4-nitrophenyl)pent-4-ynyl]-5-(4-phenoxybenzene-sulfonyl)thiazolidine-2,4-dione,
- 5-(4-Methoxybenzenesulfonyl)-5-[5-(2-methyl-4-nitrophenyl)pent-4-ynyl]thiazolidine-2,4-dione,
- 5-(4-lodobenzenesulfonyl)-5-[5-(2-methyl-4-nitrophenyl)pent-4-ynyl]thiazolidine-2,4-dione,
- 5-(4-Methoxybenzenesulfonyl)-5-[5-(2-methoxy-4-nitrophenyl)pent-4-ynyl]-thiazolidine-2,4-dione,
- 5-[5-(3-Fluoro-5-nitrophenyl)pent-4-ynyl]-5-(4-methoxybenzene-sulfonyl)thiazolidine-2,4-dione,
- 5-[5-(2,5-Dimethylphenyl)pent-4-ynyl]-5-(4-iodobenzenesulfonyl)thiazolidine-2,4-dione,
- 5-[5-(2,5-Dimethylphenyl)pent-4-ynyl]-5-(4-methoxybenzenesulfonyl)thiazolidine-2,4-dione,
- 5-[5-(2,4-Dimethylphenyl)pent-4-ynyl]-5-(4-methoxybenzenesulfonyl)thiazolidine-2,4-dione,
- 5-[5-(2,4-Dimethylphenyl)pent-4-ynyl]-5-(4-iodobenzenesulfonyl)thiazolidine-2,4-dione,
- 5-[5-(5-Chloro-2-methylphenyl)pent-4-ynyl]-5-(4-methoxybenzenesulfonyl)thiazolidine-2,4-dione,
- 5-[5-(5-Chloro-2-methylphenyl)pent-4-ynyl]-5-(4-trifluoromethoxybenzenesulfonyl)thiazolidine-2,4-dione,
- 5-[5-(4-Chloro-2-methylphenyl)pent-4-ynyl]-5-(4-trifluoromethoxybenzenesulfonyl)thiazolidine-2,4-dione,
- 5-[5-(4-Chloro-2-methylphenyl)-pent-4-ynyl]-5-(4-iodobenzenesulfonyl)thiazolidine-2,4-dione,
- 5-[5-(4-Chloro-2-methylphenyl)pent-4-ynyl]-5-(4-methoxybenzenesulfonyl)thiazolidine-2,4-dione,
- 5-[5-(4-Bromo-2-methylphenyl)pent-4-ynyl]-5-(4-ethoxybenzenesulfonyl)thiazolidine-2,4-dione,
- 5-[5-(4-Bromo-2-methylphenyl)pent-4-ynyl]-5-(4-iodobenzenesulfonyl)thiazolidine-2,4-dione,
- (4-{5-[5-(4-Methoxybenzensulfonyl)-2,4-dioxothiazolidin-5-yl]pent-1-ynyl}phenyl)carbamic Acid tert-Butyl Ester,
- (3-Chloro-4-{5-[5-(4-methoxybenzenesulfonyl)-2,4-dioxothiazolidin-5-yl]pent-1-ynyl}phenyl)carbamic Acid tert-Butyl Ester,
- N-tert-Butyl-3-{5-[5-(4-iodobenzenesulfonyl)-2,4-dioxothiazolidin-5-yl]pent-1-ynyl}-4-methylbenzamide,
- (3-{5-[5-(4-lodobenzenesulfonyl)-2,4-dioxothiazolidin-5-yl]pent-1-ynyl}-4-methylphenyl)carbamic Acid tert-Butyl Ester,
- (4-{5-[5-(4-Methoxybenzenesulfonyl)-2,4-dioxo-thiazolidin-5-yl]pent-1-ynyl}-3-methylphenyl)carbamic Acid tert-Butyl Ester,
- (3-{5-[5-(4-Methoxybenzenesulfonyl)-2,4-dioxothiazolidin-5-yl]pent-1-ynyl}-4-methylphenyl)carbamic Acid tert-Butyl Ester,
- (4-{5-[5-(4-Methoxybenzenesulfonyl)-2,4-dioxothiazolidin-5-yl]pent-1-ynyl}-3-trifluoromethylphenyl)-carbamic Acid tert-Butyl Ester,
- N-tert-Butyl-3-{5-[5-(4-methoxybenzenesulfonyl)-2,4-dioxothiazolidin-5-yl]pent-1-ynyl}-4-methyl-benzamide,
- 5-(4-Methoxybenzenesulfonyl)-5-[5-(4-trifluoromethylphenyl)pent-4-ynyl]thiazolidine-2,4-dione,
- 5-(4-Methoxybenzenesulfonyl)-5-[5-(4-trifluoromethoxyphenyl)pent-4-ynyl]-thiazolidine-2,4-dione,
- 3-{5-[5-(4-Methoxybenzenesulfonyl)-2,4-dioxo-thiazolidin-5-yl]pent-1-ynyl}-4-methylbenzoic Acid Methyl Ester,
- 5-[5-(4-tert-Butylphenyl)pent-4-ynyl]-5-(4-methoxybenzenesulfonyl)thiazolidine-2,4-dione,
- 5-[5-(4-tert-Butylphenyl)pent-4-ynyl]-5-(toluene-4-sulfonyl)thiazolidine-2,4-dione,
- 4-{5-[5-(4-Methoxybenzenesulfonyl)-2,4-dioxo-thiazolidin-5-yl]pent-1-ynyl}benzonitrile,
- 5-[5-(4-Methanesulfonylphenyl)-pent-4-ynyl]-5-(toluene-4-sulfonyl)thiazolidine-2,4-dione,
- 4-{5-[5-(4-Methoxybenzenesulfonyl)-2,4-dioxothiazolidin-5-yl]pent-1-ynyl}-3-methylbenzoic Acid Methyl Ester,
- 5-(4-Methoxybenzenesulfonyl)-5-[5-(4-pyrrol-1-yl-phenyl)pent-4-ynyl]thiazolidine-2,4-dione,
- 5-(4-lodo-benzenesulfonyl)-5-[5-(4-pyrrol-1-yl-phenyl)pent-4-ynyl]thiazolidine-2,4-dione,
- 5-[5-(4-Pyrrol-1-ylphenyl)pent-4-ynyl]-5-(4-trifluoromethoxybenzenesulfonyl)thiazolidine-2,4-dione,
- 5-(3-Methoxybenzenesulfonyl)-5-(5-thiophen-2-yl-pent-4-ynyl)thiazolidine-2,4-dione,
- 5-(4-Methylphenylsulfonyl)-5-(5-thiophen-2-yl-pent-4-ynyl)thiazolidine-2,4-dione,
- 5-(4-Methoxybenzenesulfonyl)-5-(5-thiophen-2-yl-pent-4-ynyl)thiazolidine-2,4-dione,
- 5-(4-Methoxybenzenesulfonyl)-5-(3-pyridin-3-ylprop-2-ynyl)thiazolidine-2,4-dione,
- 5-(3-Thiophen-2-yl-prop-2-ynyl)-5-(toluene-4-sulfonyl)thiazolidine-2,4-dione,
- 5-(3-Biphenyl-4-yl-prop-2-ynyl)-5-(toluene-4-sulfonyl)thiazolidine-2,4-dione,
- 5-[3-(4-Phenoxyphenyl)prop-2-ynyl]-5-(toluene-4-sulfonyl)thiazolidine-2,4-dione,
- 5-(3-Biphenyl-4-yl-prop-2-ynyl)-5-(4-methoxybenzenesulfonyl)thiazolidine-2,4-dione,
- 5-(5-Pyridin-3-yl-pent-4-ynyl)-5-(toluene-4-sulfonyl)thiazolidine-2,4-dione,
- 5-[5-(5-Amino-2-methylphenyl)pent-4-ynyl]-5-(4-methoxybenzenesulfonyl)thiazolidine-2,4-dione, (
- 3-{5-[5-(4-Methoxybenzenesulfonyl)-2,4-dioxothiazolidin-5-yl]pent-1-ynyl}-4-methylphenyl)carbamic Acid Benzyl Ester,
- (3-{5-[5-(4-Methoxybenzenesulfonyl)-2,4-dioxothiazolidin-5-yl]pent-1-ynyl}-4-methylphenyl)carbamic Acid 4-Nitro-Benzyl Ester,
- (3-{5-[5-(4-Methoxybenzenesulfonyl)-2,4-dioxothiazolidin-5-yl]pent-1-ynyl}-4-methylphenyl)carbamic Acid 4-Chloro-phenyl Ester,
- (3-{5-[5-(4-Methoxybenzenesulfonyl)-2,4-dioxothiazolidin-5-yl]pent-1-ynyl}-4-methylphenyl)carbamic Acid Methyl Ester,
- (3-{5-[5-(4-Methoxybenzenesulfonyl)-2,4-dioxothiazolidin-5-yl]pent-1-ynyl}-4-methylphenyl)carbamic Acid Isopropyl Ester,
- (3-{5-[5-(4-Methoxybenzenesulfonyl)-2,4-dioxothiazolidin-5-yl]pent-1-ynyl}-4-methylphenyl)carbamic Acid Neopentyl Ester,
- (3-{5-[5-(4-Methoxybenzenesulfonyl)-2,4-dioxothiazolidin-5-yl]pent-1-ynyl}-4-methylphenyl)carbamic Acid Butyl Ester,
- (3-{5-[5-(4-Methoxybenzenesulfonyl)-2,4-dioxothiazolidin-5-yl]pent-1-ynyl}-4-methylphenyl)carbamic Acid Isobutyl,
- N-[3-(5-{5-[(4-Methoxyphenyl)sulfonyl]-2,4-dioxo-1,3-thiazolidin-5-yl}-1-pentynyl)-4-methylphenyl]-2-methylpropanamide,
- N-[3-(5-{5-[(4-Methoxyphenyl)sulfonyl]-2,4-dioxo-1,3-thiazolidin-5-yl}-1-pentynyl)-4-methylphenyl]-3,3-dimethylbutanamide,
- N-[3-(5-{5-[(4-Methoxyphenyl)sulfonyl]-2,4-dioxo-1,3-thiazolidin-5-yl}-1-pentynyl)-4-methylphenyl]-2,2-dimethylpropanamide,
- N-[3-(5-{5-[(4-Methoxyphenyl)sulfonyl]-2,4-dioxo-1,3-thiazolidin-5-yl}-1-pentynyl)-4-methylphenyl]-2-phenylacetamide,
- N-Benzyl-N′-[3-(5-{5-[(4-methoxyphenyl)-sulfonyl]-2,4-dioxo-1,3-thiazolidin-5-yl}-1-pentynyl)-4-methylphenyl]urea,
- N-(4-Methoxyphenyl)-N′-[3-(5-{5-[(4-methoxyphenyl)sulfonyl]-2,4-dioxo-1,3-thiazolidin-5-yl}-1-pentynyl)-4-methylphenyl]urea,
- N-(4-Chlorophenyl)-N′-[3-(5-{5-[(4-methoxyphenyl)sulfonyl]-2,4-dioxo-1,3-thiazolidin-5-yl}-1-pentynyl)-4-methylphenyl]urea,
- N-[3-(5-{5-[(4-Methoxyphenyl)sulfonyl]-2,4-dioxo-1,3-thiazolidin-5-yl}-1-pentynyl)-methylphenyl]-N′-(4-methylphenyl)urea,
- 4-Chloro-N-[3-(5-{5-[(4-methoxyphenyl)-sulfonyl]-2,4-dioxo-1,3-thiazolidin-5-yl}-1-pentynyl)-4-methylphenyl]benzamide,
- 4-Methoxy-N-[3-(5-{5-[(4-methoxyphenyl)-sulfonyl]-2,4-dioxo-1,3-thiazolidin-5-yl}-1-pentynyl)-4-methylphenyl]benzamide,
- N-[3-(5-{5-[(4-Methoxyphenyl)sulfonyl]-2,4-dioxo-1,3-thiazolidin-5-yl}-1-pentynyl)-4-methylphenyl][1,1′-biphenyl]-4-carboxamide,
- 4-(tert-Butyl)-N-[3-(5-{5-[(4-methoxyphenyl)sulfonyl]-2,4-dioxo-1,3-thiazolidin-5-yl}-1-pentynyl)-4-methylphenyl]benzamide,
- 5-[5-(4-Chlorophenyl)-4-pentynyl]-5-[(5-chloro-2-thienyl)sulfonyl]-1,3-thiazolidine-2,4-dione,
- 5-[5-(4-Chlorophenyl)-4-pentynyl]-5-(2-thienylsulfonyl)-1,3-thiazolidine-2,4-dione,
- 5-[5-(4-Chlorophenyl)-4-pentynyl]-5-[(3,4-dimethoxyphenyl)sulfonyl]-1,3-thiazolidine-2,4-dione,
- 5-[5-(4-Chlorophenyl)-4-pentynyl]-5-{[4-(4-pyridinyloxy)phenyl]sulfonyl}-1,3-thiazolidine-2,4-dione,
- 5-[5-(4-Chlorophenyl)-4-pentynyl]-5-{[5-(2-pyridinyl)-2-thienyl]sulfonyl}-1,3-thiazolidine-2,4-dione,
- 5-[(5-Chloro-2-thienyl)sulfonyl]-5-[5-(2,5-dichlorophenyl)-4-pentynyl]-1,3-thiazolidine-2,4-dione,
- 5-[5-(2,5-Dichlorophenyl)-4-pentynyl]-5-(2-thienylsulfonyl)-1,3-thiazolidine-2,4-dione,
- 5-[5-(2,5-Dichlorophenyl)-4-pentynyl]-5-[(3,4-dimethoxyphenyl)sulfonyl]-1,3-thiazolidine-2,4-dione,
- 5-[5-(2,5-Dichlorophenyl)-4-pentynyl]-5-{[4-(4-pyridinyloxy)phenyl]sulfonyl),1,3-thiazolidine-2,4-dione,
- 5-[5-(2,5-Dichlorophenyl)-4-pentynyl]-5-{[5-(2-pyridinyl)-2-thienyl]sulfonyl}-1,3-thiazolidine-2,4-dione,
- tert-Butyl 3-(5-{5-[(5-chloro-2-thienyl)-sulfonyl]-2,4-dioxo-1,3-thiazolidin-5-yl}-1-pentynyl)-4-methylphenylcarbamate,
- tert-Butyl 3-{5-[2,4-dioxo-5-(2-thienylsulfonyl)-1,3-thiazolidin-5-yl]-1-pentyn-yl}-4-methylphenylcarbamate,
- tert-Butyl 3-(5-{5-[(3,4-dimethoxyphenyl)sulfonyl]-2,4-dioxo-1,3-thiazolidin-5-yl}-1-pentynyl)-4-methylphenyl-carbamate,
- tert-Butyl 3-[5-(2,4-dioxo-5-{[4-(4-pyridinyloxy)phenyl]sulfonyl}-1,3-thiazolidin-5yl)-1-pentynyl]-4-methylphenyl-carbamate,
- tert-Butyl 3-[5-(2,4-dioxo-5-{[5-(2-pyridinyl)-2-thienyl]sulfonyl}-1,3-thiazolidin-5-yl)-1-pentynyl]-4-methylphenyl-carbamate,
- N-(tert-Butyl)-3-(5-{5-[(5-chloro-2-thienyl)sulfonyl]-2,4-dioxo-1,3-thiazolidin-5-yl}-1-pentynyl)-4-methylbenzamide,
- N-(tert-Butyl)-3-{5-[2,4-dioxo-5-(2-thienylsulfonyl)-1,3-thiazolidin-5-yl]-1-pentynyl}-4-methylbenzamide,
- N-(tert-Butyl)-3-(5-{5-[(3,4-dimethoxyphenyl)sulfonyl]-2,4-dioxo-1,3-thiazolidin-5-yl}-1-pentynyl)-4-methylbenzamide,
- N-(tert-Butyl)-3-[5-(2,4-dioxo-5-{[5-(2-pyridinyl)-2-thienyl]sulfonyl}-1,3-thiazolidin-5-yl)-1-pentynyl]-4-methylbenzamide,
- 4-{5-[5-(4-Methoxybenzenesulfonyl)-2,4-dioxothiazolidin-5-yl]pent-1-ynyl}-3-methylbenzoic Acid,
- N-(4-Chlorobenzyl)-3-[5-(4-methoxybenzenesulfonyl)-2,4-dioxo-thiazolidin-4-yl]propionamide,
- N-[2-(4-Chlorophenyl)ethyl]-3-[5-(4-methoxybenzenesulfonyl)-2,4-dioxo-thiazolidin-5-yl]propionamide,
- 5-[(4Z)-5-(4-Chloro-phenyl)pent-4-enyl]-5-(toluene-4-sulfonyl)thiazolidine-2,4-dione,
- 5-[(4E)-5-(4-Chlorophenyl)pent-4-enyl]-5-(4-methoxybenzenesulfonyl)thiazolidine-2,4-dione,
- 5-[3-(4-Chlorophenyl)propyl]-5-(4-methoxybenzenesulfonyl)thiazolidine-2,4-dione,
- 5-[5-(3-Aminophenyl)pent-4-ynyl]-5-(4-methoxybenzenesulfonyl)thiazolidine-2,4-dione,
- 5-(3-Phenylallyl)-5-(toluene-4-sulfonyl)thiazolidine-2,4-dione,
- Enantiomer of(3-(5-[5-(4-Methoxybenzene sulfonyl)-2,4-dioxothiazolidin-5-yl]pent-1-ynyl}-4-methylphenyl)carbamic Acid tert-Butyl Ester (less polar),
- Enantiomer of(3-{5-[5-(4-Methoxybenzene sulfonyl)-2,4-dioxothiazolidin-5-yl]pent-1-ynyl}-4-methylphenyl)carbamic Acid tert-Butyl Ester (more polar),
- 5-[5-(4-Chlorophenyl)pent-4-ynyl]-5-(4-methoxyphenylsulfinyl)thiazolidine-2,4-dione,
- Benzyl 5-[5-(5-{[(benzyloxy)carbonyl]-amino}-2-methylphenyl)pent-4-ynyl]-5-[(4-methoxyphenyl)sulfonyl]-2,4-dioxo-1,3-thiazolidine-3-carboxylate,
- 4-Nitrobenzyl 5-[(4-methoxyphenyl)sulfonyl]-5-{5-[2-methyl-5-({[(4-nitrobenzyl)oxy]carbonyl}amino)phenyl]pent-4-ynyl}-2,4-dioxo-1,3-thiazolidine-3-carboxylate,
- Methyl 5-(5-{5-[(methoxycarbonyl)amino]-2-methylphenyl}pent-4-ynyl)-5-[(4-methoxyphenyl)sulfonyl]-2,4-dioxo-1,3-thiazolidine-3-carboxylate,
- Isopropyl 5-(5-{5-[(isopropoxycarbonyl)-amino]-2-methylphenyl}pent-4-ynyl)-5-[(4-methoxyphenyl)sulfonyl]-2,4-dioxo-1,3-thiazolidine-3-carboxylate,
- Neopentyl 5-[(4-methoxyphenyl)sulfonyl]-5-[5-(2-methyl-5-{[(neopentyloxy)carbonyl]-amino}phenyl)pent-4-ynyl]-2,4-dioxo-1,3-thiazolidine-3-carboxylate,
- Butyl 5-(5-{5-[(butoxycarbonyl)amino]-2-methylphenyl}pent-4-ynyl)-5-[(4-methoxy-phenyl)sulfonyl]-2,4-dioxo-1,3-thiazolidine-3-carboxylate,
- Isobutyl 5-(5-{5-[(isobutoxycarbonyl)amino]-2-methylphenyl}pent-4-ynyl)-5-[(4-methoxyphenyl)sulfonyl]-2,4-dioxo-1,3-thiazolidine-3-carboxylate,
- 5-[5-(4-Chlorophenyl)pent-4-ynyl]-3-(3-imidazol-1-yl-propyl)-5-(4-methoxybenzenesulfonyl)thiazolidine-2,4-dione,
- 5-[5-(4-Chlorophenyl)pent-4-ynyl]-5-(4-methoxybenzenesulfonyl)-3-methyl-thiazolidine-2,4-dione,
- 5-[5-(4-Chlorophenyl)pent-4-ynyl]-3-(2,4-diethoxybenzyl)-5-(toluene-4-sulfonyl)thiazolidine-2,4-dione,
- 5-[5-(4-Chlorophenyl)pent-4-ynyl]-5-(4-iodobenzenesulfonyl)-3-(4-nitrobenzyl)thiazolidine-2,4-dione, and
- 5-[5-(2,5-Dichlorophenyl)pent-4-ynyl]-5-(4-methoxybenzenesulfonyl)-2,4-dioxothiazolidine-3-carboxylic acid 2-methoxy ethyl ester.
- Additionally specifically preferred compounds of this invention according to Formula (I) for treating or controlling ras oncogene-dependent tumors and associated proliferative diseases in warm-blooded animals preferably mammals, most preferably humans in need thereof are the following compounds or a pharmaceutically acceptable salt thereof:
- 5-[3-(4-Chloro-phenyl)-prop-2-ynyl]-5-(napthalene-2-sulfonyl)thiazolidine-2,4-dione,
- 5-Benzenesulfonyl-5-[3-(4-chloro-phenyl)-prop-2-ynyl]thiazolidine-2,4-dione,
- 5-Benzenesulfonyl-5-[3-phenyl-prop-2-ynyl]thiazolidine-2,4-dione,
- 5-(4-Chloro-benzenesulfonyl)-5-(3-phenyl-prop-2-ynyl)thiazolidine-2,4-dione,
- 5-[3-(4-Chloro-phenyl)-prop-2-ynyl]-5-(4-fluoro-benzenesulfonyl)thiazolidine-2,4-dione,
- 5-(4-Chloro-benzenesulfonyl)-5-[3-(4-chloro-phenyl)-prop-2-ynyl]thiazolidine-2,4-dione,
- 5-(4-Bromo-benzenesulfonyl)-5-[3-(4-chloro-phenyl)-prop-2-ynyl]thiazolidine-2,4-dione,
- 5-[3-(4-Fluoro-phenyl)-prop-2-ynyl]-5-(toluene-4-sulfonyl)thiazolidine-2,4-dione,
- 5-(Toluene-4-sulfonyl)-5-[3-(p-tolyl)-prop-2-ynyl]thiazolidine-2,4-dione,
- 5-(4-Bromo-benzenesulfonyl)-5-(3-phenyl-prop-2-ynyl)thiazolidine-2,4-dione,
- 5-[3-(4-Chloro-phenyl)-prop-2-ynyl]-5-(4-methoxy-benzenesulfonyl)thiazolidine-2,4-dione,
- 5-(Naphthalene-2-sulfonyl)-5-(3-phenyl-prop-2-ynyl)thiazolidine-2,4-dione,
- 5-(Toluene-4-sulfonyl)-5-[3-(4-trifluoromethyl-phenyl)-prop-2-ynyl]thiazolidine-2,4-dione,
- 5-[3-(4-Methoxy-phenyl)-prop-2-ynyl]-5-(toluene-4-sulfonyl)thiazolidine-2,4-dione,
- 5-[3-(4-Bromo-phenyl)-prop-2-ynyl]-5-(toluene-4-sulfonyl)thiazolidine-2,4-dione,
- 5-Benzenesulfonyl-5-[3-(4-trifluoromethyl-phenyl)-prop-2-ynyl]thiazolidine-2,4-dione,
- 5-(4-Chloro-benzenesulfonyl)-5-[3-(4-fluoro-phenyl)-prop-2-ynyl]thiazolidine-2,4-dione,
- 5-[3(4-Chloro-phenyl)-prop-2-ynyl]-5(toluene-3-sulfonyl)thiazolidine-2,4-dione,
- 5-Benzenesulfonyl-5-[3-(2-chloro-phenyl)-prop-2-ynyl]thiazolidine-2,4-dione,
- 5-Benzenesulfonyl-5-[3(3,5-bis-trifluoromethyl-phenyl)-prop-2-ynyl]thiazolidine-2,4-dione,
- 5-[3(3,5-bis-trifluoromethyl-phenyl)-prop-2-ynyl]-5(toluene-4-sulfonyl)thiazolidine-2,4-dione,
- 5-Benzenesulfonyl-5-[3-(3-chloro-phenyl)-prop-2-ynyl]thiazolidine-2,4-dione,
- 5-[3(4-Chlorophenyl)-2-propynyl]-2-[(4-methylphenyl)sulfonyl]-2,4-thiazolidinedione,
- 5-[3(4-Bromo-phenyl)-prop-2-ynyl]-5-(4-chloro-benzenesulfonyl)thiazolidine-2,4-dione,
- 5-(4-Fluoro-benzenesulfonyl)-5-[3-(4-trifluoromethyl-phenyl)-2-ynyl]thiazolidine-2,4-dione,
- 5-[3(4-Chloro-phenyl)-prop-2-ynyl]-5-(quinoline-2-sulfonyl)thiazolidine-2,4-dione,
- 5-[3-(3,5-Bis-trifluoromethyl-phenyl)-prop-2-ynyl]thiazolidine-2,4-dione, and
- 5-[3-(4-Chloro-phenyl)-prop-2-ynyl]-5-(p-tolylsulfanyl)thiazolidine-2,4-dione.
- It is understood that the definition of compounds of Formula (I) when R1to R12, contain asymmetric carbons, encompass all possible stereoisomers and mixtures thereof which possess the activity discussed below. In particular, the definition encompasses racemic modifications and any optical isomers which possess the indicated activity. Optical isomers may be obtained in pure form by standard separation techniques or enantiomer specific synthesis. It is understood that this invention encompasses all crystalline forms of compounds of Formula (I). The pharmaceutically acceptable salts of the basic compounds of this invention are those derived from such organic and inorganic acids as: lactic, citric, acetic, tartaric, fumaric, succinic, maleic, malonic, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, methanesulfonic, and similarly known acceptable acids. Where R1 to R12, or Y contains a carboxyl group, salts of the compounds in this invention may be formed with bases such as alkali metals (Na, K, Li) or alkaline earth metals (Ca or Mg).
- For the compounds of Formula (I) defined above and referred to herein, unless otherwise noted, the following terms are defined:
- Halogen, as used herein means chloro, fluoro, bromo and iodo.
- Alkyl as used herein means a branched or straight chain having from 1 to 6 carbon atoms. Exemplary alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl and hexyl.
- Aryl as used herein means an aromatic radical wherein Ar is 1 -naphthyl, 2-naphthyl, 8-quinolinyl, 2-thienyl, 5-chloro-2-thienyl, 5-(2-pyridyl)-2-thienyl, 2-pyridinyl, substituted 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 2-quinolinyl, 2-pyrimidinyl, 2-benzoxazolyl, 2-benzthiazolyl, 2-benzimidazolyl, 2-furanyl, 2-benzo-[b]-furanyl, 2-benzo-[b]-furanyl, 2-benzo-[b]-thienyl or a moiety of the formula:
-
- Alkoxy as used herein means an —O-alkyl group in which the alkyl group is as previously described. Exemplary alkoxy groups include methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, and t-butoxy.
-
- is present.
- Phenyl as used herein refers to a 6-membered aromatic ring.
- Carbamic acid ester is —NHCO2R10 where preferred R10 is alkyl of 1 to 6 carbon atoms.
- Substituted carboxamide is —CONHR8 wherein R8 is alkyl of 1 to 6 carbon atoms.
- Substituted 2-pyridinyl and substituted benzyl, unless otherwise provided for herein, preferably has from 1 to 3 substituents independently selected from fluoro, chloro, bromo, iodo, nitro, cyano, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, trifluoromethyl and trifluoromethoxy.
- This invention provides a method of treatment, by administration of an effective amount of compounds of Formula (I), of ras oncogene-dependent tumors, which include cancers of the pancreas, colon, bladder, and thyroid; a method of controlling metastasis, suppressing angiogenesis, and inducing apoptosis; a method of treating Ras-associated proliferative diseases other than cancer, which include restenosis, neuro-fibromatosis, endometriosis, and psoriasis The compounds of Formula (I) may also inhibit prenylation of proteins other than Ras, and thus provide a method of treatment of diseases associated with other prenyl modifications of proteins.
- The compounds of Formula (I) inhibit farnesyl-protein transferase and the farnesylation of the oncogene protein Ras. Thus, this invention further provides a method of inhibiting farnesyl protein transferase, (e.g., Ras farnesyl protein transferase) in mammals, especially humans, by the administration of an effective amount of the compounds of Formula (I). The administration of the compounds of this invention to patients, to inhibit farnesyl protein transferase, is useful in the treatment of the cancers and other diseases described below.
- This invention provides a method for inhibiting or treating the abnormal growth of cells, including transformed cells by administering an effective amount of a compound of Formula (I). Abnormal growth of cells refers to cell growth independent of normal regulatory mechanisms (e.g., loss of contact inhibition). This includes abnormal growth of tumor cells (tumors) expressing an activated Ras oncogene; tumor cells in which the Ras protein is activated as a result of oncogenic mutation in another gene; and benign and malignant cells of other proliferative diseases in which aberrant Ras activation occurs.
- This invention also provides a method for inhibiting or treating tumor growth by administering an effective amount of a compound of Formula (I), described herein, to a mammal (e.g., a human) in need of such treatment. In particular, this invention provides a method for inhibiting or treating the growth of tumors expressing an activated Ras oncogene by administration of an effective amount of a compound of Formula (I). Examples of tumors which may be inhibited or treated include, but are not limited to, lung cancer (e.g., lung adenocarcinoma), pancreatic cancers (e.g., pancreatic carcinoma such as, for example, exocrine pancreatic carcinoma), colon cancers (e.g., colorectal carcinomas, such as, for example, colon adenocarcinoma and colon adenoma), myeloid leukemias (for example, acute myelogenous leukemia (AML)), thyroid follicular cancer, myelodysplastic syndrome (MDS), bladder carcinoma, epidermal carcinoma, breast cancer and prostate cancer.
- This invention also provides a method for inhibiting or treating proliferative diseases, both benign and malignant, wherein Ras proteins are aberrantly activated as a result of oncogenic mutation in other genes-i.e., the Ras gene itself is not activated by mutation to an oncogenic form-with said inhibition or treatment being accomplished by the administration of an effective amount of a compound of Formula (I), to a mammal (e.g., a human) in need of such treatment. For example, the benign proliferative disorder neurofibromatosis, or tumors in which Ras is activated due to mutation or overexpression of tyrosine kinase oncogenes (e.g., neu, src, abl, lck, and fyn), may be inhibited or treated by the compounds of Formula (I).
- Additionally, this invention provides a method of inhibition or treating the abnormal growth of cells, by administration of an effective amount of compounds of Formula (I), of ras-oncogene-dependent tumors, which tumors include cancers of the pancreas, colon, bladder, and thyroid. Without wishing to be bound by theory, these compounds may function through the inhibition of G-protein function, such as ras p21, by blocking G-protein isoprenylation, thus making them useful in the treatment of proliferative diseases such as tumor growth and cancer. Without wishing to be bound by theory, the compounds of Formula (I) inhibit Ras farnesyl-protein transferase, and thus antiproliferative activity of ras-transformed cells and other prenyl modifications of proteins.
-
- As shown in Scheme I, arylthiol VI where Ar is hereinbefore defined is reacted with 2 or more equivalents of a strong base such as lithium diisopropylamide, lithium bis(trimethylsilylamide), and the like followed by reaction with one or more equivalents of 5-bromothiazolidine-2,4-dione IV(Zask et al, J. Med. Chem. 1990, 33, 1418-1423) to produce a 5-arylsulfanylthiazolidine-2,4-dione VII in an aprotic solvent such as tetrahydrofuran (THF) or hexane at temperatures (e.g. 0° to −78° C.) followed by warming to about ambient temperature for 1 to 10 h.
- The 5-arylsulfanylthiazolidine-2,4-dione VII may then be oxidized to afford 5-arylsulfonylthiazolidine-2,4-dione V. Following the procedure of Zask et al (J. Med. Chem. 1990, 33, 1418-1423), the oxidation is conveniently performed using excess (2 to 20 equivalents) aqueous hydrogen peroxide in acetic acid at ambient or higher (30° to 80° C.) reaction temperatures for 1 to 10 h.
- The 5-arylsulfanylthiazolidine-2,4dione VII may also be oxidized to afford 5-arylsulfinylthiazolidine-2,4-dione Va by bubbling oxygen in the presence of isobutyraldehyde in a solvent which includes acetonitrile for 18 hours.
- The 5-arylsulfonylthiazolidine-2,4-dione V may also be prepared by reacting one or more equivalents of an alkali metal arylsulfinate VIII, where M is an alkali metal with 5-bromothiazolidine-2,4-dione IV in suitable solvents which include polar aprotic solvents such as N,N-dimethylformamide (DMF), tetrahydrofuran (THF) or protic solvents such as low molecular weight alcohols (methyl alcohol, ethyl alcohol and isopropanol and the like), or water.
-
- As shown in Scheme II arylalkynes XI, wherein Ar′ is as previously defined, and LG is a suitable leaving group which include iodo, bromo and p-toluenesulfonyloxy, can be prepared via a two step process from commercially available aryl iodides or aryl bromides where Ar′ is hereinbefoe defined or those aryl iodides or aryl bromides described in the the art. In the first step, alcohol X is prepared by the reaction of the appropriate aryl iodide or bromide with one or more equivalents of a terminal alkyne-ol IX, in the presence of a catalytic amount of a palladium(II) reagent such as dichlorobis(triphenylphosphine)palladium(II) and a catalytic amount of a copper(I) reagent such as copper(I) iodide. This reaction is also performed in the presence of one or more equivalents of a secondary or tertiary amine such as diethylamine or triethylamine. The secondary or tertiary amine may be used as solvent, or alternatively a halocarbon solvent such as chloroform may be s employed. Temperatures up to 80° C. are commonly used, with reaction times varying from 1 h to 2 days. Alkyne XI wherein Ar′ is hereinbefore defined and LG is p-toluenesulfonyloxy is most conveniently prepared from alcohol X by reaction with p-toluenesulfonyl chloride in a solvent such as dichloromethane and in the presence of N,N-dimethylaminopyridine and triethylamine at 0° C. to 30° C., from one hour to 6 hours; or when LG is iodo, alcohol X is reacted with iodine, in the presence of triphenylphosphine and imidazole in a solvent such as ether, or acetonitrile, at a temperature of 0° C. to room temperature for 8 hours to 24 hours; alternatively alkyne XI wherein LG is p-toluenesulfonyloxy is reacted with sodium iodide in acetone at room temperature from 8 hours to 36 hours to give alkyne XI wherein LG is iodo; or when LG is bromo, X is reacted with carbon tetrabromide in the presence of triphenylphosphine in a solvent such as THF at 0° C. to 35° C. for 8 hours to 72 hours to give alkyne XI wherein LG is bromo.
- Referring to Scheme III: 5-substituted-5-(arylsulfanyl)thiazolidine-2,4-diones of Formula (I) may be prepared by reaction of the appropriate 5-(arylsulfanyl)thiazolidine-2,4-dione VII with 2 or more equivalents of a base. Two equivalents of base effect deprotonation of both the thiazolidinedione nitrogen atom and at the C-5 position to form a dianion. Common bases to accomplish this deprotonation include alkali metal hydrides such as sodium hydride, alkali metal alkyls such as butyl lithium or alkali metal amide bases such as lithium diisopropylamide or lithium bis(trimethylsilyl)amide. Convenient solvents include THF and DMF. Reaction temperatures may be varied from −78° C. to room temperature. Two minutes to 1 h after the base is introduced, one or more equivalents of the appropriate alkylating agent, alkyne XI is added to the reaction mixture and this is allowed to stir at 0° C. or room temperature for a period of from 1 h to 3 days. Alkylation occurs primarily on the thiazolidindione C-5 carbon atom to afford the 5-substituted-5-(arylsulfanyl)thiazolidine-2,4-dione of Formula (I), m=0 which may then be oxidized to afford 5-arylsulfonylthiazolidine-2,4-dione of Formula (I) wherein m=2 by the procedure of Zask et al (J. Med. Chem. 1990, 33, 1418-1423). The oxidation is conveniently performed using excess (2 to 20 equivalents) aqueous hydrogen peroxide in acetic acid at ambient or higher (30° C. to 80° C.) reaction temperatures for 1 to 10 h.
- Referring to Scheme IIIa: 5-substituted-5-(arylsulfinyl)thiazolidine-2,4-diones of Formula (I) may be prepared by reaction of the appropriate 5-(arylsulfinyl)thiazolidine-2,4-dione Va in the presence of a base. Common bases include alkali metal hydrides such as sodium hydride, alkali metal alkyls such as butyl lithium or alkali metal amide bases such as lithium diisopropylamide or lithium bis(trimethylsilyl)amide. Convenient solvents include THF and DMF. Reaction temperatures may be varied from −78° C. to room temperature. Two minutes to 1 h after the base is introduced, one or more equivalents of the appropriate alkylating agent, alkyne XI is added to the reaction mixture and this is allowed to stir at 0° C. or room temperature for a period of from 1 h to 3 days. Alkylation occurs primarily on the thiazolidindione C-5 carbon atom to afford the 5-substituted-5-(arylsulfinyl)thiazolidine-2,4-dione of Formula (I), m=1.
- As shown in Scheme IV: 5-substituted-5-(arylsulfonyl)thiazolidine-2,4-diones of Formula (I) may be prepared by reaction of the appropriate 5-(arylsulfonyl)thiazolidine-2,4-dione V with 2 or more equivalents of a base. Two equivalents of base effect deprotonation of both the thiazolidinedione nitrogen atom and at the C-5 position to form a dianion. Common bases to accomplish this deprotonation include alkali metal hydrides such as sodium hydride, alkali metal alkyls such as butyl lithium or alkali metal amide bases such as lithium diisopropylamide or lithium bis(trimethylsilyl)amide. Convenient solvents include THF and DMF. Reaction temperatures vary from −78° C. to room temperature. Two minutes to 1 h after the base is introduced, one or more equivalents of the appropriate alkylating agent, alkyne XI is added to the reaction mixture and the reaction is allowed to stir at 0° C. or room temperature for a period of from 1 h to 3 days. Alkylation occurs exclusively on the thiazolidindione C-5 carbon atom to afford the 5-substituted-5-(arylsulfonyl)thiazolidine-2,4-dione of formula (I).
-
-
- As further shown in Scheme V, compounds of Formula (I), wherein at least one of R3, R4, or R5is amino, as shown in amine XIII can be prepared by hydrolysis of carbamate XII, wherein at least one of R3, R4, or R5 of Formula (I) is a t-butoxycarbonylamino group, by the use of an acid, such as trifluoroacetic acid, or aqueous hydrochloric acid at 0° C. to 60° C., from 0.5 h to 4 h.
-
-
-
-
-
-
-
- or E- or Z- —CH═CH—, by hydrogenation in the presence of palladium or platinum in a solvent such as methanol plus 5% water; alternatively, 5-arylsulfonylthiazolidine-2,4-dione V can be alkylated with XXVIII to give dione XXVII.
- The ability of the compounds of this invention to inhibit FPTase was evaluated in the standard pharmacological in vitro test procedures described below. Data for representative examples is summarized in Table I.
- Enzyme test procedure: FPTase inhibition in vitro assay was performed according to James, G. L., Brown, M. S., and Goldstein, J. L.,Methods in Enzymology, 1995, 255, 38-46; and Garcia, M. A., et al., J. Biol. Chem., 1993, 268, 18415-18420.
- Materials—Purified FPTase (Moomaw, J. F. and Casey, P. J.,J. Biol. Chem., 1992, 267, 17438-17443), purified His6-Ras, inhibitor compounds at 10 mg/ml or 10 mM in 100% DMSO, 3H—FPP (50,000 dpm/pmol) Amersham, TCA/SDS (6%/2%), TCA (6%), Glass fiber filters (0.22-0.45 m), vacuum manifold or 96 well filtration plates.
- Methods—1. Dilute FPTase inhibitors from stock solutions to 2.5× in 2.5% DMSO, 10 mM DTT, 0.5% octyl-B-glucoside. 2. Solution #1 is added to FPTase reaction in a volume of 20 ml. 3. Standard reaction mix, 50 ml, contains 50 mM Tris (7.5), 10 mM ZnCl2, 3 mM MgCl2, 20 mM KCl, 5 mM DTT, 0.2% octyl-B-glucoside, 1% DMSO, 40 mM His6-Ras, 10 ng FPTase, and various concentrations of FPTase inhibitors. 4. Incubate for 30-90 min at 25° C. 5. Stop reactions with TCA/SDS (6%/2%), hold at 40° C. for 45-60 min. 6. Filter by manifold or 96 well plate, wash filter 3-5× with TCA (6%). 7. Add scintillant to filters, measure 3H—FPP incorporation into Ras protein.
- Analysis of Results—Percent inhibition by test compounds is determined by the following:
- (cpm from precipitated Ras with test compounds)−(background cpm)×100=% inhibition.
- (cpm from precipitated Ras without test compounds)−(background cpm)
- Cell-based test procedure: Tumor inhibition in vitro assay was performed according to P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. McMohan, D. Vistica, J. Warren, H. Bokesh, S. Kenney, and M. R. Boyd,J. Natl. Cancer Instit., 1990, 82 (13), 1107-1112; L. V. Rubinstein, R. H. Shoemaker, K. D. Paull, R. M. Simon, S. Tosini, P. Skehan, D. A. Scudiero, A. Monks, and M. R. Boyd, J. Natl. Cancer Instit., 1990, 82 (13), 1113-1118; A. Monks, et al., J. Natl. Cancer Instit., 1991, 83, 757-766; M. R. Boyd and K. D. Paull, Drug Development Res., 1995, 34, 91-109; and S. P. Fricker and R. G. Buckley, Anticancer Research, 1996, 16, 3755-3760.
- Materials—Cell Lines: Human tumor cell lines LS174T, HTB39, LoVo and CaCo2. Cell Media: RPMI 1640 (or DMEM medium and McCoy's medium) with 10% Fetal Bovine Serum supplemented with L-glutamine and Pennicilin/Streptomycin. Compounds: Supplied usually as a 10 mM stock in 100% DMSO. Normal Saline: 150 mM NaCl Trichloroacetic Acid (TCA): 50% (w/v) in water. Sulforhodamine (SRB): 0.4% (w/v) in 1% Acetic Acid. Tris Base: 10 mM in water.
- Methods—Cells are plated at 2000 cells per well, per 200 μl media, and allowed to adhere overnight at 37° C. At 24 h post plating, compounds are added directly at a volume of 0.5 μl. Compound is first diluted in DMSO to generate concentrations of compound or reference standard of: 1, 5, 10 and 25 μM. Dilutions can be made in an identical 96 well plate so that compounds can be added using a multichannel micropipettor set at 0.5 μl. The cells are then incubated for four days after which the media is removed using a 12 well manifold by first tipping the plate forward at a 45 degree angle and then inserting the manifold in an upright orientation to prevent the tips of the manifold from disturbing cells at the bottom of the plate. 200 μl of normal saline is then added to each well using an 8 well multichannel pipettor, followed by the careful addition of 50 μl of 50% TCA. The plates are then incubated for 2 h at 4° C, after which the supernatant is removed using the same technique as above and the plates washed twice with 200 μl water. The plates are then air dried and 50 μl of SRB stock solution is carefully added so that the entire bottom of each well is covered. This again can be used using an 8 well multichannel pipettor. The SRB is incubated with fixed cells for 15 min at room temperature, after which the SRB is removed with the manifold as described above and the plates washed twice with 350 μl of 1% acetic acid per well each time. The plates are then air dried after which the bound SRB is released from protein by the addition of 200 μl of Tris base. Resolubilizing the SRB is aided by placing the plates on a rotator for 15-30 min. The absorbance of each well is determined at 550 or 562 nm using a microtiter plate reader.
- Analysis of Results—Each compound or dilution thereof is performed in triplicate. Outliers are identified by visual inspection of the data. Each plate should have a control (vehicle only). A standard curve is constructed by plotting the concentration of compound against the average absorbance calculated at that concentration. A curve is plotted and the concentration at which the curve passes through the 50% absorbance mark seen in the control well is the IC50 calculated for that compound.
TABLE I in vitro FTase Inhibition Assay IC50 H-Ras* IC50 K-Ras* Ex. No. μM μM 96 0.7 97 0.075-0.15 3.5-5.5 101 0.01-0.03 0.11-1.0 102 0.03-0.032 1.4 103 0.03-0.05 0.9-10 104 0.03-0.054 0.23-0.9 105 0.05-0.15 1.5-1.7 106 0.23-0.25 1.3-1.7 107 0.18-0.2 0.62-0.7 108 0.13-0.18 9->10 109 0.065-0.13 1.4-2.1 110 0.4 7 111 0.11-0.15 0.3-0.55 112 0.59-0.60 1.4-1.5 113 0.05-0.06 0.75-0.8 114 0.013-0.032 0.032-0.32 115 0.012-0.32 0.16-0.23 116 0.005-0.01 0.017-0.04 117 0.02-0.03 0.51-1.0 118 0.07 1.9 119 0.13-0.14 1.3-1.7 120 0.018-0.032 0.53-1.0 121 0.12 1.6 122 0.03-0.05 0.23-1.0 123 0.08-0.082 1.0-2.8 124 0.052-0.08 0.91-1.3 125 0.03 0.4 126 0.09 1.7 127 0.12-0.14 1.3-1.5 128 0.001-0.032 0.02-0.22 129 0.1 0.6-0.79 130 0.023-0.056 0.32-1.0 131 0.006-0.032 0.08-0.31 132 0.041-0.073 0.21-1.0 133 0.04-0.2 0.054-1.0 134 0.014-0.85 0.43-0.68 135 0.02-0.032 1.9-2.1 136 0.043-0.05 1.0-1.9 137 0.021-0.4 0.037-0.8 138 0.023-0.032 0.3-0.42 139 0.17-0.14 0.6-5.0 140 0.15-0.3 1.0-3.6 141 0.021-0.032 0.30-0.34 142 0.017-0.03 0.04-1.0 143 0.03 0.85 144 0.04-0.041 0.32-0.55 145 1.2-1.7 5.6-10 147 0.0068-0.21 0.08-0.1 148 0.0045-0.12 0.023-0.031 149 0.45-0.5 1.0-4.9 150 0.0074-0.032 0.016-0.068 151 0.53-0.7 0.21-1.0 152 0.011-0.016 0.1-0.23 153 0.17-0.2 1.0-6.1 154 0.07-0.15 1.0-2.5 155 0.01-0.32 0.42-0.44 157 0.27 5.0 158 0.15 3.8 159 0.65 >10 161 0.9 10 162 1.21 4.0 163 1.3 10 164 0.15 >10 166 0.15 5.3 167 1.5 10 168 0.28 10 169 0.1 1.8 170 0.38 4.7 171 0.2 3.3 175 0.01-0.032 0.053-0.52 176 0.0032-0.032 0.03-0.32 177 0.011-0.032 0.086-0.1 178 0.017-0.032 0.01 179 0.002-0.032 0.005-0.07 180 0.002-0.032 0.007-0.09 181 0.01-0.032 0.10-0.13 182 0.005-0.01 0.032-0.056 189 0.10 1.2 217 0.10 8.5 220 0.09 3.0 222 0.0033 0.033 223 0.063 >1 226 0.03-0.05 0.1-3.2 227 0.007-0.01 0.21-0.4 228 0.004-0.07 0.23-1 229 0.006-0.02 0.1-0.7 230 0.003-0.0035 0.02-0.5 231 0.01-0.021 0.1-1 232 0.005-0.01 0.04-0.64 233 2.9 10 - Compounds of this invention were tested in cell-based assays against human tumor cell lines DLD-1 and LoVo and ras-transformed rat fibroblast cell lines, RAT-H-ras and RAT-K-ras, and the parent cell line RAT-2, as described under Assays. The range observed for inhibition of cell growth was IC50=7 to 18 μM. The results are displayed in Table I.
- The following examples (239-267) of the invention were tested using the procedure described above with changes in the materials used as described below. The results are displayed in Table II.
- Materials—Cell Lines: Human tumor cell lines DLD-1 and LoVo; ras-transformed rat fibroblast cell lines, RAT-H-ras and RAT-K-ras (growth inhibited by standard FPTase inhibitors), and the parent cell line RAT-2 (resistant to standard FPTase inhibitors). Cell Media: RPMI 1640 (or DMEM medium and McCoy's medium) with 10% Fetal Bovine Serum supplemented with L-glutamine and Pennicilin/Streptomycin. Compounds: Supplied usually as a 10 mM stock in 100% DMSO. Normal Saline: 150 mM NaCl Trichloroacetic Acid (TCA): 50% (w/v) in water. Sulforhodamine (SRB): 0.4% (w/v) in 1% Acetic Acid. Tris Base: 10 mM in water.
TABLE II in vitro FTase Inhibition Assay IC50 (wi. H- IC50 (wi. K- Ras) Ras) Ex. No. μM μM 239 0.7 10 240 0.5 >10 241 1.5 >10 242 1 >10 243 0.3 10 244 0.1 7 245 0.05 3 246 0.3 10 247 0.3 10 248 0.45 5.5 249 0.4 6 250 1.5 10 251 0.15 8.5 252 0.08 8 253 0.09 4.5 254 0.5 >10 255 0.15 10 256 0.8 10 257 0.035 >10 258 2 10 259 0.15 6.5 260 0.1 3 261 0.3 3 262 0.07 2 263 0.15 6.5 264 0.3 >10 265 1.5 >10 266 0.5 >10 267 5 >10 - Examples 239-267of this invention were tested in cell-based assays against human tumor cell lines DLD-1 and LoVo and ras-transformed rat fibroblast cell lines, RAT-H-ras and RAT-K-ras, and the parent cell line RAT-2, as described under Assays. The range observed for inhibition of cell growth was IC50=7 to >40 μM. Results are displayed in Table II.
- Compounds of this invention were tested for in vivo effects in rats against various tumors. For the compound of example 114, when tested against a K-ras dependent human colon carcinoma (LoVo), the following results were obtained (Table III):
TABLE III In Vivo Data for the Compound of Example 114 A Drug Treatment mg/kg b c d b c d b c d per dose Day 8 % T/C (p) Day 15 % T/C (p) Day 22 % T/C (p) 0.5% 88 308 598 Methocel 0.4% Tween 80 Cpd. 61 70 0.10 238 77 0.14 454 76 0.08 (100 PO) Cpd. 45 51 0.02 110 36 <.01 255 43 <.01 (75 IP) Cpd. 65 74 0.15 146 47 0.02 258 43 <0.01 (50 IP) Cpd. 31 35 <0.01 125 41 <.01 251 42 <.01 (100 IP) Vincristine 14 16 <0.01 24 8 <.01 84 14 <.01 (1 IP) 2% Tween 39 121 198 in D5W Cpd. 86 221 0.95 182 150 0.84 324 163 0.92 (75* IP) 20% BCD 62 146 339 in 0.1 N HCl Cpd. 50 81 0.22 138 95 0.44 299 88 0.31 (100 PO) A Drug Treatment mg/kg b c d b c d e per dose Day 29 % T/C (p) Day 36 % T/C (p) S/T 0.5% 748 1264 10/10 Methocel 0.4% Tween 80 Cpd. 608 81 0.20 934 74 0.09 10/10 (100 PO) Cpd. 504 67 0.09 764 60 0.03 8/10 (75 IP) Cpd. 445 59 0.07 964 76 0.16 5/10 (50 IP) Cpd. 341 46 0.01 559 44 0.01 9/10 (100 IP) Vincristine 139 19 <0.01 194 15 <.01 9/10 (1 IP) 2% Tween 287 424 10/10 in D5W Cpd. 478 167 0.92 666 157 0.91 10/10 (75* IP) 20% BCD 499 813 10/10 in 0.1 N HCl Cpd. 641 128 0.77 872 107 0.60 9/10 (100 PO) - Examples 100, and 103,when tested in rats against Rat-2 fibroblasts transformed by oncogenic H-ras for 11 days, i.p., the following results were obtained for day 11 (Table IV):
TABLE IV Ex. No. Dose, mg/kg % T/C 100 100 44 100 30 60 100 10 100 103 100 No efficacy at this dose - In a similar model when tested in rats against Rat-2 fibroblasts transformed by oncogenic K-ras for 25 days, i.p, the compound of example 100 showed no efficacy at 100 mg/kg.
- Based on the results of these standard pharmacological test procedures, the compounds of this invention are useful as agents for treating, inhibiting or controlling ras-associated diseases by inhibiting farnesyl-protein transferase enzyme, when administered in amounts ranging from about 10 to about 200 mg/kg of body weight per day. A preferred regimen for optimum results would be from about 10 mg to about 100 mg/kg of body weight per day and such dosage units are employed that a total of from about 100 mg to about 1000 mg of the active compound for a subject of about 70 kg of body weight are administered in a 24 hour period.
- The dosage regimen for treating mammals may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation. A decidedly practical advantage is that these active compounds may be administered in any convenient manner such as by the oral, intravenous, intramuscular or subcutaneous routes.
- The active compounds may be orally administered, for example, with an inert diluent or with an assimilable edible carrier, or they may be enclosed in hard or soft shell gelatin capsules, or they may be compressed into tablets or they may be incorporated directly with the food of the diet. For oral therapeutic administration, these active compounds may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers and the like. Such compositions and preparations should contain at least 0.1% of active compound. The percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 2% to about 60% of the weight of the unit. The amount of active compound in such therapeutically useful compositions is such that a suitable dosage will be obtained. Preferred compositions or preparations according to the present invention are prepared so that an oral dosage unit form contains between 10 and 1000 mg of active compound. The tablets, troches, pills, capsules and the like may also contain the following: a binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose, or saccharin may be added or a flavoring agnet such as peppermint, oil of wintergreen or cherry flavoring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills or capsules may be coated with shellac, sugar or both. A syrup or elixir may contain the active compound, sucrose, as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavoring such as cherry or orange flavor. Of course, any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts used. In addition, these active compounds may be incorporated into sustained-release preparations and formulations.
- These active compounds may also be administered parenterally or intraperitoneally. Solutions or suspensions of these active compounds as a free base or pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures therof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth or microorganisms.
- The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and starage and must be prepared against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid poly-ethylene glycol), suitable mixtures thereof, and vegetable oils.
- The present invention accordingly provides a pharmaceutical composition which comprises a compound of Formula (I) of this invention in combination or association with a pharmaceutically acceptable carrier. In particular, the present invention provides a pharmaceutical composition which comprises an effective amount of a compound of this invention and a pharmaceutically acceptable carrier.
- As used in accordance with this invention, the term providing an effective amount of a compound means either directly administering such compound, or administering a prodrug, derivative, or analog which will form an effective amount of the compound within the body.
- The present invention provides a method of treatment of ras oncogene-dependent tumors, such as cancers of the pancreas, colon, bladder, and thyroid; a method of controlling metastasis, suppressing angiogenesis, and inducing apoptosis; a method of treating Ras-associated proliferative diseases other than cancer, such as restenosis, neuro-fibromatosis, endometriosis, and psoriasis. The compounds of the present invention may also inhibit prenylation of proteins other than Ras, and thus provide a method of treatment of diseases associated with other prenyl modifications of proteins.
- The invention will be more fully described in conjunction with the following specific examples which are not to be construed as limiting the scope of the invention.
- To a solution of 5-bromothiazolidine-2,4-dione (6.66 g, 34.0 mmol, Zask et al, J. Med. Chem. 1990, 33, 1418-1423) and 3-methoxybenzenethiol (5.00 g, 35.7 mmol) in dry THF (150 mL) at −78° C. was added sodium bis(trimethylsilyl)amide (1.0M in THF, 56 mL, 56 mmol) dropwise. After 30 min. the reaction mixture was warmed to room temperature. After an additional hour, 2N HCl was added to pH=1. The layers were separated and the aqueous phase was extracted with ethyl acetate. The combined organic phase was dried (MgSO4), concentrated and flash chromatographed (3:1 hexanes:ethyl acetate) to provide 5-(3-methoxyphenyl-4-sulfanyl)thiazolidine-2,4-dione, as a white solid (4.86 g, 56%); a sample of 5-(3-methoxyphenyl-4-sulfanyl)-thiazolidine-2,4-dione (4.70 g, 18.4 mmol) was oxidized with 9.4 ml of 30% hydrogen peroxide in 50 ml of acetic acid at 45° C. for 3 hours to give 3.4 g (64%) of the title compound as a glass; NMR(CDCl3) δ3.9 (s,3H), 5.53 (s,1H), 7.3 (m,1H), 7.42 (s,1H), 7.53 (m,2H); MS m/Z 285.9 (M−H) (calcd. For C10H9NO5S2)
- In the manner of Example 1 above 4-fluorobenzenethiol and bromothiazolidinedione gave 5-(4-fluorophenyl-4-sulfanyl)-thiazolidine-2,4-dione, which on oxidation gave the title compound [U.S. Pat. No. 5,605,918; February 1997;Wrobel, et al.].
- To a solution of 5-bromothiazolidinedione (5.94 g, 30.3 mmol) in 100 ml of absolute ethanol was added sodium 4-iodophenylsulfinate (9.67 g, 33.3 mmol)and this slurry was stirred for about 18 hours at room temperature. Solvent was removed and the residue was combined with water and was acidified with 2N hydrochloric acid. The organic portion was chromatographed on silica gel with hexanes-ethyl acetate (3:1) to give 5.8 g (50%) of the title compound, mp 190-193° C.
- In a like manner to the procedure of Example 3 above, the following aryl sulfinate salts which are either commercially available, or are prepared by the reduction of the corresponding sulfonyl chloride with sodium iodide in acetone (Harwood, Julia, and Thuillier, Tetrahedron, 1980, 36, 2483-2487), were reacted with 5-bromothiazolidinedione to give the indicated product, 5-arylsulfonylthiazolidinediones of Examples 4-17:
EX. No. SULFINATE SALT PRODUCT MELTING POINT ° C. 4 Sodium 4-Trifluoro- 5-(4-Trifluoromethoxy- 108-110 methoxybenzenesulfinate benzenesulfonyl)-thiazol- idine-2,4-dione 5 Sodium 3-Nitrobenzene 5-(3-Nitrobenzenesulfonyl)- 139-140 sulfinate thiazolidine-2,4-dione 6 Sodium 4-Nitrobenzene 5-(4-Nitrobenzenesulfonyl)- 182-183 sulfinate thiazolidine-2,4-dione 7 Sodium 4-(Pyridin-4- 5-[4-(Pyridin-4-yloxy)- 160 with yloxy)benzenesulfinate benzenesulfonyl]-thiazolidine-2,4- decomp. dione 8 Sodium 4-Phenoxy- 5-(4-Phenoxybenzene sulfonyl)- 160-162 benzene-sulfinate thiazolidine-2,4-dione 9 Sodium 4-Benzyloxy- 5-(4-Benzyloxybenzene- 190-200 benzenesulfinate sulfonyl)-thiazolidine-2,4-dione decomp. 10 Sodium 3,4-Dimethoxy- 5-(3,4-Dimethoxybenzene- 220-222 benzene sulfinate sulfonyl)-thiazolidine-2,4-dione 11 Sodium N-Acetyl-3-amino- N-[5-(2,4-Dioxothiazolidine-5- 217-219 4-methoxyphenyl-sulfinate sulfonyl)-2-methoxy-phenyl]- acetamide 12 Sodium 5-Chloro- 5-(5-Chloro-thiophene-2- 133-135 thiophene-2-sulfinate sulfonyl)-thiazolidine-2,4-dione 13 Sodium Thiophene-2- 5-(Thiophene-2-sulfonyl)- 176-177 sulfinate thiazolidine-2,4-dione 14 Sodium 5-Pyridin-2-yl- 5-(5-Pyridin-2-yl-thiophene-2- 168-170 thiophene-2-sulfinate sulfonyl)-thiazolidine-2,4-dione 15 Sodium 4-Butoxybenzene 5-(4-Butoxybenzenesulfonyl)- 120-121 sulfinate thiazolidine-2,4-dione 16 Sodium 1-Naphthalenyl) 5-[(1-Naphthalenyl)sulfonyl]-2,4- 187-188 sulfinate thiazolidinedione 17 Sodium (8-Quinolinyl) 5-[(8-Quinolinyl)sulfonyl]-2,4- amorphous sulfinate thiazolidinedione solid - A solution of 1,4-dichloro-2-iodobenzene (20.0 g, 73.3 mmol), 4-pentyn-1-ol (6.17 g, 73.3 mmol), bistriphenylphosphine(Pd II) chloride (1.03 g, 1.47 mmol), and copper(I) iodide (0.14 g, 0.733 mmol) in 400 ml of diethylamine was stirred under nitrogen for three days. This was diluted with dichloromethane and the oily layer was adsorbed onto silica gel and eluted with hexanes-ethyl acetate (5:1) to give 5-(2,5-dichloro-phenyl)pent-4-yn-1-ol, 13.7 g (82%); NMR (CDCl3) δ1.9 (m,2H), 2.6 (t,2H), 3.85 (t,2H), 7.2 (dd,1H), 7.28 (m,1H), 7.4 (d,2H).
- Preparation of the title compound with 4-bromophenyl methyl sulphone (5.87 g, 25 mmol) and 4-pentyn-1-ol (2.1 g, 25 mmol) according to the procedure in Example 18 yielded 5.12 g (87%) of yellow oil which was characterized as 5-(4-Methanesulfonylphenyl)pent-4-yn-1-ol: NMR (CDCl3) δ1.88-1.93 (m,2H), 2.56-2.60 (t, J=6.99, 2H), 3.04 (s,3H), 3.80-3.84 (t, J=6.15,2H), 7.56 (d, J=5.1, 2H), 7.85 (d,J=4.8, 2H). MS m/Z 239 (M+H cald. for C12H14O3S 238.3)
- In a manner described in Example 19 immediately above the following acetylenic alcohols of Examples 20-48 were prepared from the corresponding iodobenzene or bromobenzene and 4-pentyn-1-ol (structures were confirmed as above by NMR):
EX. No. PRODUCT Mass Spectrum M+ 20 5-(2-Methyl-5-nitrophenyl)pent-4-yn-1-ol 220 (M + H) 21 5-(2-Methoxy-5-nitrophenyl)pent-4-yn-1-ol 235.0 22 5-(2-Methoxy-4-nitrophenyl)pent-4-yn-1-ol 235.0 23 5-(4-Nitro-2-trifluoromethylphenyl)pent-4-yn-1-ol 273.0 24 5-(3-Fluoro-5-nitrophenyl)pent-4-yn-1-ol 223.0 25 5-(3-Fluoro-4-methoxy-5-nitrophenyl)pent-4-yn-1-ol 254.2 (M + H) 26 5-(4-Methoxy-2-nitrophenyl)pent-4-yn-1-ol 234.2 (M + H) 27 [3-Chloro-4-(5-hydroxypent-1-ynyl)phenyl]-carbamic Acid tert-Butyl Ester 28 5-(4-Pyrrol-1-ylphenyl)pent-4-yn-1-ol 226.2 (M + H) 29 5-(2,5-Dimethylphenyl)pent-4-yn-1-ol 189.1 (M + H) 30 5-(5-Chloro-2-methylphenyl)pent-4-yn-1-ol 208.8 (M + H) 31 5-(4-Chloro-2-methylphenyl)pent-4-yn-1-ol 208.0 32 5-(2,4-Dimethylphenyl)pent-4-yn-1-ol 188.1 33 5-(2-Methyl-4-nitrophenyl)pent-4-yn-1-ol 219.0 34 5-(4-Bromo-2-methylphenyl)pent-4-yn-1-ol 253.0 35 3-(5-Hydroxypent-1-ynyl)-4-methylbenzoic Acid Methyl 232.1 Ester 36 4-(5-Hydroxypent-1-ynyl)-3-methylbenzoic Acid Methyl 232.1 Ester 37 5-(4-tert-Butylphenyl)pent-4-yn-1-ol 38 [4-Methyl-3-(5-hydroxypent-1-ynyl)phenyl] carbamic Acid tert-Butyl Ester 39 5-(2-Chlorophenyl)pent-4-yn-1-ol 40 5-(2,4-Dichlorophenyl)pent-4-yn-1-ol 41 4-(5-Hydroxypent-1-ynyl)trifluoromethyl benzene 42 4-(5-Hydroxypent-1-ynyl)trifluoromethoxy-benzene 43 [3-Methyl-4-(5-hydroxypent-1-ynyl)phenyl] carbamic Acid tert-Butyl Ester 44 N-tert-Butyl-3-(5-hydroxypent-1-ynyl)-4- methylbenzamide 45 4-(5-Hydroxypent-1-ynyl)phenylcarbamic Acid tert-Butyl Ester 46 3-(5-Hydroxypent-1-ynyl)-4-methylbenzoic Acid Methyl Ester 47 5-(4-Chlorophenyl)pent-4-yn-1-ol 48 5-(3-Chlorophenyl)pent-4-yn-1-ol - In a manner described in Example 18 above, 5-hexyn-1-ol was reacted with 1-chloro-4-iodobenzene to give the title compound, MS m/Z exact mass 209.724 (M+H) (calcd. For C12H13OCl 209.70).
- In a manner described in Example 18 above, 10-undecyn-1-ol was reacted with 1-chloro-4-iodobenzene to give the title compound; NMR (CDCl3) δ1.21-1.50 (m, 10H), 1.50-1.65 (m, 4H), 2.36-2.41 (m,2H), 3.61-3.66(m,2H), 7.16-7.31 (m, 4H).
- Preparation of the title compound with commercial available 4-bromo-diphenyl ether (5.93 g, 23.8 mmol) according to the procedure in Example 18 yielded 440 mg (8.2%) of brown oil which was characterized as 3-(4-phenoxyphenyl)prop-2-yn-1-ol:
- NMR (CDCl3) δ4.50 (d, J=6), 6.91 (d, J=2.01, 1H), 6.93 (d, J=2.01, 1H), 7.01 (d, J=0.63, 1H), 7.04 (d, J=1.17, 1H), 7.11-7.16 (m, 1H), 7.36 (d, J=0.6, 1H),7.38 (d, J=2.52, 2H), 7.41 (d, J=1.92, 1H). MS m/z 224.08 (M+ calcd. for C15H12O2=224.08)
- In a manner described in Example 18 above, propargyl alcohol was reacted with 4-bromobiphenyl to give the title compound as white crystals: NMR (CDCl3) δ4.53 (d, J=4.74, 2H), 7.38 (d, J=7.17, 1H), 7.42-7.60 (m, 8H). MS m/z 208 (M+ calcd. for C15H12O=208.3).
- In a manner described in Example 18 above, propargyl alcohol was reacted with 2-bromothiophene to give the title compound as a brown oil which was used in the next step without further purification.
- 5-(4-Chlorophenyl)pent-4-yn-1-ol (35.7 g, 182 mmol), 4-dimethylaminopyridine (8.9 g, 73 mmol), p-toluenesulfonyl chloride (34.7 g, 182 mmol), and 62 ml of triethylamine were combined in 330 ml of dichloromethane at 0° C. The mixture was stirred for 30 min. at 0° then 18 hours at room temperature. Dilution with 200 ml of dichloromethane followed by washing with brine, drying over magnesium sulfate, filtration through silica gel with hexane-ethyl acetate, 8:1, gave a yellow solid on evaporation. Crystallization from ether gave 5-(4-Chlorophenyl)pent-4-yn-1-ol p-toluenesulfonate as colorless crystals (31.7 g, 49% yield). This was converted to the title compound by reaction with sodium iodide in acetone, and was used in subsequent reactions with no further purification; MS m/z 303.9 (M+ calcd. for C11H10ClI=304.6).
- Preparation of the title compound with tosylated alcohol of Example 19, 5-(4-methanesulfonylphenyl)pent-4-yn-1-ol (3.14 g, 8.35 mmol), NaI (6.26 g, 41.76 mmol) following the procedure of Example 54 yielded 2.8 g (96%) of the title compound as a red oil: NMR (CDCl3) δ2.06-2.15 (m, 2H), 2.58-2.63 (t, J=6.78, 2H), 3.04 (s, 3H), 3.33-3.37 (t, J=6.69, 2H), 7.57 (d, J=1.77, 2H), 7.85 (d, J=4.95, 2H). MS m/z 348.9 (M+H cald. for C12H13O2S 348=349.2).
- 5-(2,5-Dichlorophenyl)pent-4-yn-1-ol (13.7 g, 59.8 mmol), triphenylphosphine (20.4 g, 77.8 mmol), and imidazole (5.71 g, 83.8 mmol) in a mixed solvent (100 ml acetonitrile-150 ml ether) was stirred under nitrogen at 0° C., and to this was slowly added iodine (21.3 g, 83.8 mmol). The solution was allowed to warm to room temperature and stirring was continued for 18 hours. This was chromatographed on silica gel with hexane to give the title compound (14.7 g,72%), MS m/z 337.9 (M−H calcd. for C11H9Cl2I=338.0).
- In the manner described in Example 55, above, the following alcohols were converted to the corresponding iodides of Examples 56-88, and structures were confirmed as above by NMR:
EX. No. ALCOHOL PRODUCT MASS SPECTRUM 56 5-(2,4-Dichlorophenyl)-pent- 1,5-Dichloro-2-(5-iodo- 337.9 4-yn-1-ol pent-1-ynyl)benzene 57 5-(2-Methyl-5-nitro- 2-(5-Iodopent-1-ynyl)-1- 330 phenyl)pent-4-yn-1-ol methyl-4-nitro-benzene 58 5-(2-Methoxy-5-nitro- 2-(5-Iodopent-1-ynyl)-1- 345.1 phenyl)pent-4-yn-1-ol methoxy-4-nitro-benzene 59 5-(2-Methoxy-4-nitro- 1-(5-Iodopent-1-ynyl)-2- 345.0 phenyl)pent-4-yn-1-ol methoxy-4-nitro-benzene 60 5-(4-Nitro-2-trifluoro-methyl- 1-(5-Iodopent-1-ynyl)-4- 383.0 phenyl)pent-4-yn-1-ol nitro-2-trifluoro- methylbenzene 61 5-(3-Fluoro-5-nitro- 1-Fluoro-3-(5-iodopent-1- 334 phenyl)pent-4-yn-1-ol ynyl)-5-nitrobenzene 62 5-(3-Fluoro-4-methoxy-5- 1-Fluoro-5-(5-iodopent-1- nitrophenyl)pent-4-yn-1-ol ynyl)-2-methoxy-3- nitrobenzene 63 5-(4-Methoxy-2-nitro- 1-(5-Iodopent-1-ynyl)-4- phenyl)pent-4-yn-1-ol methoxy-2-nitro-benzene 64 [3-Chloro-4-(5-hydroxy-pent- [3-Chloro-4-(5-iodo-pent-1- [mp 104- 1-ynyl)-phenyl]-carbamic ynyl)phenyl]-carbamic acid 106° C.] acid tert-butyl ester tert-butyl ester 65 5-(4-Pyrrol-1-yl-phenyl)-pent- 1-[4-(5-Iodopent-1-ynyl)- 335.7 4-yn-1-ol phenyl]-1H-pyrrole 66 5-(2,5-Dimethylphenyl)- 1-(5-Iodopent-1-ynyl)-2,5- 298.0 pent-4-yn-1-ol dimethyl-benzene 67 5-(5-Chloro-2-methyl- 4-Chloro-2-(5-iodopent-1- 317.9 phenyl)-pent-4-yn-1-ol ynyl)-1-methyl-benzene 68 5-(4-Chloro-2-methyl- 4-Chloro-1-(5-iodopent-1- 317.9 phenyl)pent-4-yn-1-ol ynyl)-2-methyl-benzene 69 5-(2,4-Dimethyl-phenyl)pent- 1-(5-Iodopent-1-ynyl)-2,4- 298.0 4-yn-1-ol dimethyl-benzene 70 5-(2-Methyl-4-nitro-phenyl)- 1-(Iodopent-1-ynyl)-2- 328.9 pent-4-yn-1-ol methyl-4-nitrobenzene 71 5-(4-Bromo-2-methyl-phenyl) 4-Bromo-1-(5-iodopent-1- 361.9 pent-4-yn-1-ol ynyl)-2-methyl-benzene 72 3-(5-Hydroxypent-1-ynyl)-4- 3-(5-Iodopent-1-ynyl)-4- 341.9 methylbenzoic acid methyl methylbenzoic acid methyl ester ester 73 4-(5-Hydroxy-pent-1-ynyl)-3- 3-(5-Iodopent-1-ynyl)-4- 341.9 methylbenzoic acid methyl methylbenzoic Acid Methyl ester Ester 74 [4-Methyl-3-(5-hydroxypent- [3-(5-Iodopent-1-ynyl)-4- 399.9 1-ynyl)phenyl]carbamic acid methylphenyl]carbamic tert-butyl ester acid tert-butyl ester 75 5-(2-Chlorophenyl)-pent-4- 1-Chloro-2-(5-iodopent-1- 304.0 yn-1-ol ynyl)benzene 76 5-(2,4-Dichlorophenyl)pent- 2,4-Dichloro-1-(5-iodo- 337.9 4-yn-1-ol pent-1-ynyl)benzene 77 4-(5-Hydroxypent-1- 1-(5-Iodopent-1-ynyl)-4- 337.9 ynyl)trifluoromethyl-benzene trifluoromethylbenzene 78 4-(5-Hydroxypent-1- 1-(5-Iodopent-1-ynyl)-4- ynyl)trifluoromethoxy- trifluoromethoxy-benzene benzene 79 [3-Methyl-4-(5-hydroxypent- [4-(5-Iodopent-1-ynyl)-3- 399.9 1-ynyl)-phenyl]carbamic methylphenyl]carbamic Acid tert-Butyl Ester Acid tert-Butyl Ester 80 N-tert-Butyl-3-(5- N-tert-Butyl-3-(5-iodo-pent- 383.8 hydroxypent-1-ynyl)-4- 1-ynyl)-4-methyl- methylbenzamide benzamide 81 4-(5-hydroxypent-1- [4-(5-Iodopent-1-ynyl)- 385.9 ynyl)phenylcarbamic Acid phenyl]carbamic Acid tert- tert-Butyl Ester Butyl Ester 82 3-(5-Hydroxypent-1-ynyl)-4- 3-(5-Iodopent-1-ynyl)-4- methylbenzoic Acid Methyl methylbenzoic Acid Methyl Ester Ester 83 5-(3-Nitrophenyl)pent-4-yn- 1-(5-Iodopent-1-ynyl)-3- 315.8 1-ol nitrobenzene 84 5-(4-Nitrophenyl)pent-4-yn- 1-(5-Iodopent-1-ynyl)-4- 315.9 1-ol nitrobenzene 85 5-(4-tert-Butylphenyl)pent-4- 1-tert-Butyl-4-(5-iodo-pent- 326.0 yn-1-ol 1-ynyl)benzene 86 5-(3-Chlorophenyl)pent-4- 1-Chloro-3-(5-iodopent-1- 304.0 yn-1-ol ynyl)benzene 87 6-(4-Chlorophenyl)hex-5-yn- 1-(4-Chlorophenyl)-6-iodo- 1-ol 1-hexyne 88 11-(4-Chlorophenyl)-undec- 1-(4-Chlorophenyl)-11- 10-yn-1-ol iodo-1-undecyne - A solution of 3-(4-phenoxyphenyl)prop-2-yn-1-ol of Example 51 (415 mg, 1.85 mmol), triphenylphosphine (514 mg, 1.96 mmol), carbon tetrabromide (650 mg, 1.96 mmol) in THF (3 ml) was stirred at room temperature for 3 days. Evaporation of the solution, and chromatography of the residue gave the title compound as a brown oil: NMR (CDCl3) δ4.16 (s, 2H), 6.91 (d, J=2.1, 1H), 6.93 (d, J=2.1, 1H), 7.01 (d, J=0.93, 1H), 7.04 (d, J=1.14, 1H), 7.12-7.17 (m, 1H), 7.36 (d, J=0.75, 1H), 7.39 (d, J=1.98, 2H), 7.42 (d, J=2.64, 1H). MS m/z 288 (M+1 calcd. for C15H11BrO 287.155).
- In the manner described in Example 89, above, the following alcohols were converted to the corresponding bromides of Examples 90-91:
mass EX. No. ALCOHOL PRODUCT spectrum 90 3-Thiophene-2-ylprop-2- 2-(3-Bromoprop-1-ynyl)-thiophene 201.9 (M + H) yn-1-ol 91 3-Biphenyl-4-ylprop-2-yn- 4-(3-Bromoprop-1-ynyl)- 270 (M − H) 1-ol biphenyl - To a solution of 5-(4-methoxyphenyl-4-sulfanyl)-thiazolidine-2,4-dione [U.S. Pat No. 5,605,918; February 1997; Wrobel, et al.](1.00 g, 3.92 mmol)in THF (40 ml) was added NaH (0.34 g, 8.62 mmol) at 0° C. and stirring was continued for 30 minutes. To this was added a solution of 1-(4-chlorophenyl)-5-iodo-1-pentyne (1.25 g, 4.12 mmol)in 3 ml of THF. This was then stirred at room temperature for 18 hours, and then quenched in water. The resultant oil was chromatographed on silica gel using hexane:ethyl acetate (4:1) to give the title compound as a pale yellow solid, m.p. 106-109° C.
- In the manner described in Example 92 immediately above, the appropriate substituted alkyl iodide was reacted with a substituted-phenyl thiazolidinedione to give the following compounds of Examples 93-96:
- MS m/z 444.2 (calcd for C22H20ClNO3S2 445.99).
- mp 54-56° C., MS m/z 514.0 (calcd. for C27H30ClNO3 516.1).
- This was used in the next step without further purification
- This was used in the next step without further purification
- To a solution of 5-[5-(4-Chlorphenyl)pent-4-ynyl]-5-(4-methoxyphenyl sulfanyl)-thiazolidine-2,4-dione of Example 92 above, (0.87 g, 2.0 mMol) in glacial acetic acid (30 ml) at 60° C. was added 30% hydrogen peroxide (0.82 ml, 8.0 mmol). After 30 minutes the reaction mixture was evaporated and the residue was subjected to chromatography to give the title compound, MS (M−H) m/z 462.0 (calcd. For C21H18CINO5S2 463.96).
- 5-[6-(4-Chlorophenyl)hex-5-ynyl]-5-(4-methoxyphenylsulfanyl)-thiazolidine-2,4-dione (0.30 g, 0.81 mmol) and isobutyraldehyde (0.37 ml, 4.04 mmol) were dissolved in acetonitrile (40 ml). Oxygen was bubbled through this solution for 18 hours, and then the solution was evaporated and the residue was subjected to chromatography on silica gel (hexane-ethyl acetate, 1:1) to give 0.108 g, 28% yield of the title compound, mp 145-148° C., MS m/z 476.0.
- 5-[11-(4-Chlorophenyl)undec-10-ynyl]-5-(4-methoxyphenylsulfanyl)-thiazolidine-2,4-dione was converted to the title compound using the procedure of Example 98 immediately above, mp 114-121° C.
- To a solution of 5-(4-methoxyphenylsulfonyl)-thiazolidine-2,4-dione [U.S. Pat. No. 5,605,918; February 1997; Wrobel, et al.]((2.74 g, 9.5 mMol) in DMF (50 ml) was added sodium hexamethyldisilazide (1.0 M solution in THF—19.0 ml, 19.0 mmol) at room temperature, under nitrogen, and this was stirred for 15 minutes. To this was added 1-(4-chlorophenyl)-5-iodo-1-pentyne (2.70 g, 9.5 mmol) over 5 minutes, and this solution was stirred overnight at room temperature. The reaction mixture was quenched in water, and the solid that was obtained was recrystallized from methanol to give 1.59 g of the title compound as colorless crystals, m.p. 172-174°; NMR (CDCl3) δ1.59 (m, 1H); 2.0(m, 1H); 2.36 (dq (doublet of quartets?), 1H); 2.5 (t, 2H); 2.67 (dq, 1H); 3.88 (s, 3H); 7.0 (d, 2H); 7.26 (s, 4H) 7.86 (d, 2H)
- In a manner essentially that of Example 100, the following products of Examples 101-171 were obtained by alkylation of an arylthiazolidine-2,4-dione with the appropriate iodo or bromo compound. All structures were verified by NMR and gave spectra consistent with that shown in Example 100:
Ex. melting mass No. Product point ° C. spectrum m/z (M − H) 101 5-[5-(2-Chlorophenyl)pent-4-ynyl]-5-(4- 133-135 463.0 methoxybenzenesulfonyl)thiazolidine-2,4- dione 102 5-[5-(3-Chlorophenyl)pent-4-ynyl]-5-(4- 134-136 463.0 methoxybenzenesulfonyl)thiazolidine-2,4- dione 103 5-[5-(4-Chlorophenyl)pent-4-ynyl]-5-(p- 176-177 447.0 tolylsulfonyl)thiazolidine-2,4-dione 104 5-[5-(4-Chlorophenyl)pent-4-ynyl]-5-(4- 157-159 558.8 iodobenzenesulfonyl)thiazolidine-2,4-dione 105 5-[5-(4-Chlorophenyl)pent-4-ynyl]-5-(4- 450.9 fluorobenzenesulfonyl)thiazolidine-2,4- dione 106 5-[5-(4-Chlorophenyl)pent-4-ynyl]-5-(4- 193-194 525.0 phenoxybenzenesulfonyl)-thiazolidine-2,4- dione 107 5-[5-(4-Chlorophenyl)pent-4-ynyl]-5- 150-153 483.0 (naphthalene-2-sulfonyl)thiazolidine-2,4- dione 108 N-(4-{5-[5-(4-Chlorophenyl)pent-4-ynyl]-2,4- 232 490.0 dioxothiazolidine-5- decomp. sulfonyl}phenyl)acetamide 109 5-[5-(4-Chlorophenyl)pent-4-ynyl]-5- pale 484.0 (quinoline-8-sulfonyl)thiazolidine-2,4-dione yellow solid 110 5-[5-(4-Chlorophenyl)pent-4-ynyl]-5-(4- tan solid 477.9 nitrobenzenesulfonyl)thiazolidine-2,4-dione 111 5-(4-Benzyloxybenzenesulfonyl)-5-[5-(4- 181-184 539.0 chlorophenyl)pent-4-ynyl]-thiazolidine-2,4- dione 112 5-(4-Butoxybenzenesulfonyl)-5-[5-(4- 116-118 505.0 chlorophenyl)-pent-4-ynyl]-thiazolidine-2,4- dione 113 5-[5-(4-Chlorophenyl)pent-4-ynyl]-5- 172-174 483.0 (naphthalene-1-sulfonyl)-thiazolidine-2,4- dione 114 5-[5-(2,5-Dichloro-phenyl)pent-4-ynyl]-5-(4- 124-126 497.4 methoxy-benzenesulfonyl)-thiazolidine-2,4- dione 115 5-[5-(2,5-Dichloro-phenyl)pent-4-ynyl]-5-(4- yellow 593.3 iodobenzenesulfonyl)-thiazolidine-2,4-dione amorphous solid 116 5-[5-(2,5-Dichlorophenyl)pent-4-ynyl]-5-[4- 179-180 560.5 (pyridin-4-yloxy)benz- decomp. enesulfonyl]thiazolidine-2,4-dione 117 5-[5-(2,4-Dichlorophenyl)pent-4-ynyl]-5-(4- 129-133 497.4 methoxybenzenesulfonyl)-thiazolidine-2,4- dione 118 5-(4-Methoxybenzenesulfonyl)-5-[5-(3- 126-130 473.5 nitrophenyl)pent-4-ynyl]thiazolidine-2,4- dione 119 5-[5-(3-Nitrophenyl)pent-4-ynyl]-5-(4- 190-191 535.6 phenoxybenzenesulfonyl)thiazolidine-2,4- dione 120 5-(4-Iodobenzenesulfonyl)-5-[5-(4- 205-207 569.4 nitrophenyl)pent-4-ynyl]thiazolidine-2,4- dione 121 5-(4-Methoxybenzene sulfonyl)-5-[5-(4- 156-158 473.5 nitrophenyl)pent-4-ynyl]thiazolidine-2,4- dione 122 5-(4-Methoxybenzene sulfonyl)-5-[5-(2- yellow oil 487.5 methyl-5-nitrophenyl)pent-4- ynyl]thiazolidine-2,4-dione 123 5-(4-Methoxybenzenesulfonyl)-5-[5-(2- orange 503.5 methoxy-5-nitrophenyl)pent-4- solid ynyl]thiazolidine-2,4-dione 124 5-[5-(2-Methyl-5-nitrophenyl)pent-4-ynyl]-5- 203-204 549.6 (4-phenoxybenzenesulfonyl-thiazolidine- 2,4-dione 125 5-(4-Iodobenzenesulfonyl)-5-[5-(2-methyl-5- 188-190 583.4 nitrophenyl)pent-4-ynyl]-thiazolidine-2,4- dione 126 5-[5-(2-Methyl-5-nitrophenyl)-pent-4-ynyl]- 168-172 507.6 5-(naphthalene-1-sulfonyl)-thiazolidine-2,4- dione 127 5-[5-(2-Methyl-5-nitrophenyl)pent-4-ynyl]-5- 197-200 507.6 (naphthalene-2-sulfonyl)-thiazolidine-2,4- dione 128 5-[5-(2-Methyl-4-nitrophenyl)pent-4-ynyl]-5- 199 572.6 [4-(pyridin-4-yloxy)- decomp. benzenesulfonyl]thiazolidine- 2,4-dione 129 5-[5-(2-Methyl-4-nitrophenyl)pent-4-ynyl]-5- 210-212 549.6 (4-phenoxybenzenesulfonyl)-thiazolidine- 2,4-dione 130 5-(4-Methoxybenzenesulfonyl)-5-[5-(2- yellow 487.5 methyl-4-nitrophenyl)-pent-4-ynyl]- glass thiazolidine-2,4-dione 131 5-(4-Iodobenzenesulfonyl)-5-[5-(2-methyl-4- 150-152 657.5 nitrophenyl)pent-4-ynyl]-thiazolidine-2,4- dione 132 5-(4-Methoxybenzenesulfonyl)-5-[5-(2- yellow 503.5 methoxy-4-nitrophenyl)pent-4- gum ynyl]thiazolidine-2,4-dione 133 5-[5-(3-Fluoro-5-nitrophenyl)pent-4-ynyl]-5- white 491.5 (4-methoxybenzenesulfonyl)-thiazolidine- solid 2,4-dione 134 5-[5-(2,5-Dimethylphenyl)pent-4-ynyl]-5-(4- 129-130 552.4 iodobenzenesulfonyl)-thiazolidine-2,4-dione 135 5-[5-(2,5-Dimethylphenyl)pent-4-ynyl]-5-(4- 149-150 456.6 methoxybenzenesulfonyl)-thiazolidine-2,4- dione 136 5-[5-(2,4-Dimethylphenyl)pent-4-ynyl]-5-(4- 155-156 456.6 methoxybenzenesulfonyl)-thiazolidine-2,4- dione 137 5-[5-(2,4-Dimethylphenyl)pent-4-ynyl]-5-(4- 153-154 552.4 iodobenzenesulfonyl)-thiazolidine-2,4-dione 138 5-[5-(5-Chloro-2-methylphenyl)pent-4- 121-122 477.0 ynyl]-5-(4-methoxybenzene-sulfonyl)- thiazolidine-2,4-dione 139 5-[5-(5-Chloro-2-methylphenyl)pent-4-ynyl]- 196 549.0 5-(4-trifluoromethoxybenzene-sulfonyl)- decomp. thiazolidine-2,4-dione 140 5-[5-(4-Chloro-2-methylphenyl)pent-4- 197 559.9 ynyl]-5-(4-trifluoromethoxy- decomp. benzenesulfonyl)-thiazolidine-2,4-dione 141 5-[5-(4-Chloro-2-methylphenyl)-pent-4- 93-99 591.4 ynyl]-5-(4-iodobenzene-sulfonyl)- thiazolidine-2,4-dione 142 5-[5-(4-Chloro-2-methylphenyl)pent-4- yellow 477.0 ynyl]-5-(4-methoxybenzene-sulfonyl)- foam thiazolidine-2,4-dione 143 5-[5-(4-Bromo-2-methy-phenyl)pent-4- white 540.0 ynyl]-5-(4-methoxybenzene-sulfonyl)- foam thiazolidine-2,4-dione 144 5-[5-(4-Bromo-2-methylphenyl)pent-4-ynyl]- 146-147 617.3 5-(4-iodobenzenesulfonyl)-thiazolidine-2,4- dione 145 (4-{5-[5-(4-Methoxybenzensulfonyl)-2,4- yellow 543.7 dioxothiazolidin-5-yl]pent-1- solid ynyl}phenyl)carbamic Acid tert-Butyl Ester 146 (3-Chloro-4-{5-[5-(4-methoxybenzene yellow oil 578.1 sulfonyl)-2,4-dioxothiazolidin-5-yl]pent-1- ynyl}phenyl)carbamic Acid tert-Butyl Ester 147 N-tert-Butyl-3-{5-[5-(4-iodo- white 637.5 benzenesulfonyl)-2,4-dioxothiazol-idin-5- powder yl]-pent-1-ynyl}-4-methyl-benzamide 148 (3-{5-[5-(4-Iodobenzenesulfonyl)-2,4- 172-175 653.5 dioxothiazolidin-5-yl]-pent-1-ynyl}-4- methylphenyl)carbamic Acid tert-Butyl Ester 149 (4-{5-[5-(4-Methoxybenzenesulfonyl)-2,4- yellow 557.7 dioxo-thiazolidin-5-yl]pent-1-ynyl}-3- solid methylphenyl)carbamic Acid tert-Butyl Ester 150 (3-{5-[5-(4-Methoxybenzenesulfonyl)-2,4- 116-118 557.7 dioxothiazolidin-5-yl]pent-1-ynyl}-4- methylphenyl)carbamic Acid tert-Butyl Ester 151 (4-{5-[5-(4-Methoxybenzenesulfonyl)-2,4- tan solid 611.6 dioxothiazolidin-5-yl]pent-1-ynyl}-3- trifluoromethylphenyl)-carbamic Acid tert- Butyl Ester 152 N-tert-Butyl-3-{5-[5-(4-methoxy- 205-208 541.7 benzenesulfonyl)-2,4-dioxothiazol-idin-5- yl]pent-1-ynyl}-4-methyl-benzamide 153 5-(4-Methoxybenzenesulfonyl)-5-[5-(4- 160-163 496.5 trifluoromethylphenyl)pent-4- ynyl]thiazolidine-2,4-dione 154 5-(4-Methoxybenzenesulfonyl)-5-[5-(4- 120-123 512.5 trifluoromethoxyphenyl)pent-4- ynyl]thiazolidine-2,4-dione 155 3-{5-[5-(4-Methoxybenzenesulfonyl)-2,4- 119-121 500.6 dioxo-thiazolidin-5-yl]-pent-1-ynyl}-4- methylbenzoic Acid Methyl Ester 156 5-[5-(4-tert-Butylphenyl)pent-4-ynyl]-5-(4- yellow oil 484.6 methoxybenzenesulfonyl)-thiazolidine-2,4- dione 157 5-[5-(4-tert-Butylphenyl)pent-4-ynyl]-5- 134-138 468.6 (toluene-4-sulfonyl)thiazolidine-2,4-dione 158 4-{5-[5-(4-Methoxybenzenesulfonyl)-2,4- 174-178 453.5 dioxo-thiazolidin-5-yl]pent-1- ynyl}benzonitrile 159 5-[5-(4-Methanesulfonylphenyl)-pent-4- 190-193 490.6 ynyl]-5-(toluene-4-sulfonyl)-thiazolidine-2,4- dione 160 4-{5-[5-(4-Methoxybenzenesulfonyl)-2,4- 128-130 500.6 dioxothiazolidin-5-yl]pent-1-ynyl}-3- methylbenzoic Acid Methyl Ester 161 5-(4-Methoxybenzenesulfonyl)-5-[5-(4- 206-207 493.6 pyrrol-1-yl-phenyl)pent-4-ynyl]-thiazolidine- 2,4-dione 162 5-(4-Iodo-benzenesulfonyl)-5-[5-(4-pyrrol-1- 194-195 589.5 yl-phenyl)pent-4-ynyl]-thiazolidine-2,4-dione 163 5-[5-(4-Pyrrol-1-ylphenyl)pent-4-ynyl]-5-(4- 204-206 547.6 trifluoromethoxybenzenesulfonyl)- thiazolidine-2,4-dione 164 5-(3-Methoxybenzenesulfonyl)-5-(5- 133-135 434.5 thiophen-2-yl-pent-4-ynyl)-thiazolidine-2,4- dione 165 5-(4-Methylphenylsulfonyl)-5-(5-thiophen-2- brown 390.5 yl-pent-4-ynyl)-thiazolidine-2,4-dione gum 166 5-(4-Methoxybenzenesulfonyl)-5-(5- 60-66 434.5 thiophen-2-yl-pent-4-ynyl)-thiazolidine-2,4- dione 167 5-(4-Methoxybenzenesulfonyl)-5-(3-pyridin- tan solid 403.0 3-ylprop-2-ynyl)-thiazolidine-2,4-dione 168 5-(3-Thiophen-2-yl-prop-2-ynyl)-5-(toluene- brown 392.1 4-sulfonyl)-thiazolidine-2,4-dione solid 169 5-(3-Biphenyl-4-yl-prop-2-ynyl)-5-(toluene- 179-180 462 4-sulfonyl)-thiazolidine-2,4-dione 170 5-[3-(4-Phenoxyphenyl)prop-2-ynyl]-5- 64-66 478.1 (toluene-4-sulfonyl)-thiazolidine-2,4-dione 171 5-(3-Biphenyl-4-yl-prop-2-ynyl)-5-(4- orange methoxybenzenesulfonyl)-thiazolidine-2,4- oil dione - In the manner of Example 100 above, 5-iodo-1-pentyne is reacted with 5-(toluene-4-sulfonyl)thiazolidine-2,4-dione to give the title compound, mp 226° C., THEORY: C,53.4, H,4.48, N,4.15 FOUND: C,53.3, H,4.58, N,4.13.
- A solution of 5-pent-4-ynyl-5-(toluene-4-sulfonyl)-thiazolidine-2,4-dione(1.0 mmol), 4-pentyn-1-ol (1.0 mmol), bistriphenylphosphine(Pd II) chloride (0.20 mmol), and copper(I) iodide (0.10 mmol) in 50 ml of diethylamine was stirred under nitrogen for three days. This was diluted with dichloromethane and the product was purified by chromatography to give the title compound as a light beige solid, mp 173-176° C., THEORY: C,57.95, H,4.38 N,6.76. FOUND: C,57.68, H,4.35, N,6.70.
- (3-{5-[5-(4-Methoxybenzenesulfonyl)-2,4-dioxo-thiazolidin-5-yl]pent-1-ynyl}-4-methylphenyl)carbamic acid, tert-butyl ester was subjected to acid hydrolysis which gave the title compound as a brown solid, MS m/Z 458.9 (calcd. For C22H22N2O5S2 458.56).
- The following general procedure was used to prepare the compounds of Examples 175 to 194. A solution of 1.15 g (2.5 mmol) of compound of Example 174, above, in a total of 50 mL of dichloromethane was divided equally in ten-20 mL scintillation vials. To each vessel was added 0.13 mL (3 eq), of diisopropylethylamine, the appropriate acylating agent (1.2 eq, 0.3 mmol) and the mixture was allowed to react in an orbital shaker overnight. Crude reaction mixtures were checked by Mass Spec for product. Once product formation was confirmed, the solutions were evaporated to dryness under reduced pressure, taken up in 1 mL of dichloromethane and purified via preparative HPLC. Each product fraction was then evaporated to dryness in the vacuum apparatus, characterized via mas spectrometry.
Ex. Mass Spectrum No. Product (M − H) 175 (3-{5-[5-(4-Methoxybenzenesulfonyl)-2,4- 591.1 dioxothiazolidin-5-yl]pent-1-ynyl}-4- methylphenyl)carbamic Acid Benzyl Ester 176 (3-{5-[5-(4-Methoxybenzenesulfonyl)-2,4- 636.1 dioxothiazolidin-5-yl]pent-1-ynyl}-4- methylphenyl)carbamic Acid 4-Nitro-Benzyl Ester 177 (3-{5-[5-(4-Methoxybenzenesulfonyl)-2,4- 611.0 dioxothiazolidin-5-yl]pent-1-ynyl}-4- methylphenyl)carbamic Acid 4-Chloro-phenyl Ester 178 (3-{5-[5-(4-Methoxybenzenesulfonyl)-2,4- 515.0 dioxothiazolidin-5-yl]pent-1-ynyl}-4- methylphenyl)carbamic Acid Methyl Ester 179 (3-{5-[5-(4-Methoxybenzenesulfonyl)-2,4- 543.1 dioxothiazolidin-5-yl]pent-1-ynyl}-4- methylphenyl)carbamic Acid Isopropyl Ester 180 (3-{5-[5-(4-Methoxybenzenesulfonyl)-2,4- 571.1 dioxothiazolidin-5-yl]pent-1-ynyl}-4- methylphenyl)carbamic Acid Neopentyl Ester 181 (3-{5-[5-(4-Methoxybenzenesulfonyl)-2,4- 557.1 dioxothiazolidin-5-yl]pent-1-ynyl}-4- methylphenyl)carbamic Acid Butyl Ester 182 (3-{5-[5-(4-Methoxybenzenesulfonyl)-2,4- 557.1 dioxothiazolidin-5-yl]pent-1-ynyl}-4- methylphenyl)carbamic Acid Isobutyl 183 N-[3-(5-{5-[(4-Methoxyphenyl)sulfonyl]-2,4-dioxo-1,3- 526.9 thiazolidin-5-yl}-1-pentynyl)-4-methylphenyl]-2- methylpropanamide 184 N-[3-(5-{5-[(4-Methoxyphenyl)sulfonyl]-2,4-dioxo-1,3- 555.0 thiazolidin-5-yl}-1-pentynyl)-4-methylphenyl]-3,3- dimethylbutanamide 185 N-[3-(5-{5-[(4-Methoxyphenyl)sulfonyl]-2,4-dioxo-1,3- 541.0 thiazolidin-5-yl}-1-pentynyl)-4-methylphenyl]-2,2- dimethylpropanamide 186 N-[3-(5-{5-[(4-Methoxyphenyl)sulfonyl]-2,4-dioxo-1,3- 574.9 thiazolidin-5-yl}-1-pentynyl)-4-methylphenyl]-2- phenylacetamide 187 N-Benzyl-N′-[3-(5-{5-[(4-methoxyphenyl)-sulfonyl]-2,4- 589.9 dioxo-1,3-thiazolidin-5-yl}-1-pentynyl)-4-methylphenyl]urea 188 N-(4-Methoxyphenyl)-N′-[3-(5-{5-t(4-methoxy 606.0 phenyl)sulfonyl]-2,4-dioxo-1,3-thiazolidin-5-yl}-1-pentynyl)-4- methylphenyl]urea 189 N-(4-Chlorophenyl)-N′-[3-(5-{5-[(4-methoxy- 609.9 phenyl)sulfonyl]-2,4-dioxo-1,3-thiazolidin-5-yl}-1-pentynyl)-4- methylphenyl]urea 190 N-[3-(5-{5-[(4-Methoxyphenyl)sulfonyl]-2,4-dioxo-1,3- 590.0 thiazolidin-5-yl}-1-pentynyl)- -methylphenyl]-N′-(4- methylphenyl)urea 191 4-Chloro-N-[3-(5-{5-[(4-methoxyphenyl)-sulfonyl]-2,4-dioxo- 596.0 1,3-thiazolidin-5-yl}-1-pentynyl)-4-methylphenyl]benzamide 192 4-Methoxy-N-[3-(5-{5-[(4-methoxyphenyl)-sulfonyl]-2,4- 590.9 dioxo-1,3-thiazolidin-5-yl}-1-pentynyl)-4- methylphenyl]benzamide 193 N-[3-(5-{5-[(4-Methoxyphenyl)sulfonyl]-2,4-dioxo-1,3- 636.9 thiazolidin-5-yl}-1-pentynyl)-4-methylphenyl][1,1′-biphenyl]- 4-carboxamide 194 4-(tert-Butyl)-N-[3-(5-{5-[(4-methoxyphenyl)-sulfonyl]-2,4- 617.0 dioxo-1,3-thiazolidin-5-yl}-1-pentynyl)-4- methylphenyl]benzamide - The following general procedure was used to prepare the compounds of Examples 195 to 213. A solution of 800 mg of each sulfone in 20 mL anhydrous DMF was distributed evenly among 4 vials (0.57-0.75 mmol each). To each was added 2.1 eq 1.0M NaHMDS under a stream of N2 and reacted in an orbital shaker for 45 min. 1.05 equivalents of the appropriate alkylating agent was dissolved in 2 mL DMF and added under N2 to the above vials. The reactions were allowed to shake overnight at room temp.
- Each vial was diluted with 5 ml H2O, acidified with 2NHCl, then extracted with ethyl acetate. Crude extracts were evaporated to dryness under reduced pressure in a vacuum apparatus, dissolved in 1 mL of dichloromethane, then purified via preparative HPLC. The product fractions were collected, and evaporated to dryness under reduced pressure and analyzed via MS and NMR.
Mass Ex. Spectrum No. Product (M − H) 195 5-[5-(4-Chlorophenyl)-4-pentynyl]-5-[(5-chloro-2- 473.8 thienyl)sulfonyl]-1,3-thiazolidine-2,4-dione 196 5-[5-(4-Chlorophenyl)-4-pentynyl]-5-(2- 439.9 thienylsulfonyl)-1,3-thiazolidine-2,4-dione 197 5-[5-(4-Chlorophenyl)-4-pentynyl]-5-[(3,4- 494.0 dimethoxyphenyl)sulfonyl]-1,3-thiazolidine-2,4-dione 198 5-[5-(4-Chlorophenyl)-4-pentynyl]-5-{[4-(4- 527.0 pyridinyloxy)phenyl]sulfonyl}-1,3-thiazolidine-2,4- dione 199 5-[5-(4-Chlorophenyl)-4-pentynyl]-5-{[5-(2-pyridinyl)- 516.9 2-thienyl]sulfonyl}-1,3-thiazolidine-2,4-dione 200 5-[(5-Chloro-2-thienyl)sulfonyl]-5-[5-(2,5- 509.8 dichlorophenyl)-4-pentynyl]-1,3-thiazolidine-2,4- dione 201 5-[5-(2,5-Dichlorophenyl)-4-pentynyl]-5-(2- 473.8 thienylsulfonyl)-1,3-thiazolidine-2,4-dione 202 5-[5-(2,5-Dichlorophenyl)-4-pentynyl]-5-[(3,4- 527.9 dimethoxyphenyl)sulfonyl]-1,3-thiazolidine-2,4-dione 203 5-[5-(2,5-Dichlorophenyl)-4-pentynyl]-5-{[4-(4- 560.9 pyridinyloxy)phenyl]sulfonyl}-1,3-thiazolidine-2,4- dione 204 5-[5-(2,5-Dichlorophenyl)-4-pentynyl]-5-{[5-(2- 550.9 pyridinyl)-2-thienyl]sulfonyl}-1,3-thiazolidine-2,4- dione 205 tert-Butyl 3-(5-{5-[(5-chloro-2-thienyl)-sulfonyl]-2,4- 569.0 dioxo-1,3-thiazolidin-5-yl}-1-pentynyl)-4- methylphenylcarbamate 206 tert-Butyl 3-{5-[2,4-dioxo-5-(2-thienyl-sulfonyl)-1,3- 533.0 thiazolidin-5-yl]-1-pentyn-yl}-4- methylphenylcarbamate 207 tert-Butyl 3-(5-{5-[(3,4-dimethoxy-phenyl)sulfonyl]- 587.1 2,4-dioxo-1,3-thiazol-idin-5-yl}-1-pentynyl)-4- methylphenylcarbamate 208 tert-Butyl 3-[5-(2,4-dioxo-5-{[4-(4- 620.1 pyridinyloxy)phenyl]sulfonyl}-1,3-thiazol-idin-5-yl)- 1-pentynyl]-4-methylphenylcarbamate 209 tert-Butyl 3-[5-(2,4-dioxo-5-{[5-(2-pyrid-inyl)-2- 610.0 thienyl]sulfonyl}-1,3-thiazol-idin-5-yl)-1-pentynyl]-4- methylphenylcarbamate 210 N-(tert-Butyl)-3-(5-{5-[(5-chloro-2-thienyl)sulfonyl]- 553.0 2,4-dioxo-1,3-thiazolidin-5-yl}-1-pentynyl)-4- methylbenzamide 211 N-(tert-Butyl)-3-{5-[2,4-dioxo-5-(2-thienylsulfonyl)- 517.1 1,3-thiazolidin-5-yl]-1-pentynyl}-4-methylbenzamide 212 N-(tert-Butyl)-3-(5-{5-[(3,4- 571.1 dimethoxyphenyl)sulfonyl]-2,4-dioxo-1,3-thiazolidin- 5-yl}-1-pentynyl)-4-methylbenzamide 213 N-(tert-Butyl)-3-[5-(2,4-dioxo-5-{[5-(2-pyridinyl)-2- 594.0 thienyl]sulfonyl}-1,3- thiazolidin-5-yl)-1-pentynyl]-4-methylbenzamide - To a solution of 4-{5-[5-(4-methoxybenzenesulfonyl)-2,4-dioxo-thiazolidin-5-yl]pent-1-ynyl}-3-methylbenzoic acid methyl ester (Example 160) (0.29 g, 0.536 mmol) in THF (30 ml plus sufficient methanol to dissolve the substrate) was added lithium hydroxide (0.75 ml of 1.0M in water), and this solution was stirred at room temperature for 3 days. Dilution with water and acidification gave a solid which was crystallized from hexane-ethyl acetate to give the title compound as a light yellow solid mp 182-184° C. THEORY: C, 56.66, H,4.34, N,2.87. FOUND: C,56.39, H,4.60, N,2.80.
- To a solution of 5-(4-methoxybenzenesulfonyl)-thiazolidine-2,4-dione [U.S. Pat. No. 5,605,918; February 1997; Wrobel, et al.] ((5.0 g, 17.4 mmol) in 150 ml of DMF was added sodium bistrimethylsilylamide (36.6 ml of 1.0 M solution in THF) and this solution was stirred for 15 minutes. To this was added methyl 3-iodopropionate (17.4 mmol) and this solution was stirred for three hours and then was subjected to an aqueous workup. The product was chromatographed (silica gel, hexane-ethyl acetate-dichloromethane, 1:1:1) to give methyl 3-[5-(4-methoxybenzenesulfonyl)-2,4-dioxothiazolidin-4-yl]propionate, 4.48 g. This was hydrolyzed with lithium hydroxide, THF, methanol to give 3-[5-(4-methoxybenzenesulfonyl)-2,4-dioxothiazolidin-4-yl]propionic acid which was used without further purification in the following procedure:
- To a solution of the above acid (0.4 g, 1.1 mmol) in 15 ml of dichloromethane plus 2 ml of DMF was added 4-chlorobenzylamine (0.2 ml, 1.67 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.255 g, 1.33 mmol), and this was stirred at room temperature for 18 hours. Aqueous workup, and chromatography (silica gel, chloroform-methanol—5%) gave the title compound as a colorless solid, mp 90° C. and decomposes over wide range.
- In a like procedure to Example 215, above, 4-chlorophenethylamine gave the title compound as a white powder, mp 189° C. with decomposition.
- A sample of 5-[5-(4-chlorophenyl)pent-4-ynyl]-5-(p-tolylsulfonyl)-thiazolidine-2,4-dione (Example 103) was hydrogenated in the presence of Lindlars catalyst in ethanol to give the title compound as a white solid, NMR (CDCl3) δ2.47 (s, 3H), 5.57 (apparent d of triplets, J=7.3, 11.6 Hz, 1H), 6.42 (br d, J=11.6 Hz, 1H) MS m/Z 499.0495 (M+ calcd. for C21H20ClNO4S2 499.0523).
- A mixture of 4-pentyn-1-ol, 1.05 eq tri-n-butyltinhydride and a catalytic amount of 1,1′-azobis(cyclohexanecarbonitrile), was heated to 55° C. overnight. The mixture was cooled, then purified on silica gel using 6:1 hex: EtOAc to 4:1 as eluent to give 86% yield of tri-n-butyl(4-pentenol)-5-ylstannane as a clear liquid which contained both cis and trans isomers. Then, 4-chloroiodobenzene (1.0 equiv.) was dissolved in anhydrous DMF under a nitrogen atmosphere. Tri-n-butyl(4-pentenol)-5-ylstannane(1.0 equiv.) was added, followed by tetrakis-triphenylphosphinePd(0)(0.1 equiv.) and Cul (0.75 equiv.). The reaction was stirred at room temperature overnight. The reaction was diluted with ether, filtered through a small pad of celite and an excess of saturated aqueous NH4Cl was added, and this was stirred for 1 h. Combined organics were washed with brine, and dried over MgSO4 to afford a tan semi-solid. This was purified using silica and 4:1 Hex: MeOtBu to 1:1. Obtained three cuts: 20% pure ‘Z’ isomer, 26% mix, 19.6% ‘E’ isomer (desired trans isomer) which was a light tan low melting solid.
- A solution of imidazole (1.3 equiv.) and triphenylphosphine (1.3 equiv.) in acetonitrile-ether was cooled to 0° C. Iodine (1.4 equiv.) was added in three portions, and the solution was then allowed to warm to room temp overnight.
- The mixture was dissolved in methylene chloride, and directly preadsorbed onto silica gel and purified using 25:1 Hexanes: EtOAc as eluent to give the iodo-compound as a clear liquid. In an oven-dried round bottom flask under nitrogen was dissolved the sulfone in anhydrous DMF. Sodium hexamethyldisilazide (1.0 M solution in THF—2.1 equiv.) was added dropwise at room temperature and allowed to react at room temp for one hour. The iodide (1.1 equiv.) was dissolved in DMF, then added in one portion to the above solution., and allowed to react overnight.
- The reaction was diluted with water, acidified to approx. pH 2 using 2N HCl, extracted with ethyl acetate (3×), combined organics, washed with brine, dried over MgSO4 and concentrated to afford an oil which was purified on silica gel using 1:2:1 CH2Cl2: hex: EtOAc to afford the title compound, 36% as an off-white solid, mp 182-184° C., E-double bond—NMR (CDCl3) δ6.18 (td, 1H, J=22.5 Hz), 6.31 (d, 1H, J=22.5 Hz).
- A sample of 5-[3-(4-Chlorophenyl)prop-2-ynyl]-5-(4-methoxy-benzenesulfonyl)-thiazolidine-2,4-dione (U.S. Pat. No. 5,605,918; February 1997; Wrobel, et al.) was hydrogenated in the presence of palladium on charcoal (10%) in methanol plus 2% water to give the title compound as a colorless glass, NMR (CDCl3) δ1.57 (m, 1H); 1.97 (m, 1H); 2.20 (triplet of doublet), 1H); 2.45 (m, 1H); 2.61 (q, 2H); 3.92 (s, 3H); 7.0 (dd, 4H); 7.26 (d, 2H) 7.98 (d, 2H).
- A sample of 5-(4-methoxybenzenesulfonyl)-5-[5-(3-nitrophenyl)pent-4-ynyl]-thiazolidine-2,4-dione of Example 118 was reduced with iron in acetic acid to give the title compound as crystals, m.p. 135-138° C.
- Alkylation with cinnamyl bromide (222 mg, 1.13 mmol) of 5-(4-methylphenylsulfonyl)-thiazolidine-2,4-dione (271 mg, 1.00 mmol) following the procedure in Example 3 yield 32 mg (8%) of light yellow oil which was identified as 5-(3-Phenylallyl)-5-(toluene-4-sulfonyl)-thiazolidine-2,4-dione: NMR (CDCl3) δ2.49 (s, 3H), 3.06-3.13 (m, 1H), 3.34-3.42 (m, 1H), 6.01-6.11 (m, 1H), 6.60 (d, J=15.69, 1H), 7.26-7.26-7.31 (m, 5H), 7.42 (d, J=8.13, 2H), 7.85 (d, J=8.34, 2H) MS m/z 388.1 (M+H cald. for C19H17NO4S2 387.48)
- The compound of Example 150 was chromatographed on a chiral column with hexane-ethanol 4:1 to give a less polar enantiomer, retention time 14.5-16 min.
- Continued chromatography of the compounds in Example 223 gave a more polar enantiomer, retention time 19-21 min.
- 5-(4-methoxyphenyl-4-sulfanyl)-thiazolidine-2,4-dione [U.S. Pat. No. 5,605,918; February 1997; Wrobel, et al.] was oxidized as described for Example 98 to give the title compound: NMR (CDCl3) δ3.80 (S, 3H), 5.77 (S, 1H), 7.04 (d, 2H), 7.62 (d, 2H).
- By the method of Example 92, the compound of Example 224, above, is converted to the title compound.
- In the isolation of products of Examples 175 to 194 the N-3-acylated products of Examples 227 to 234 were isolated and the structures were verified by mass spectrometry and NMR:
Ex. No. Compound 226 Benzyl 5-[5-(5-{[(benzyloxy)carbonyl]-amino}-2- methylphenyl)pent-4-ynyl]-5-[(4- methoxyphenyl)sulfonyl]-2,4-dioxo-1,3-thiazolidine- 3-carboxylate 227 4-Nitrobenzyl 5-[(4-methoxyphenyl)sulfonyl]-5-{5-[2- methyl-5-({[(4-nitro benzyl)oxy]carbonyl}amino) phenyl]pent-4-ynyl}-2,4-dioxo-1,3-thiazolidine-3- carboxylate 228 Methyl 5-(5-{5-[(methoxycarbonyl)amino]-2- methylphenyl}pent-4-ynyl)-5-[(4- methoxyphenyl)sulfonyl]-2,4-dioxo-1,3-thiazolidine- 3-carboxylate 229 Isopropyl 5-(5-{5-[(isopropoxycarbonyl)-amino]-2- methylphenyl}pent-4-ynyl)-5-[(4- methoxyphenyl)sulfonyl]-2,4-dioxo-1,3-thiazolidine- 3-carboxylate 230 Neopentyl 5-[(4-methoxyphenyl)sulfonyl]-5-[5-(2- methyl-5-{[(neopentyloxy)carbonyl]- amino}phenyl)pent-4-ynyl]-2,4-dioxo-1,3- thiazolidine-3-carboxylate 231 Butyl 5-(5-{5-[(butoxycarbonyl)amino]-2- methylphenyl}pent-4-ynyl)-5-[(4-methoxy- phenyl)sulfonyl]-2,4-dioxo-1,3-thiazolidine-3- carboxylate 232 Isobutyl 5-(5-{5-[(isobutoxycarbonyl)-amino]-2- methylphenyl}pent-4-ynyl)-5-[(4- methoxyphenyl)sulfonyl]-2,4-dioxo-1,3-thiazolidine- 3-carboxylate - The compound of Example 97 is reacted with 1,3-dibromopropane and potassium carbonate in DMF to give 5-[5-(4-chlorophenyl)pent-4-ynyl]-3-(3-bromopropyl)-5-(4-methoxybenzenesulfonyl)-thiazolidine-2,4-dione, and this is reacted with imidazole, sodium salt in DMF, and in the presence of a catalytic amount of potassium iodide to give the title compound as a light tan solid, mp 111-113° C.
- 5-[5-(4-Chlorophenyl)pent-4-ynyl]-5-(4-methoxybenzenesulfonyl)-thiazolidine-2,4-dione (Example 100) is reated with sodium hydride in DMF, followed by methyl iodide to give the title compound as colorless crystals, mp 113-115° C.
- 5-(Toluene-4-sulfonyl)thiazolidine-2,4-dione [U.S. Pat. No. 5,605,918; February 1997; Wrobel, et al.] was reacted with 2,4-diethoxybenzyl alcohol in the presence of triphenylphosphine and diethyl diazodicarboxylate to give the title compound as colorless crystals, mp 121-123° C.
- The product of Example 237 is reacted with sodium hexamethyldisilazide in DMF, followed by the addition of 1-chloro-4-(5-iodopent-1-ynyl)-benzene to give the title compound as colorless crystals, mp 151-153° C.
- 5-[5-(4-Chlorophenyl)pent-4-ynyl]-5-(4-iodobenzenesulfonyl)-thiazolidine-2,4-dione is reacted with 4-nitrobenzyl bromide and potassium carbonate in DMF to give the title compound as a light tan solid, mp 172-175° C.
-
- 5-[5-(2,5-Dichlorophenyl)pent-4-ynyl]-5-(4-methoxybenzenesulfonyl)-thiazolidine-2,4-dione is reacted with (2-methoxyethoxy)chloroformate and diisopropylethylamine in methylene chloride to give the title compound as a solid, MS m/z 599.8 (calcd. for C25H23Cl2NO8S2 600.5).
- Examples 239-267 were synthesized using the methods described in U.S. Pat. Nos. 5,605918 and 5,574051 and in Wrobel, J., et al.,J. Med. Chem. 1998, 41 (7), 1084-91.
- 5-[3-(4-Chloro-phenyl)-prop-2-ynyl]-5-(napthalene-2-sulfonyl)-thiazolidine-2,4-dione
- 5-Benzenesulfonyl-5-[3-(4-chloro-phenyl)-prop-2-ynyl]-thiazolidine-2,4-dione
- 5-Benzenesulfonyl-5-[3-phenyl-prop-2-ynyl]-thiazolidine-2,4-dione
- 5-(4-Chloro-benzenesulfonyl)-5-(3-phenyl-prop-2-ynyl)-thiazolidine-2,4-dione
- 5-[3-(4-Chloro-phenyl)-prop-2-ynyl]-5-(4-fluoro-benzenesulfonyl)-thiazolidine-2,4-dione
- 5-(4-Chloro-benzenesulfonyl)-5-[3-(4-chloro-phenyl)-prop-2-ynyl]-thiazolidine-2,4-dione
- 5-(4-Bromo-benzenesulfonyl)-5-[3-(4-chloro-phenyl)-prop-2-ynyl]-thiazolidine-2,4-dione
- 5-[3-(4-Fluoro-phenyl)-prop-2-ynyl]-5-(toluene-4-sulfonyl)-thiazolidine-2,4-dione
- 5-(Toluene-4-sulfonyl)-5-[3-(p-tolyl)-prop-2-ynyl]-thiazolidine-2,4-dione
- 5-(4-Bromo-benzenesulfonyl)-5-(3-phenyl-prop-2-ynyl)-thiazolidine-2,4-dione
- 5-[3-(4-Chloro-phenyl)-prop-2-ynyl]-5-(4-methoxy-benzenesulfonyl)-thiazolidine-2,4-dione
- 5-(Naphthalene-2-sulfonyl)-5-(3-phenyl-prop-2-ynyl)-thiazolidine-2,4-dione
- 5-(Toluene-4-sulfonyl)-5-[3-(4-trifluoromethyl-phenyl)-prop-2-ynyl]-thiazolidine-2,4-dione
- 5-[3-(4-Methoxy-phenyl)-prop-2-ynyl]-5-(toluene-4-sulfonyl)-thiazolidine-2,4-dione
- 5-[3-(4-Bromo-phenyl)-prop-2-ynyl]-5-(toluene-4-sulfonyl)-thiazolidine-2,4-dione
- 5-Benzenesulfonyl-5-[3-(4-trifluoromethyl-phenyl)-prop-2-ynyl]-thiazolidine-2,4-dione
- 5-(4-Chloro-benzenesulfonyl)-5-[3-(4-fluoro-phenyl)-prop-2-ynyl]-thiazolidine-2,4-dione
- 5-[3-(4-Chloro-phenyl)-prop-2-ynyl]-5-(toluene-3-sulfonyl)-thiazolidine-2,4-dione
- 5-[3-(3-Chloro-phenyl)-prop-2-ynyl]-5-(toluene-4-sulfonyl)-thiazolidine-2,4-dione
- 5-Benzenesulfonyl-5-[3-(2-chloro-phenyl)-prop-2-ynyl]-thiazolidine-2,4-dione
- 5-Benzenesulfonyl-5-[3-(3,5-bis-trifluoromethyl-phenyl)-prop-2-ynyl]-thiazolidine-2,4-dione
- 5-[3-(3,5-bis-trifluoromethyl-phenyl)-prop-2-ynyl]-5-(toluene-4-sulfonyl)-thiazolidine-2,4-dione
- 5-Benzenesulfonyl-5-[3-(3-chloro-phenyl)-prop-2-ynyl]-thiazolidine-2,4-dione
- 5-[3-(4-Chlorophenyl)-2-propynyl]-2-[(4-methylphenyl)sulfonyl]-2,4-thiazolidinedione
- 5-[3-(4-Bromo-phenyl)-prop-2-ynyl]-5-(4-chloro-benzenesulfonyl)-thiazolidine-2,4-dione
- 5-(4-Fluoro-benzenesulfonyl)-5-[3-(4-trifluoromethyl-phenyl)-prop-2-ynyl]-thiazolidine-2,4-dione
- 5-[3-(4-Chloro-phenyl)-prop-2-ynyl]-5-(quinoline-2-sulfonyl)-thiazolidine-2,4-dione
- 5-[3-(3,5-Bis-trifluoromethyl-phenyl)-prop-2-ynyl]-thiazolidine-2,4-dione
- 5-[3-(4-Chloro-phenyl)-prop-2-ynyl]-5-(p-tolylsulfanyl)-thiazolidine-2,4-dione
Claims (20)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/226,815 US6605628B1 (en) | 2001-08-24 | 2002-08-23 | Method of using 5-(arysulfonyl)-, 5-(arylsulfanyl)-and 5-(arylsulfanyl)thiazolidine-2,4-diones for inhibition of farnesyl-protein transferase |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31462101P | 2001-08-24 | 2001-08-24 | |
US10/226,815 US6605628B1 (en) | 2001-08-24 | 2002-08-23 | Method of using 5-(arysulfonyl)-, 5-(arylsulfanyl)-and 5-(arylsulfanyl)thiazolidine-2,4-diones for inhibition of farnesyl-protein transferase |
Publications (2)
Publication Number | Publication Date |
---|---|
US20030144301A1 true US20030144301A1 (en) | 2003-07-31 |
US6605628B1 US6605628B1 (en) | 2003-08-12 |
Family
ID=27616371
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/226,815 Expired - Fee Related US6605628B1 (en) | 2001-08-24 | 2002-08-23 | Method of using 5-(arysulfonyl)-, 5-(arylsulfanyl)-and 5-(arylsulfanyl)thiazolidine-2,4-diones for inhibition of farnesyl-protein transferase |
Country Status (1)
Country | Link |
---|---|
US (1) | US6605628B1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090177416A1 (en) * | 2005-12-23 | 2009-07-09 | Gcoder Systems Ab | Positioning pattern |
US9056862B2 (en) | 2011-05-10 | 2015-06-16 | National University Corporation Kobe University | Thioxothiazolidine derivative having Ras function inhibitory effect |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2184739A1 (en) | 1994-03-08 | 1995-09-14 | Jay E. Wrobel | Thiazolidinedione derivatives as anti-hyperglycemic agents |
US5958957A (en) * | 1996-04-19 | 1999-09-28 | Novo Nordisk A/S | Modulators of molecules with phosphotyrosine recognition units |
-
2002
- 2002-08-23 US US10/226,815 patent/US6605628B1/en not_active Expired - Fee Related
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090177416A1 (en) * | 2005-12-23 | 2009-07-09 | Gcoder Systems Ab | Positioning pattern |
US9056862B2 (en) | 2011-05-10 | 2015-06-16 | National University Corporation Kobe University | Thioxothiazolidine derivative having Ras function inhibitory effect |
Also Published As
Publication number | Publication date |
---|---|
US6605628B1 (en) | 2003-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9963440B2 (en) | Multisubstituted aromatic compounds as inhibitors of thrombin | |
US6403581B1 (en) | Method of inhibition of farnesyl-protein transferase using substituted benz (cd) indol-2-imine and-amine derivatives | |
KR100449600B1 (en) | N-[(Substituted Five-Membered Diaza Diunsaturated Ring)Carbonyl] Guanidine Derivatives for the Treatment of Ischemia | |
US6649629B2 (en) | Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use | |
SK9622000A3 (en) | Inhibition of raf kinase using aryl and heteroaryl substituted heterocyclic ureas | |
JP2001526220A (en) | Inhibition of RAF kinase using substituted heterocyclic ureas | |
KR20060022649A (en) | Aryl substituted pyrazole-amide compounds useful as kinase inhibitors | |
JP2002537378A (en) | Metalloprotease inhibitors of aromatic sulfone hydroxamic acids | |
HU222277B1 (en) | Substituted biphenylsiloxazole sulfonamides and pharmaceutical compositions containing them | |
KR20030016269A (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
HU211474A9 (en) | Azole compounds, their production and use | |
NZ336134A (en) | Bicyclic inhibitors of protein farnesyl transferase for treatment of cancer, restenosis and atherosclerosis | |
KR100204697B1 (en) | Triazolylated tertiary amine compound or salt thereof | |
IE49356B1 (en) | New pleuromutilin derivatives,their production use and pharmaceutical compositions containing them | |
EP2662367A1 (en) | Novel indole or indazole derivative or salt thereof | |
MX2008000891A (en) | PYRAZOLE DERIVATIVES AS CBl MODULATORS. | |
RU2377238C2 (en) | Imidazole derivatives active to cb1 receptor | |
CA2412270A1 (en) | Pyrrole derivatives for treating aids | |
US6784184B2 (en) | 5-(arylsulfonyl)-,5-(arylsulfinyl), and 5-(arylsulfanyl)-thiazolidine-2,4-diones useful for inhibition of farnesyl-protein transferase | |
US6605628B1 (en) | Method of using 5-(arysulfonyl)-, 5-(arylsulfanyl)-and 5-(arylsulfanyl)thiazolidine-2,4-diones for inhibition of farnesyl-protein transferase | |
WO2012134233A2 (en) | Sulphamide derivative having an adamantyl group and a pharmaceutically acceptable salt thereof | |
US6740675B2 (en) | 3-substituted-3-(substitutedsulfonyl or sulfanyl)pyrrolidine-2,5-diones useful for inhibition of farnesyl-protein transferase | |
US6716862B2 (en) | 5-(Substituted)-5-(substitutedsulfonyl or sulfanyl) thiazolidine-2,4-diones useful for inhibition of farnesyl-protein transferase | |
WO2002078696A1 (en) | Compounds and methods | |
CZ20002988A3 (en) | Derivatives of N-{(substituted five-membered di- or triaza-di-unsaturated ring)carbonyl} guanidine for treating ischemia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: AMERICAN CYANAMID COMPANY, NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:AYRAL-KALOUSTIAN, SEMIRAMIS;EPSTEIN, JOSEPH WILLIAM;BIRNBERG, GARY HAROLD;AND OTHERS;REEL/FRAME:013237/0701;SIGNING DATES FROM 20020821 TO 20020822 |
|
AS | Assignment |
Owner name: WYETH HOLDINGS CORPORATION, NEW JERSEY Free format text: CHANGE OF NAME;ASSIGNOR:AMERICAN CYANAMID COMPANY;REEL/FRAME:014038/0964 Effective date: 20021231 |
|
CC | Certificate of correction | ||
FPAY | Fee payment |
Year of fee payment: 4 |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
LAPS | Lapse for failure to pay maintenance fees |
Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20110812 |